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ABSTRACT
Cancer initiation and progression are multistep processes that rely on the generation and
accumulation of non-lethal mutations, which deregulate function of tumor suppressor genes and
activate oncogenic pathways. Evolving through a landscape of heterogeneous somatic mutations,
mutated cells undergo subsequent selection pressures and the one endowed with the greatest fitness
advantage survives giving rise to genetically diverse cell populations resulting in intratumor
heterogeneity (ITH). Presence of abnormal number of centrosomes is one of the key factors
contributing towards ITH. Clustering of amplified centrosomes allows cancer cells to avoid mitotic
spindle multipolarity that could otherwise result in cell death either by mitotic catastrophe or a
high-grade multipolar division yielding intolerably severe aneuploidy. Thus, centrosome

clustering enables low-grade chromosomal missegregation and their unequal distribution to
daughter cells resulting chromosomal instability (CIN), thus contributing to neoplastic
transformation. Owing to the presence of genetically different cells in a tumor, monotargeted
therapy spares clones lacking therapy-specific targets giving them the opportunity to repopulate
the tumor with immunity toward the applied therapy and propensity to recur. Therefore, ITH poses
major challenges to both clinicians and drug developers as it precludes detection of low-level
clones, prediction of tumor evolution, development of drugs to target specific clones and
evaluation of effective, yet non-toxic combinatorial regimens to combat ITH.
I envision that a comprehensive quantitative analysis of centrosome amplification (CA), which is
a bona-fide driver of ITH might help better understand clinical behavior and improve therapeutic
management of tumors. To this end, my research, presented here, primarily focuses on testing i)
the impact of centrosome amplification and centrosome clustering protein (KIFC1) on clinical
outcomes in multiple malignancies and ii) the role of tumor hypoxia in inducing centrosome
amplification in cancer. Collectively, my findings reveal that CA and KIFC1 are prognostic and
predictive in multiple malignancies and that tumor hypoxia plays a crucial role in inducing CA in
tumors. This body of work expands our knowledge in causes and clinical implications of CA to
help guide treatment decisions and development of precision medicine for multiple malignancies.

INDEX WORDS: Centrosome amplification, Centrosome clustering, Hypoxia, KIFC1,
Intratumoral heterogeneity, Cancer
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1
1.1

INTRODUCTION

Centrosome structure and centrosome cycle

The centrosome is the main microtubule (MT)-organizing center in all mammalian cells; it plays
important roles in various cellular processes such as cell division, mitotic spindle assembly,
polarity, and migration. Structurally, a centrosome is composed of a pair of centrioles (each
measure 200 by 400 nm)[1] arranged orthogonally connected through linker proteins and
surrounded by a dynamic collection of 200 -300 centrosome-associated proteins collectively
called as the pericentriolar matrix (PCM)[2, 3]. The mother centriole regulates PCM organization,
stabilization, and size[4]. The PCM proteins include cell cycle regulators and proteins that help in
organizing and nucleating microtubules thus, helping centrosomes to perform their key role as
microtubule organizing centers. With recent advancements in the studies, it has become clear that
role of centrosomes extends well beyond just the microtubule organizers. Multiple studies have
shown that centrosomes function as coordination centers in eukaryotic cells and with the
interaction of multiple cytoplasmic proteins major decisions regarding the cellular processes are
made.
Similar to DNA replication, centrosome duplication also occurs only once per cycle (cell cycle
control). Another level of regulation is the copy number control where only one centriole, i.e.,
daughter centriole is produced from the pre-existing mother centriole[4]. Any defect or disturbance
in the regulation of these mechanisms can affect the proper execution of various processes that
result in the centrosomal abnormalities. Alterations in centrosome number and structure lead to
defects in the mitotic spindle organization and consequently in chromosome instability, which is
a major source of aneuploidy in cancers.

2

1.2

How cells generate extra centrosomes?

Centrosome amplification (CA) refers to the presence of supernumerary (numerical amplification)
or abnormally large centrosomes (structural amplification),[5, 6] and occurs early in pre-cancerous
and pre-invasive lesions and is linked to aggressiveness in several types of cancer. There are
several pathways that can lead to the acquisition of extra centrosomes, which are not mutually
exclusive. Deregulation of the centrosome duplication cycle leads to the centriole overduplication
and formation of supernumerary centrosomes via consecutive rounds of centrosome reproduction
or fast concurrent formation of daughter centrioles around the existing centrioles giving rise to
numerical amplification. Another cause of numerical amplification is the failure of cytokinesis,
owing to which polyploid cells with supernumerary centrosomes are generated. On occasion,
numerical amplification also arises from fragmentation of the pericentriolar matrix. Similarly,
several factors account for structural defects which include accumulation of excessive PCM
around the centrioles (likely due to deregulated expression of genes coding for centrosomal
components or altered posttranslational modifications), resulting in centrosomes that appear
altered in size.[7] PCM size is regulated by centrioles, free cytoplasmic αβ-tubulin, centrobin,
kinases like PLK1 and CHK1, and several coiled-coil proteins like pericentrin and CPAP [8-10].
The mechanisms undergirding structural CA in cancer are still poorly defined, although several
stimulators of PCM assembly are overexpressed in cancer (e.g., PLK1 [11] and CHK1 [12]),
cancer cells often harbor supernumerary centrioles (which could then recruit excessive PCM), and
the PCM expands following DNA damage [13]. Another possible reason for structural aberration
can be tight clustering of centrosomes, which thus cannot be individually distinguished. Another
possible reason for this can be structural defects in centrioles; this is a completely unexplored area
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because the size of normal centriole is very small and requires very sophisticated microscopy
techniques especially for tumor samples. [5]
In addition, deregulation of the oncogenes or tumor suppressor genes which regulates
expression of centrosome-associated genes have been shown to lead to the formation of
supernumerary centrosomes. For, e.g., the expression of an important protein Polo like kinase 4
(PLK4) is regulated by various factors. A transcriptional factor KLF14 transcriptionally represses
expression of PLK4 and thus knock out of KLF14 has been shown to result in centrosome
amplification via an increase in expression of PLK4[14]. Similarly, p53 which is a tumor
suppressor gene also negatively regulates expression of PLK4 and thus induces centrosome
amplification indirectly through PLK4[15]. In addition, HPV-16 viral E6 and E7 oncoproteins
have been shown to disrupt host cell cycle checkpoints important for oncogenic transformation
that results in disruption of normal centriole duplication (increased PLK4 mRNA levels) induces
centrosome amplification (CA)[16].
Another important factor which deregulates expression of the several centrosome-associated genes
is the tumor microenvironment. Tumor hypoxia is one of the most critical component of tumor
microenvironment. Although studies have reported that hypoxia increases levels of CA associated
proteins such as Aurora-A/STK15 protein and PLK4 [17-19], the mechanism under grinding this
phenomenon is not well understood. Thus, understanding the mechanism by which hypoxia
induces CA is the primary goal of the first manuscript in this dissertation (Chapter 2).

Prognostic and predictive role of Centrosome amplification in human cancers
Theodor Boveri postulated a century ago that multiple centrosomes are seen in cancer cells and
may lead to tumorigenesis. Since then, centrosomes have been studied in growing list of human
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cancers including bladder, blood, bone and soft tissue, brain, breast, cervix, colorectum, head and
neck, hepatobiliary tract, kidney, ovary, prostate, and hematological malignancies. From these
observations, the question naturally arises whether supernumerary centrosomes are simply
innocent bystanders or whether they play a causative role in fueling tumor evolution. Studies have
reported that CA occurs in precancerous and preinvasive lesions (including DCIS) , indicating that
CA is an early event in tumorigenesis and is involved in the transition from early to advanced
stages of carcinogenesis. Furthermore, one landmark study demonstrated that induction of CA
could initiate tumor formation and metastasis in flies [5]. Multiple studies have reported that
centrosome amplification correlates with high-grade tumors and poor prognosis [16]. In prostate,
head and neck and breast cancers, CA is correlated with the lymph node and distant metastasis.
Thus, it is becoming increasingly understood that rather than serving as a mere beacon of
malignancy, supernumerary centrosomes actually drive malignant transformation. Indeed, several
threads of evidence now suggest the association of CA with more aggressive tumors raising the
possibility that CA could be an evolutionarily-favored trait that confers advantageous
characteristics on the cells that harbor this feature and could promote tumor progression and
aggressiveness. In sum, CA is associated with several indices of aggressiveness, like genomic
instability, cell migration, and metastasis which may indicate the propensity of a tumor to
metastasize, although further study to substantiate this paradigm is required in clinical models with
high rates of metastasis. Thus, testing the role of CA in the underlying aggressive disease course
in one of the highly metastasized and aggressive cancer i.e, Pancreatic adenocarcinoma is the
primary goal of the study described in the second manuscript in this dissertation (Chapter 3).
Furthermore, the role of CA in predicting tumor recurrence has been highlighted in multiple
malignancies such as urothelial cancers and head and neck squamous cell carcinoma (HNSCC)
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highlighting its potential as a biomarker for advanced disease [26]. In HNSCC it has been
observed that tumor margins with higher CA recur more frequently than those with less CA. These
findings are interesting as ideally, the tumor margins should be free of malignant cells but if CA
is observed in the tumor margins that indicates either presence of malignant or potentially
malignant cells harboring CA in these tumor margins. This escape of the premalignant cells from
histological detection may be a potential cause of tumor recurrence. Similarly, a high rate of
recurrence is observed in the ductal carcinoma in situ and due to the lack of accurate recurrence
risk prediction models patients are often under or over treated. Studies have shown that CA is
present in the precancerous and preinvasive lesions of the breast. In addition, genes whose
deregulation has been previously implicated in induction of CA such as Cyclin-d, Aurora-A, Nek2,
and p53 are also deregulated in DCIS. Thus, there is tantalizing possibility that the organellar-level
differences may exist between recurrent and nonrecurrent DCIS. To this end evaluating the role of
CA to predict the risk of LR after lumpectomy (breast conservation surgery) is the primary goal
of the study described in the third manuscript of this dissertation (Chapter 4).

1.3

Drawbacks of current quantitation methods of Centrosome amplification

Although the extent of CA in tumor samples can be readily quantified by using simple
immunohistochemical methods that are clinically adaptable and cost-effective, the quantitative
techniques currently used to measure CA suffer severe drawbacks. Most of the studies have
considered the numerical amplification as a measure of centrosome amplification. Although some
recent studies have highlighted the role of structural amplification and quantitated them using
either volume of gamma-tubulin spots or centriolar length but were not able to show all this in the
human clinical samples. Moreover, the clustered centrosomes have often been misquantified as
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structurally amplified centrosomes. Furthermore, none of the studies have made a clear distinction
regarding the contribution of structural and numerical amplification towards the progression of the
disease in cancer. A rigorous statistical analysis of correlations between clinicopathologic factors
(such as tumor grade, stage, outcome) and CA has not been performed yet. Thus, a true systematic
quantitation technique which includes both structural and numerical amplification is urgently
needed as a foundation for centrosome-based risk assessment in clinical tissue samples. In the
study presented in the third manuscript (Chapter 4) of this dissertation, we have presented a novel
methodology to quantitate both numerical and structural centrosomal aberrations in tumor
samples. Our analytical pipeline allows robust interrogation of the ability of centrosomal overload
to predict the risk of LR after lumpectomy.

1.4

Centrosome clustering and chromosomal instability

Presence of extra centrosomes leads to the formation of the multi-polar mitotic spindles and
ultimately undergoes the mitotic catastrophe. In cancer cells, excess centrosomes cluster into two
polar groups during mitosis, giving rise to pseudo-bipolar spindles which undergoes a transient
multipolar stage. This multipolar intermediate favors the formation of merotelic attachment of
individual kinetochores to more than one spindle pole. Such inappropriate attachments can cause
missegregation of whole chromosomes and/or chromosomal breakage which gives rise to a lagging
chromosome which may result in chromosome missegregation and aneuploidy. The quantity of
microtubules involved in merotelic attachments dictates the behavior of the merotelically attached
chromosome [20]. If the microtubules oriented on the wrong spindle pole are few the chromosome
segregation proceeds without apparent impairment whereas if equal number of microtubules are
attached to the right and wrong spindle poles, the chromosome lags during anaphase due to strong,
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opposite poleward forces, but ultimately it tends to segregate to the right cell as a micronucleus.
Thus, inappropriate attachments cause missegregation of whole chromosomes and/or
chromosomal breakage which gives rise to a lagging chromosome and these chromosomes
becomes trapped in and are either removed from the site or the cleavage furrow regresses resulting
in the polyploidy. [21]. Furthermore, even if the lagging chromosome segregates to the right cell
as a micronucleus, micronuclear DNA replicates aberrantly and asynchronously with primary
nuclear DNA, resulting in rapid accrual of complex, clustered chromosome rearrangements [2225]. Thus, if it is, equi-merotely it results in “all-at-once,” catastrophic mutagenesis, which permits
rapid karyotype evolution and if many microtubules are attached to the wrong pole (multimerotely) [20], results in aneuploidy. Furthermore, clustered supernumerary centrosomes are
inherited by progeny cells, leading to a perpetuation of chromosomal instability (CIN) in the cell
lineage and can promote aggressive disease features [26].
Whether CIN promotes or inhibits tumorigenesis depends on the type of cell (some being
inherently more tolerant of DNA damage and aneuploidy than others), its genetic background (e.g.,
pre-existing p53 mutations), the specific karyotype that is acquired (e.g., gain vs. loss of an
oncogene), and the rate of CIN (with moderate levels tolerated better than extreme levels). It has
been presented in multiple studies that CA induction in mice with the suppressed function of p53
leads to tumorigenesis. Single-cell genome sequencing has revealed that major aneuploid
rearrangements (which can be caused by CA) occur early in breast tumor evolution, followed by
incremental clonal diversification over time [27, 28]. Furthermore, studies have shown that TNBC
the most heterogeneous subtype of breast cancer exhibits highest CA among all subtypes and CA
is associated with poor overall survival in these patients. Intriguingly, high grade serous ovarian
adenocarcinoma shares similar genomic features with triple negative breast cancer (TNBC) as per
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reports from Cancer Genome Atlas (TCGA) Network analysis; in particular, the deregulated
pathways characterizing HGSOC are very similar to those in TNBC [29]. Specifically, the most
common mutations present in both kinds of tumors (HGSOC and TNBC) are of p53 and BRCA1/2.
Given that the BRCA1 and BRCA2 tumor suppressor genes directly preserve genomic stability by
regulating DNA repair, p53-mediated cell cycle checkpoint control as well as centrosome
duplication cycle [30-32]. Mutations in these genes predisposes a cell for the development of CA
leading to CIN. Furthermore, HGSOC tumors frequently overexpress cyclin E and Aurora-A,
resulting in aberrant activation of the centrosome duplication cycle that induces centrosome
amplification (CA), [33-35]. If CA is more extensive in HGSOC, it stands to reason that their cells
may rely more staunchly on clustering molecules, such as KIFC1, for survival; thus, clustering
molecules may be particularly valuable prognostic biomarkers and predictors of response to
declustering drugs in HGSOC patients. Evaluation of KIFC1 as a prognostic biomarker in HGSOC
is the goal of the study described in the fourth manuscript in this dissertation (Chapter 5).

1.5

KIFC1 the centrosome clustering protein is a cancer cell-specific target

KIFC1, also known as HSET, is a nonessential kinesin motor protein, that plays a crucial role in
centrosome clustering in cancer cells [36, 37]. Knockdown of KIFC1 was shown to induce
multipolar spindle defects and cell death in mitotic cancer cell lines containing extra centrosomes
like MDA-MB 231[37] whereas it had no effect on cell division in a variety of control cell lines
like BJ fibroblasts, which virtually exhibits no CA, mouse NIH-3T3 fibroblast sand human breast
MCF-7, which exhibit only low level of CA [37]. Studies have shown that KIFC1 is elevated in
several cancer types [38-41], including, breast, ovarian and colon cancer [42]. Thus, in cancer
cells, the role of KIFC1 becomes indispensable due to the presence of supernumerary centrosomes.
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This differential dependence of cancer cells on KIFC1 for viability makes KIFC1 a cancer-cell
selective therapeutic target for “centrosome-rich” cancers, including those of the breast, prostate,
bladder, colon, and brain. In addition, it has been shown in multiple studies that KIFC1 is
overexpressed in chemoresistant (resistance against tubulin targeted drugs like docetaxel, taxane,
and tamoxifen) breast and prostate cancers and that inhibition of KIFC1 have been seen to increase
the sensitivity of cancer cells to taxanes. Thus, it is reasonable to suspect that KIFC1 might act as
a therapeutic target for the chemoresistant cancers which exhibit high levels of CA. Numerical and
structural CA has been reported in CRCS and researchers have reported CA and chromosomal
instability in several CRC cell lines suggesting a link between CA and CIN in CRCs. In another
study, it was reported that inactivation of p53 in CRC cells HCT116 lead to a 3.5-fold increase in
tetraploidization. Loss or mutation of p53 gene is the most frequent genetic lesion in CRCs and is
the reason behind resistance to 5-fluorouracil, the first-choice chemotherapy drug for CRC. Given
that i) the p53 mutated CRCs exhibit higher levels of CA and ii) the traditional chemotherapies are
not effective it becomes reasonable to state that centrosome declustering drugs might serve as the
novel therapeutic target in this cancer. Thus, studying the role of KIFC1 as a therapeutic target and
the mechanism as in how the expression of KIFC1 is regulated in p53 null/mutant CRCs is the
main goal of the study presented in chapter 6 (manuscript 5) of this dissertation.
1.6

Griseofulvin, a novel KIFC1 inhibitor

Griseofulvin (GF) is an antifungal drug that is known to induce centrosome declustering. Multiple
studies have shown that GF inhibits proliferation of the tumor cells by inducing multipolarity. The
mechanism of action through which GF causes centrosome declustering is not very well
understood. Recently it has been shown that GF works with the similar mechanism of action as
other tubulin interactive agents where they act by binding a specific site of tubulin to inhibit the
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formations of microtubules. The consequent suppression of microtubule dynamics leads to
centrosome declustering, multipolar mitosis, and cell death. Inhibition of centrosome clustering by
suppressing the kinesin KIFC1 selectively kills cancer cells containing extra centrosomes [37, 43].
Several KIFC1 inhibitors - AZ82 [44], CW069 [45, 46], and PJ34 [47, 48]- have been developed
that induce multipolar mitosis, preferentially in cancer cells, in vitro, and in vivo. All these drugs
work through different mechanisms and have shown high levels of toxicity in in vitro and in vivo
models; therefore, they have not paved their way to clinical trials yet. GF [49], has attracted
extensive interest as a potential anticancer agent due to its low toxicity and [50-53] greater
efficiency in inhibiting proliferation of tumor cells. Furthermore, it has been shown aneuploid
CRC cells display higher sensitivity to GF, delay aster formation and microtubular regrowth and
display centrosome declustering. Understanding the mechanisms by which GF acts can pave the
way for rational design and synthesis of more effective and cancer cell specific “kinder and
gentler” chemotherapy, the secondary goal of the study described in the fifth manuscript in this
dissertation (Chapter 6).
1.7

Docetaxel-induced polyploidization underlying drug resistance and disease relapse in
cancer

Drug resistance against tubulin targeted drugs like Docetaxel, taxane and tamoxifen is a major
issue in cancer therapeutics. Though the use of these drugs prolongs overall and progression-free
survival in multiple malignancies their clinical utility is strictly limited due to disease relapse.
Several lines of thought exist to explain the disease relapse after a modest increase in overall
survival and one of the most intriguing mechanisms illustrated in various studies is the formation
of giant multinucleated polyploid (MP) cells after therapeutic intervention with either taxanebased chemotherapy including docetaxel or DNA damaging agents. These polyploid cells can be
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a result of DNA over-replication [54], abrogated mitotic checkpoint [55] or failed cytokinesis
[56]. It was long assumed that these giant polyploid cells do not survive and die due to “mitotic
catastrophe” subsequent to multipolar cell division. But, recent evidence indicated that while most
polyploid cells succumb to cell death, a small percentage of them survive and produce viable
progeny [57, 58]. The mechanism of generation of viable clones from these polyploid cells is
poorly understood. Alos, the knowledge about the characteristics of these polyploid cells which
protects them from chemotherapy and imparts aggressive cellular features is also not sufficient to
design therapies which can help eliminate these giant cells following docetaxel treatment. Thus,
understanding the mechanism of the generation of polyploid cells and their chemoresistance nature
is the primary goal of the study presented in the sixth manuscript in the dissertation (Chapter 7).
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2.1

Abstract
Centrosome amplification (CA) and aberrant mitoses are considered beacons of

malignancy. Cancer cell doubling times in patient tumors are longer than in cultures, but
differences in CA between tumors and cultured cells are uncharacterized. We compare mitoses
and CA in patient tumors, xenografts, and tumor cell lines. We find that mitoses are rare in-patient
tumors compared with xenografts and cell lines. Contrastingly, CA is more extensive in-patient
tumors and xenografts (~35-50% cells) than cell lines (~5-15%), although CA declines in patientderived tumor cells over time. Intratumoral hypoxia may explain elevated CA in vivo because
exposure of cultured cells to hypoxia or mimicking hypoxia pharmacologically or genetically
increases CA, and that HIF-1α induces CA in tumor cells by transcriptionally regulating expression
of centrosome associated protein PLK4. HIF1α and hypoxic gene signature expression correlate
with CA and centrosomal gene signature expression in breast tumors. These results highlight the
importance of utilizing low-passage-number patient-derived cell lines in studying CA to more
faithfully recapitulate in vivo cellular phenotypes.
2.2

Introduction
Cancer has always been reckoned as a mass of abnormal cells growing rapidly in a

deregulated manner. This basic rationale underlies the inception of chemotherapeutic strategies
targeting mitosis and development of antimitotic drugs. Since cancer cells divide at a more rapid
rate than normal cells, disruption of mitosis has been perceived as the most effective and selective
therapeutic strategy against malignant cells. Although mitosis-targeting drugs, such as inhibitors
of Aurora kinases, Polo-like kinases, and Kinesin-spindle protein, have been very successful in
preclinical trials, their poor performance in the clinical setting has raised doubts about the
relevance of this chemotherapeutic strategy.[1] Multiple studies affirm that the rationale
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undergirding the development of mitosis-targeting drugs is flawed as, frequent mitosis is not a
hallmark of human cancers, as previously postulated.[1, 2] In contrast with immortalized cell
cultures and xenograft models, which are most frequently used to assess the efficacy of antimitotic
drugs, human tumors tend to have very low mitotic rates (with the mean mitotic index in many
tumor types being <1%).[2] Furthermore, the mean doubling time of a variety of human tumors is
>100 days, much higher than that of tumors in pre-clinical models. Although recent cell culture
studies have been highly informative, they bear limited conformity with events in vivo. Another
important factor affecting the potential relevance of cell culture data is drug bioavailability. The
drug concentration in the tumor microenvironment varies significantly in vivo, with drug
concentrations rising, peaking, and falling as the drug circulates and then is removed from the
body. In a study evaluating single-cell responses to the antimitotic drug paclitaxel in murine
xenograft tumors as compared with cell culture, mitotic frequency was found to be lower in tumors
than in cell culture.[3] Interestingly, the peak mitotic index in tumors exposed to paclitaxel was
lower and the tumor cells survived longer after mitotic arrest, becoming multinucleated rather than
dying directly from mitotic arrest, as opposed to cell cultures. Thus, the in vivo tumor
microenvironment was found to be far less pro-apoptotic than the environment of cultured cells.
Another cancer cell-specific trait, CA, which refers to the presence of supernumerary or
abnormally large centrosomes,[4, 5] occurs early in pre-cancerous and pre-invasive lesions and is
linked to aggressiveness in several types of cancer. CA is believed to drive tumor progression by
promoting chromosomal instability and the generation of aggressive tumor clones that are more
capable of rapid metastasis. However, the presence of more than two centrosomes within a cell
may result in the formation of multipolar spindles, leading to “mitotic catastrophe”[4] and eventual
cell death. To avoid this, cancer cells cluster supernumerary centrosomes into two polar groups to
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allow formation of a “pseudobipolar” mitotic spindle, a phenomenon that leads to their ultimate
survival.[4-8] Given that cancer cells rely heavily on centrosome clustering mechanisms for
viability, putative centrosome declustering agents have emerged as promising anticancer drugs.[911] [12] Most studies of these drugs rely on cancer cell lines and tumor cell line xenograft models,
yet it is unknown how faithfully they recapitulate the profound CA often observed in patient
tumors or whether there is a potentially superior model.

Herein, we quantified the prevalence of mitoses and CA in patient tumors compared with
tumor cell lines and tumor cell line xenografts. We report that CA, but not mitotic index, is found
at high levels in patient tumors, suggesting that CA may be a more valuable chemotherapeutic
target than mitosis. We also found that CA progressively declines, and mitotic index progressively
increases in culture, suggesting differences exist between the in vivo and in vitro
microenvironments that have important ramifications for experimental design. Most often, cells
cultured in vitro are supplied with copious amounts of oxygen, perhaps to fulfill the metabolic
requirement of the voraciously growing log-phase cancer cells. However, in solid tumors, the
oxygen concentrations in many regions of the tumor may be severely inadequate resulting in a
hypoxic tumor deprived of oxygen.[13] We report here that induction of hypoxia or mimicking
hypoxic conditions induces CA in vitro via HIF-1α and that HIF-1α induces CA in tumor cells by
transcriptionally regulating expression of centrosome associated protein PLK4. Moreover, HIF-1α
expression was found to correlate with CA in breast tumors. Ultimately, our study emphasizes the
limitations of traditional cell culture models for studying CA and highlights the importance of lowpassage patient-derived cell lines as being more representative of the true clinical scenario.
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2.3
2.3.1

Materials and methods
Clinical tissue samples

Formalin-fixed paraffin-embedded slides of breast, pancreatic and bladder cancer tissue were
procured from Northside Hospital and Emory University Hospital, in Atlanta. The Institutional
Review Board of Northside hospital and Emory University approved all aspects of the study. Fresh
tumor samples (samples obtained by partial mastectomy pretreatment) were procured from West
Georgia Hospital, Lagrange under approved protocols. Methods were carried out in accordance
with approved guidelines and informed consent was obtained from all subjects. Descriptive
statistics for patient and clinicopathologic characteristics are provided in Tables 2.3.1-3.

2.3.2 Established tumor cell lines
MDA-MB-231, MIA PaCa-2, T24, CFPAC, CAPAN1, HCT116-p53-/-, HCT116 p53WT, PC3
and DU145 cell lines were obtained from American type cell culture (ATCC) and were grown in
standard conditions. Briefly, grown in Dulbecco's Modified Eagle's medium (DMEM), RPMI or
Hyclones 5A medium as per instructions supplemented with 10% Hyclone fetal bovine serum
(FBS) and 1% penicillin/streptomycin. Cells were maintained in humidified 5% CO2 atmosphere
at 37°C. Patient-derived tumor cell lines: Tumor cells were isolated from a TNBC patient tumor
(partial mastectomy) obtained from West Georgia hospital. To isolate tumor cells for culture, the
tumor tissue was first minced into small pieces and then was digested in a mixture of DMEM/F12
medium containing 2 mg/ml bovine serum albumin, 2 mg/ml collagenase type IV, and 2 mg/ml
hyalurodinase at 37°C for 30-40 min with continuous agitation. After the tumor chunks were
completely digested, cells were filtered through a 70 µm mesh, centrifuged at 2,000 rpm for 10
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minutes, resuspended in fresh DMEM/F12 supplemented with 10% FBS and 1% penicillin, and
plated in 10 mm culture dishes in humidified 5% CO2 atmosphere at 37°C.
2.3.3

Tumor cell line xenografts

All animal experiments were performed in compliance with Institutional Animal Care and Use
Committee guidelines. For implantation into nude mice, MBD-MB-231 cells were washed with
PBS, digested with trypsin, resuspended in DMEM 1X containing 10% FBS, and pooled. After
centrifugation, cells were resuspended in Matrigel (BD Biosciences Discovery Labware, Bedford,
MA)-DMEM 1X (1:3) at a concentration of 1×106 cells/100 μL, 100 μL of which was
subcutaneously implanted into the dorsa of 6-week-old female Bald/nu mice (Harlan SpragueDawley, Indianapolis, IN). Tumor volumes were monitored constantly for 6 weeks, and after that
tumors were excised and fixed in 10% formalin, embedded in paraffin, sectioned at 5 µm, and
immunolabeled for centrosomes (γ-tubulin) and mitotically-active cells (Ph3).
2.3.4

Lysate preparation and immunoblotting

Cells were cultured to ~80% confluence and protein lysates were prepared as described
previously.[39] Briefly cells were scraped with 250ul of 1x lysis prepared from 10x cell lysis
buffer (Cell Signaling). The 1x lysis buffer contained 1 mM b-glycerophosphate, 20 mM Tris–
HCl (pH 7.5), 1 mM Na2EDTA, 1 mM Na3VO4, 150 mM NaCl, 1 mM EGTA, 2.5 mM
Na4P2O7, 1ug/ml leupeptin, and 1 % Triton. 10% Protease inhibitor was added to prevent
degradation of proteins. Cell lysates were fractionated using 10 % SDS-PAGE gel Fresh tissue
sections were sonicated and lysates were then prepared using the same lysis buffer. Polyacrylamide
gel electrophoresis was used to resolve the proteins, which were transferred onto polyvinylidene
fluoride membranes (Millipore). The Pierce ECL chemiluminescence detection kit (Thermo
Scientific) was used to visualize the immune-reactive bands. β-actin was used as loading control.
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2.3.5 Immunohistofluoresence staining
Formalin-fixed paraffin-embedded tissue slides were deparaffinized followed by serial rehydration
in ethanol baths (100%, 95%, 70% and 50%). Antigens were retrieved by heating in a pressure
cooker in citrate buffer (pH 6.0) at psi 15 for 30 min. Blocking was performed by incubating the
slides with the ultra-vision protein block (Life Sciences) for 30 min. Tissue samples were then
incubated overnight with primary mouse antibody against γ-tubulin (Table X) at 1:1000 dilution)
at 4°C, followed by washing 3X with PBS. The samples were then incubated with secondary
antibody (Alexa-488 anti-mouse) at 1:2000 dilution for 2 h, at 37°C followed by washing 3X with
PBS. Finally, coverslips were mounted with Prolong-Gold Antifade Reagent with DAPI
(Invitrogen).
2.3.6

Immunohistochemical staining and scoring

Deparaffinization

and

antigen

retrieval

were

performed

as

described

as

for

immunohistofluoresence staining. Thereafter, the tissues were immunolabeled using antibody
against Ph3 (dilution 1:1000) or HIF-1α (1:1000). Ph3-positive cells were counted in 10 randomly
selected fields (~500 cells) to determine the percentage of mitotic cells. Enzymatic antibody
detection was performed with the Universal LSAB + Kit/HRP (DAKO, CA, USA). HIF-1α
staining intensity was scored as 0=none, 1=low, 2=moderate, or 3=high, and the percentage of
positive cells (i.e., with 1+ staining intensity) from 10 randomly selected fields (~500 cells) was
determined. The product of the staining intensity and the percent of positive cells (nuclei)
constituted the WI.
2.3.7 Immunocytofluorescence staining
Cells were grown on glass coverslips, fixed with ice-cold methanol for 10 min, and then blocked
with 2% bovine serum albumin/1XPBS/0.05% Triton X-100 at 37°C for 1 h. Coverslips were
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incubated in primary antibodies against γ-tubulin and α-tubulin at 1:2000 dilution for 1 h at 37°C,
washed with 2% bovine serum albumin/1XPBS for 10 min at room temperature, and then
incubated in 1:2000 Alexa 488- or 555-conjugated secondary antibodies (Invitrogen; Carlsbad,
CA). Cells were mounted with Prolong Gold Antifade Reagent with DAPI (Invitrogen).
2.3.8 Microscopy
Images of tissue samples were taken utilizing the Zeiss LSC 700 confocal microscope
(Oberkochen, Germany) and were processed with Zen software (Oberkochen, Germany).
Magnifications and more details on imaging is provided in individual sections.
2.3.9

Quantitation of centrosome amplification

Numbers and volumes of γ-tubulin foci were used as indicators of numerical and structural
centrosome amplification, respectively. Since gamma-tubulin is present in both centrioles and the
PCM, above-normal volumes of γ-tubulin foci represent the cumulative structural volume
amplification of both PCM and centrioles. Centrosomal volumes were calculated using the 3D
measurement module from the Zeiss imaging software. Average centrosomal volumes ranged
between 0.22-0.76 μm3 in normal breast, 0.20-0.56 μm3 in normal pancreas, and 0.20-0.74 μm3 in
normal bladder tissue. The percentage of cells with >2 centrosomes as quantitated from 10
randomly selected fields (around 500 cells) in tumor areas pre-marked by a pathologist was
determined for each tissue type as well as cell lines (Supplementary Figure. 2.7.1). CA was
calculated as a percentage by adding the percent cells harboring more than two centrosomes and
the percent cells harboring centrosomes with volume larger than 0.76 µm3, 0.56 µm3 and 0.74 µm3
for breast, pancreatic and bladder tissues respectively. A more detailed description of the
quantitation process along with a schematic is given in the supplementary materials and
Supplementary Figure.1.
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2.3.10 Induction of hypoxia and mimicking hypoxic conditions
Hypoxia chamber: Cells grown on glass coverslips were either placed in a hypoxic modulated
incubator chamber (flushed with 1% O2 gas mixture at 20 L/min for 7-10 minutes every 3-6 hrs)
or a normoxic incubator. After 48 h, cells were trypsinized and lysates were prepared for
immunoblotting assays. To pharmacologically induce hypoxia cells were treated with 100µm of
Cocl2 for 24 hrs. Further to stabilize HIF-1 α in normoxic conditions cells were treated with 1mM
DMOG (SIGMA) for 24 hrs and 5µM MG132 for 5 hrs. Glass coverslips having cells were fixed
with ice cold methanol and staining was performed as described in cell staining section
2.3.11 HIF-1α overexpression
HIF-1α was genetically overexpressed by transfecting cells with GFP-tagged degradation resistant
HIF -1α. HA-HIF-1α P402A/P564A-pcDNA3 was a generous gift from Dr. Willian Kaelin
(Addgene plasmid # 18955).[40] Cells at a confluency of ̴70% were transfected using
Lipofectamine 2000 according to the manufacturer’s instructions.
2.3.12 HIF-1α gene knock out
The gene knockout of HIF-1α was performed using CRISPR/Cas 9 method. Where in, guide RNAs
to target the human HIF-1α gene was designed using the (http://tools.genome-engineering.org)
source. Two individual sgRNAs were designed to target exon 1 of HIF-1α (sgRNA1,
5’CACCGTTTCTTGTCGTTCGCGCCGC3’;

sgRNA2,

5’AAACGCGGCGCGAACGACAAGAAAC 3’). sgRNA-encoding oligonucleotides was cloned
into pSpCas9-2A-GFP (PX458) (a generous gift from Feng Zhang (Addgene plasmid # 48138)
(using standard procedures www.genome-engineering.org)[41]. Transfection of the MDA-MB
231 and MDA-MB 468 cells was performed as described under the section of HIF-1α OE. As a
negative control for the transfection efficiency vector pSpCas9-2A-GFP was used. The
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pSpCas9(BB)-2A-GFP plasmid was GFP tagged hence the sgRNA and Cas9 expressing cells were
sorted using FACS. The sorted GFP positive cells were expanded and the knockout in these cells
was verified by exposing these cells to hypoxia followed by immunoblotting for HIF-1α.
2.3.13 ChIP assay
Briefly, MDA-MB-231 and MDA-MB-468 cells were plated at a density of 2.5 x 106 and were
cultured in hypoxic and normoxic conditions for 48 hrs. Following the hypoxic and normoxic
treatment the cells were crosslinked with 1% formaldehyde; crosslinking was stopped by the
addition of 0.125M glycine. Cells were lysed, and the nuclear fraction will be sonicated to shear
the crosslinked DNA into an average of 500 bp of sheared DNA. Sonicated lysates were run on a
1% agarose gel to ensure proper fragment size. The sonicated lysates were pre-cleared with
salmon-sperm coated agarose beads for an hour at 4o C, followed by washing and lysates were
divided equally. Half of the lysate was Immunoprecipitated (IP) with 5µg of the HIF-1α antibody
and another half of lysates was immunoprecipitated with control (IgG) antibody (function as
nonspecific binding control) and 1% of the lysate was used as input. IP samples were isolated by
Protein A/salmon sperm beads and were washed in increasing salt concentration buffers (low salt,
high salt, LiCl and 1X TE buffers) followed by elution of DNA and reversal of crosslinks
(overnight with 5M NaCl at 65˚C followed by treatment with proteinase K at 45˚C). IP’d DNA
were isolated using phenol: chloroform: isopropanol mix (Invitrogen). Following extraction, qRTPCR amplification was performed on the immunoprecipitated DNA and the total input DNA.
Primers were designed to amplify the region of the PLK4 gene that contained the full promoter
activity as well as the HIF-1α -responsive regions. The values obtained in the qPCR were
normalized to the total amount of DNA put into the reaction (percent input will be used as internal/
positive control).
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2.3.14 PLK4 and VEGF reporter plasmid construction
Genomic DNA will be isolated from the HEK293 (Human Kidney epithelial cells) to serve as
template for the PCR amplification of 1Kb promoter of human PLK4 gene containing HREs. After
PCR cleanup the Promoter was cloned into the pGL4.51 expression vector (which has a luciferase
reporter, cytomegalovirus promoter, and ampicillin resistance gene) (Promega) using standard
subcloning procedure. MAX Efficiency DH5α competent E. coli was transformed with the vector
using heat shock followed by plating on LB agar with 50 µg/ml ampicillin for selection of
transformed clones. The plasmid DNA from individual colonies obtained was purified using a
commercial spin column. Sequencing was performed to confirm the clones containing PLK4 insert
with the correct promoter sequence cloned in the proper orientation, which was then be used for
transfections. Similarly, VEGF reporter plasmid was constructed.
2.3.15 Dual luciferase assay
For PLK4 reporter assays, cells were transfected with 500 ng of PLK4 reporter plasmids with 500
ng pRL-TK plasmids. As a positive control another culture of cells was transfected with VEGF
reporter plasmids with the pRL- TK plasmid. Lipofectamine 2000 (Invitrogen) was used as a
transfection reagent. For each transfection, plasmids were premixed with the transfection reagent.
Twenty-four hours after transfection, the cells were transferred to a hypoxia chamber (1% O2) or
maintained in normoxia (20% O2). After 48 hours, the cells were harvested, and a Dual Luciferase
reporter assay system (Promega) was used for sequential measurements of firefly and Renilla
luciferase activities). Firefly luciferase activity was normalized to the Renilla luciferase activity.
Each sample was analyzed in quadruplicates, and each transfection was repeated three times.
Quantification of luciferase activities and calculation of relative ratios was carried out using a
luminometer (TD-20/20; Turner Designs, Sunnyvale, CA, USA).
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2.3.16 Statistical analyses
Unless otherwise stated in the methods and results sections, statistical analyses were performed
using two-tailed Student’s t-tests. The criterion for statistical significance for all analyses was
p<0.05. Survival analysis (simple Cox model) was performed using SPSS Statistics version
21(IBM).

2.4

Results

2.4.1 Mitotic index is lower in-patient tumors than tumor cell lines and xenografts
To corroborate the view that tumor cells in patients’ bodies are not as mitotically active as
cancer cells in vitro, we first compared the mitotic indices of patient tumors and established tumor
cell lines from different tissue types, including breast, pancreas and bladder. To this end, we
quantitated phosphohistone H3 (Ph3)-positive (i.e., mitotic) cells microscopically in 20 paraffinembedded patient tumor samples (surgical resection) for each cancer type as well as their
representative established tumor cell lines. In addition, breast tumor cell line xenografts were
analyzed. Descriptive statistics regarding patient and clinicopathologic characteristics for tumor
samples utilized are given in Tables 2.4.1, 2.4.2 and 2.3.3. Mitotic indices were approximately 7fold, 3-fold, and 8-fold higher in MDA-MB-231 breast cancer cells, MIA PaCa-2 pancreatic cancer
cells, and T24 bladder cancer cells compared with patient tumors of the respective cancer types.
By contrast, mitotic indices were similar between MDA-MB-231 xenografts and cell cultures
(Figure. 2.4.1A, B). These studies suggest that established tumor cell lines, whether in cultures or
xenografted in nude mice, display higher mitotic indices than patient tumors.
Table 2.4.1 Descriptive statistics for patient and clinicopathologic characteristics in the
analysis of centrosome amplification and mitotic index in breast tumors.
Variable
Level
Number
Percentage
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Race

AA
EA

4
16

20
80

Gender

Male
Female

0
20

0
100

1
2
3

9
5
6

45
25
30

I
II
III
IV

10
7
1
2

50
35
5
10

ER-/PRER-/PR+
ER+/PR+

8
1
11

40
5
55

0

0

7
13

35
65

8
12

40
60

Grade

Stage

ER/PR Expression

CA (%)

Mitotic Index

Low (<10%)
Moderate
(10-40%)
High (>40%)
<1
1~6

ER: Estrogen Receptor; PR: Progesterone Receptor; CA: Centrosome Amplification; AA: African
American; EA: European American

Table 2.4.2Descriptive statistics for patient and clinicopathologic characteristics in the
analysis of centrosome amplification and mitotic index in bladder tumors.
Variable

Level

Number

Percentage

Race

AA

13

65

EA

7

35

1

7

35

2

0

0

3

13

65

Grade
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Invasive
Status

CA (%)

Mitotic

Non-invasive

7

35

Invasive

13

65

Low (<10%)

0

0

Moderate (10-40%)

11

55

High (>40%)

9

45

<1

18

90

Index

1-6
2
10
CA: Centrosome Amplification; AA: African American; EA: European American
Table 2.4.3Descriptive statistics for patient and clinicopathologic characteristics in the
analysis of centrosome amplification and mitotic index in pancreatic tumors.
Variable
Level
Number
Percentage
AA
9
45
Race
EA
11
55
Gender

Male
Female

11
9

55
45

≤2
>2

3
17

15
85

Grade

Low
High

10
10

50
50

PNI

Yes
No

17
3

85
15

LVI

Yes
No

15
5

75
25

Stage T

1
2
3

2
2
16

10
10
80

Stage N

1
0
Unknown

15
4
1

75
20
5

Stage M

Yes
No
Unknown

19
0
1

95
0
5

Tumor
(cm)

size

30

LN Positive

CA (%)

≤5
>5
Low (<10%)
Moderate
(10-40%)
High (>40%)
<1

15
5

75
25

0

0

14
6

70
30

5

25

Mitotic Index
(MI)

1-6
9
45
>6
6
30
CA: Centrosome Amplification; AA: African American; EA: European American; PNI: PeriNeural Invasion; LVI: Lympho-Vascular Invasion
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Figure 2.4.1 Human tumors display lower mitotic indices than tumor cell lines and
xenografts.
A. Representative immunofluorescent confocal micrographs of tumor cell lines labeled for the
mitotic marker phosphohistone H3 (Ph3). Red arrows: Ph3-positive cells. Scale bar (white), 5µm.
Bi, Bii. Representative immunohistochemical micrographs of a patient breast tumor and an MDAMB-231 xenograft labeled for Ph3. Red arrows: Ph3-positive cells. Scale bar (red), 20 µm C.
Mitotic indices in patient tumors, tumor cell lines, and MDA-MB-231 xenografts. *p<0.05,
**p<0.01.
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2.4.2 CA is higher in-patient tumors and xenografts than tumor cell lines
Having established the low frequency of mitoses in various patient tumor types, we next
compared the extent of CA between patient tumor samples and respective tumor cell lines for each
cancer type. Breast tumor cell line xenografts were also analyzed. To accomplish this, we
microscopically visualized centrosomes in 20 cases for each tissue type along with the specific
cell lines. Centrosomes were immunofluorescently stained with anti-gamma tubulin antibody and
co-stained with DAPI. Basically, CA can be of two types- numerical and structural. Numerical
amplification can arise from several processes but the main mechanism underlying this phenotype
is deregulation of the centrosome duplication cycle, which leads to centriole overduplication and
formation of supernumerary centrosomes. Another cause of numerical amplification is failure of
cytokinesis, owing to which polyploid cells with supernumerary centrosomes are generated. On
occasion,

numerical

amplification

arises

from

fragmentation

of

the

pericentriolar

matrix.[14]Similarly several factors account for structural defects which includes accumulation of
excessive PCM around the centrioles (likely due to deregulated expression of genes coding for
centrosomal components or altered posttranslational modifications), resulting in centrosomes that
appear altered in size[15]. Another possible reason for structural aberration can be tight clustering
of centrosomes, which thus cannot be individually distinguished. Third possible reason for this
can be structural defects in centrioles; this is a completely unexplored area because the size of
normal centriole is very small and requires very sophisticated microscopy techniques especially
for tumor samples[4].
In light of the numerous challenges mentioned above, we used the volumes of the gammatubulin foci as indicators of structural centrosome aberration/amplification. While pancreatic,
bladder, and breast tumors exhibited 35%, 36%, and 50% CA, respectively, their corresponding
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cultured cell lines exhibited 15%, 10% and 23% CA, respectively (Figure. 2.4.2 A, B). Centrosome
clustering was extensive among patient tumors with CA (see inset, Figure. 2.4.2 Ai). Next, we
determined whether CA in the MDA-MB-231 cell lines persists following subcutaneous
implantation into nude mice. Remarkably, CA in tumor xenografts excised at the end of six weeks
was nearly double that of the native MDA-MB-231 cell line, similar to the level of CA found in
patient breast tumors (Figure. 2.4.2 B). Taken together, these studies clearly demonstrate a high
prevalence of CA in human tumors and MDA-MB-231 xenografts but not in cultured tumor cell
lines and suggest that differences between the in vivo tumor microenvironment and culture plate
are at least partly responsible for this observation.
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Figure 2.4.2 Human tumors have high centrosome amplification compared to cultured
cells.
A) i. Bladder, pancreatic, and breast tumors along with normal adjacent tissue immunostained for
centrosomes (γ-tubulin, green) and counterstained with DAPI (blue). Yellow arrows, numerical
centrosome amplification; red arrows, structural centrosome amplification. Scale bar (red), 20 µm.
Aii. Confocal micrographs of centrosome amplification and clustering in various tumor cell lines.
Centrosomes and microtubules were immunolabeled for γ-tubulin (green) and α-tubulin (red),
respectively, and DNA was counterstained with DAPI (blue). Scale bar (white) 5 µm. Aiii.
Confocal micrographs of centrosome amplification and clustering in MDA-MB-231 xenografts.
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Scale bar (red), 20 µm. B. Quantitation of centrosome amplification in human tumors, tumor cell
lines, and tumor cell line xenografts. 500 cells were counted in each case. *p<0.05, **p<0.01.
2.4.3

CA and mitotic index in patient-derived tumor cells change differently with passaging

Our observations of the vast disparity in the degree of CA observed in patient tumors and cultured
tumor cell lines cast doubt on the clinical relevance of tumor cell lines that are extensively utilized
for studying CA. We thus reasoned that patient-derived tumor cell lines at a low passage number
may mimic the cellular traits observed in tumor tissues and can emerge as a more useful
representative model to conduct in vitro studies. We thus examined the degree of CA in patientderived tumor cell lines by isolating tumor cells from a triple-negative breast cancer (TNBC) and
quantitating CA with passaging. CA in the original tumor sample was ~45% (Figure. 2.4.3 A, Bi).
Intriguingly, when tumor cells were dissociated from the tumor mass and cultured, CA
progressively declined after passage 2. Passage 3 cells showed a significant 3-fold reduction in CA
compared with passage 2 cells (Figure. 3Bi), and by passage 5 the degree of CA fell to ~10%, a
level that and was sustained through passage 10 (Figure. 2.4.3A, B). We also observed extensive
centrosome clustering in cells from passages 2 and 3 as well as in the original tumor tissue (Figure.
2.4.3A, inset). Taken together, our data underscore the higher concordance of centrosomal traits
between low passage number (passage 2-3) patient-derived tumor cells and cells found in patient
tumor tissues and xenografts.
In addition, we assessed the change in mitotic index in patient-derived tumor cells with
passaging, which differed remarkably from our observations of CA with passaging. The mitotic
index did not change significantly until passage 10, at which time it was ~3-fold higher than in the
original tumor (Figure. 2.4.3Bii). Taken together, these experiments reveal striking differences in
the pace and direction of changes in CA and mitotic index from intratumoral values in patient-
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derived tumor cells in culture, suggesting that centrosome homeostasis and mitosis are
differentially impacted by differences in the in vivo and in vitro microenvironments.

Figure 2.4.3 Centrosome amplification and mitotic index in patient tumors and patientderived tumor cells with passaging.
A. Confocal micrographs of centrosome amplification and mitotic figures in the original patient
tumor and cells isolated from the tumor and cultured through passage 10 (P10). Insets: centrosome
amplification and clustering. Scale bar, 5 µm. Bi. Quantitation of centrosome amplification at
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various passage numbers compared with the original tumor. * and # indicate that CA is
significantly higher in the original tumor and P2, respectively, when compared with P3, P5, P8
and P10 (p<0.05). Bii. Mitotic index at various passage numbers compared with the original tumor.

2.4.4

Hypoxia enhances CA via HIF-1α in cultured cells

Given that a hypoxic microenvironment is one of the major potential differences between tumor
cells in vitro and in vivo, we rationally hypothesized that hypoxia could underlie the divergence
in CA observed in vivo, both in patient tumors and MDA-MB-231 xenografts (which have been
shown to be hypoxic[16]), and established tumor cell lines grown in vitro, where oxygen is
abundant. To test this hypothesis, we exposed MDA-MB-231 and MDA-MB-468 breast cancer
cells to hypoxia for 48 h using a hypoxic chamber flushed with a 1% O2 gas mixture. The presence
of hypoxia was confirmed by upregulation of HIF-1α (Figure. 2.4.4B). As shown in Figure. 2.4.4,
cells grown in hypoxic conditions for 48 h showed numerical CA, with both clustered and
dispersed centrosomes, as well as structural CA, with enlarged γ-tubulin foci (representing
individual centrosomes with excessive γ-tubulin accumulation named as PCM accumulation see
representative images in Figure. 2.4.4A). Following hypoxia, upregulation of proteins whose
overexpression drives CA (Cyclin E, Aurora A, and PLK4) and centrosome structural proteins
(pericentrin and γ-tubulin) was observed (Figure. 4B, with additional data and description provided
in Supplementary Figure. 2.4.4C), along with a significant ~1.5-fold increase in CA (Figure.
2.4.4C). Moreover, the average centrosomal volume in cells grown under hypoxic conditions was
nearly double the volume in cells grown under normoxic conditions (Figure. 2.4.4D). These results
suggest that the presence of hypoxia in patients’ tumors could explain, at least in part, the vast
differences in CA observed in vivo and in vitro.
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Figure 2.4.4 Hypoxia enhances centrosome amplification.
A. Confocal micrographs of centrosome amplification in MDA-MB-231 cells after 48 h of hypoxia
(Hx) or normoxia (Nx). Both numerical centrosome amplification (with centrosomes dispersed or
clustered) and structural centrosome amplification (“PCM,” indicating abnormally large individual
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γ-tubulin foci) were observed. Scale bar, 5 µm. B. Immunoblots of the hypoxia marker HIF1-α,
proteins whose overexpression drives centrosome amplification (PLK4, Cyclin E, and Aurora A),
and centrosome structural proteins (pericentrin and γ-tubulin) in MDA-MB-231 cells exposed to
24 and 48 h of hypoxia (Hx). C. Quantitation of centrosome amplification in MDA-MB-231 48 h
after hypoxia. Scale bar, 5 µm. D. Average centrosomal volumes in normoxic (Hx) and hypoxic
(Hx) MDA-MB-231 cells. *p<0.05, **p<0.001.
2.4.5 Mimicking hypoxia through pharmacologic and genetic methods enhances centrosome
amplification
To bolster the findings of our hypoxia chamber experiments, we also mimicked hypoxic conditions
in normoxia using pharmacologic and genetic methods in MDA-MB-231 and MDA-MB-468 cells.
Hypoxia upregulates transcription factor hypoxia inducible factor 1 which undergoes proteasomal
degradation in normoxic conditions. [17-19] So, to stabilize HIF-1α in normoxic conditions we
treated the cells with CoCl2, a HIF-1α-stabilizer,[20] which resulted in a ~1.5 fold increase in the
CA compared with untreated cells (Fig 2.3.5A, E and Supplementary Figure. 2.7.2A1), similar to
what we found in the hypoxia chamber experiments. To further characterize the observed
centrosomal abnormalities, we co-immunolabeled γ-tubulin and centrin-2 (a centriolar marker)
and performed the quantitation as described in Supplementary Figure. 2.7.3A-C. We found that γtubulin foci invariably overlapped with centrin-2 foci in both CoCl2-treated and untreated cells,
suggesting that the supernumerary γ-tubulin foci observed represent bona fide centrosomes and
not mere fragments of pericentriolar material. Moreover, we failed to observe supernumerary
centrin-2 foci in enlarged γ-tubulin foci, suggesting that the enlarged γ-tubulin foci represent
structurally augmented centrosomes and not supernumerary centrosomes so tightly clustered as to
be indistinguishable. The increased CA in CoCl2-treated cells was substantiated by protein
immunoblotting, which revealed increases in centrosome structural proteins as well as proteins
whose overexpression drives centrosome amplification compared with untreated cells (Figure.

1

All supplemental data, tables, and figures appear in Appendix A for this chapter
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2.4.5B, with additional data and original blots provided in Supplementary Figure. 2.7.4). We next
treated the cells with dimethyloxalylglycine (DMOG), which stabilizes HIF-1α in normoxic
conditions[21], and MG132, which inhibits 26S proteasomal degradation of HIF-1α[22].
Treatment with either DMOG or MG132 treatment increased CA nearly ~1.5-fold (data shown in
Supplementary Figure. 2.7.6C), in alignment with our other observations. We confirmed the
increase in CA by protein immunoblotting (Supplementary Figure. 2.7.6B).
Next to confirm that the increase in CA under hypoxia was due to HIF-1α we overexpressed
HIF-1α by transfecting cells cultured under normoxic conditions with GFP-tagged degradationresistant HIF-1α. Transfected cells showed higher CA (~28%) under normoxic conditions than
vector controls (~21%) (Supplementary Figure. 6A) and increase in CA was further confirmed
with protein immunoblotting (Figure. 2.4.5C). We also knocked-out HIF-1α gene using
CRISPR/CAS9 method (details in methods) and exposed these transfected cells to hypoxic
conditions and found that levels of centrosomal proteins and proteins whose overexpression drives
CA were lower than in vector controls (Figure. 2.4.4D and original blots shown in Supplementary
Figure.2.7.5). In addition, cells transfected with vector control showed higher CA (~21%)
(representative images Supplementary Figure. 2.7.6A) than HIF-1α knocked out cells, indicating
that hypoxia induces CA via HIF-1α. Collectively, these experiments substantiate the paradigm
that hypoxic conditions in the tumor microenvironment may account for differences in CA
observed between patient tumors/ tumor cell line xenografts and established tumor cell lines.
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Figure 2.4.5 Mimicking hypoxia through pharmacologic and genetic methods enhances
centrosome amplification.
A. Confocal micrographs of centrosome amplification (numerical, including dispersed and
clustered configurations, and structural) in MDA-MB-231 cells in control conditions (top panel)
and after 24 h CoCl2 treatment (bottom panel). Scale bar, 5 µm. B. Immunoblots of HIF-1α and
centrosomal proteins in control and CoCl2-treated MDA-MB-231 and MDA-MB-468 cells. C.
Immunoblots of HIF1α and centrosomal proteins in MDA-MB-231 and MDA-MB-468 transfected
with empty vector or degradation-resistant HIF-1α. D. Immunoblots of HIF-1α and centrosomal
proteins in MDA-MB-231 and MDA-MB-468 transfected with Cas9-sgRNA (HIF-1α) construct
or control vector (pSpCas9-2A-GFP). E. Quantitation of numerical (including dispersed and
clustered configurations) and structural (“PCM”) centrosome amplification per microscopic
examination for Cocl2 treated and untreated MDA-MB-231 and MDA-MB-468 cells.

2.4.6 Hypoxia is associated with CA in breast tumors
We next examined the relationship between HIF-1α levels and CA in breast cancer
samples. To this end, we first immunohistochemically labeled 24 breast cancer and uninvolved
adjacent normal tissue samples (samples obtained by partial mastectomy pretreatment) for HIF-1α
and calculated weighted indices (WIs) for nuclear HIF-1α. Adjacent serial sections from the same
tumors were also immunofluorescently labeled for γ-tubulin (Figure. 2.4.6A, B). CA was
calculated as described in the Supplementary Figure. 2.7.1. Descriptive statistics of patient and
clinicopathological characteristics, CA levels, and biomarker WIs are given in Table 2.4.4. HIF1α WI was higher in the tumor areas when compared with adjacent normal tissue. In addition, a
strong positive correlation between nuclear HIF-1α WI and CA was found in breast tumor samples
(Spearman’s rho p=0.722, p<0.001).

In addition, we found that higher nuclear HIF-1α was associated with worse overall
survival (p=0.041; HR=1.03). We also compared the expression levels of HIF-1α and centrosome
structural proteins (γ-tubulin and pericentrin) in fresh frozen clinical samples and uninvolved
adjacent tissue from a pair of patients, one with TNBC and the other with non-TNBC.
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Immunoblots showed higher expression of HIF1- α and centrosomal proteins in both tumor types
in comparison with their normal adjacent tissues (Figure. 2.4.6). Finally, using public microarray
datasets, we investigated whether centrosomal gene expression is enriched in breast tumors
characterized by a hypoxic gene expression signature. We found that breast tumors with high
expression of hypoxia-associated genes exhibited higher expression of centrosomal genes than
breast tumors with low expression of hypoxia-associated genes regardless of mitotic index (which
could otherwise confound analyses given that centrosomal genes are upregulated in mitosis)
(Supplementary Figure. 2.7.7 and Supplementary Tables 2.7.1-5). Furthermore, a score based on
the top 10 overexpressed centrosomal genes in breast tumors characterized by high levels of
hypoxia-associated genes predicted worse distant metastasis-free survival in 94 node-negative
breast cancer patients in multivariable analysis adjusting for various possible confounders
(HR=3.39, p=0.011), whereas a hypoxia score previously shown to have prognostic ability in
multiple cancers[23, 24] was non-significant in this full model (see Supplementary text and
Supplementary Figure. 2.7.7 for more details). Together with our in vitro findings, these clinical
data analyses support the hypothesis that hypoxia/HIF-1α drive CA in patient breast tumors and
contribute to poor outcomes, such as distant metastasis.
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Figure 2.4.6 Higher HIF-1α expression is associated with higher CA.
A. Representative immunohistochemical micrographs of human breast tumors stained for HIF-1α.
Green arrows indicate HIF-1α-positive cells. Scale bar (red), 20 µm. B. Breast tumors along with
normal adjacent tissue were immunostained for γ-tubulin (green), and DAPI-stained (blue) to
visualize centrosomes, and DNA. C. Immunoblots showing the levels of hypoxia and centrosomal
markers in patient tumor samples (T) and their adjacent normal (N) tissues.

Table 2.4.4 Descriptive statistics for patient and clinicopathologic characteristics in the
analysis of centrosome amplification and HIF-1α in breast tumors.
Percentag
Variable
Level
Number
e
Race

EA
AA

Grade

4
1
0

1
2
3

Stage

1

I
II
III
IV
N/A

1
3
2
0
1
0
8
2
1
2

58%
42%
4%
13%
83%

42%
33%
8%
4%
8%
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ER/PR/HER2
Expression
CA%

ER-/PR-/HER2Low (<10%)
Moderate (10%40%)
High (>40%)

2
4

100%

5
1

21%

3

13%

6

67%

2.4.7 Hypoxia induces CA via HIF-1α in multiple cancer cells
Furthermore, we wanted to explore if the association of hypoxia with CA was true for all cancers
(prostate, pancreatic and colorectal) or was specific for the breast cancer cells. Therefore, we
mimicked hypoxic conditions in normoxia using pharmacologic and genetic methods in prostate
cancer (PC3 and DU145), pancreatic cancer (CFPAC and CAPAN1) and colorectal cancer
(HCT116 p53-/- and HCT116 p53WT) cells. We observed that the stabilization HIF-1α in
normoxic conditions resulted in an increase in the CA in all cells compared with untreated cells
(Fig 2.4.7) and increase in CA was further confirmed with immunoblotting.

Next, we

overexpressed HIF-1α by transfecting cells cultured under normoxic conditions with GFP-tagged
degradation-resistant HIF-1α. All the transfected cells showed higher CA under normoxic
conditions than the corresponding vector controls (Figure. 2.4.7 and 2.4.8B) and increase in CA
was further confirmed with protein immunoblotting (Figure. 2.4.8A). Collectively, these
experiments substantiate the paradigm that hypoxic conditions in the tumor microenvironment
may enhance the CA observed in the tumor cells.
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Figure 2.4.7 Mimicking hypoxia through pharmacologic and genetic methods enhances
centrosome amplification-representative confocal micrographs.
Confocal micrographs of centrosome amplification (numerical and structural) in CAPAN-1,
CFPAC, DU145, PC3, HCT116 p53-/- and HCT116 WT cells in control conditions and after 24 h
CoCl2 treatment. Scale bar, 5 µm.
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Figure 2.4.8 Mimicking hypoxia through pharmacologic and genetic methods enhances
centrosome amplification- Immunoblots of HIF1α and centrosomal proteins and
quantitation of CA
A)Immunoblots of HIF1α and centrosomal proteins in CAPAN-1, CFPAC, DU145, PC3, HCT116
p53-/- and HCT116 WT cells transfected with empty vector or degradation-resistant HIF-1α. B)
Immunoblots of HIF-1α and centrosomal proteins in control and CoCl2-treated CAPAN-1,
CFPAC, DU145, PC3, HCT116 p53-/- and HCT116 WT cells. C) Bar graph representing the
quantitation of numerical (including dispersed and clustered configurations) and structural
(“PCM”) centrosome amplification per microscopic examination for Cocl2 treated and untreated
CAPAN-1, CFPAC, DU145, PC3, HCT116 p53-/- and HCT116 WT cells.
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2.4.8

HIF-1α induces CA in tumor cells via transcriptionally regulating expression of PLK4

Given that the expression of centrosome-associated protein PLK4 increased with stabilization of
HIF-1α and that the literature evidence support the hypoxia-mediated overexpression of PLK4, we
suspected that HIF-1α might transcriptionally regulate expression of PLK4. To this end, first, we
performed ChIP assay to confirm if the HIF1α binds to HIF-1α-responsive elements (HREs) that
are present in the promoter region of PLK4 genes to regulate their transcription. Our results from
Chip indicated HIF-1α interaction, with the HRE motif from genomic DNA of MDA-MB 231 and
MDA-MB-468 cells under hypoxic conditions, was significantly (p=0.04) higher when compared
with the cells cultured under normoxic conditions (Figure 2.4.9 A-D).
Next, we performed luciferase reporter assay to confirm the role of the HIF-1α in transcriptional
regulation of PLK4. One representative cell line from each cancer type was co-transfected with
Plk4 reporter plasmid and pRL- TK plasmid. As a positive control, another culture of cells was
transfected with VEGF reporter plasmid AND pRL- TK plasmid. The transfected cells were
exposed to hypoxia or normoxia and after 48hrs the relative firefly luciferase activity was
measured (normalized to Renilla luciferase activity). Our results indicated that RLU activity for
the cells cultured under hypoxia for both PLK4 and VEGF reporters was significantly higher
(p<0.05) when compared to the cells cultured under normoxic conditions (Figure 2.4.9 E and F).
There was  3-fold increase in relative luciferase activity of all the cell lines for both Plk4 plasmid
and VEGF. Thus, the results clearly suggest that HIF-1α transcriptionally regulate expression of
Plk4.
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Figure 2.4.9 HIF-1 transcriptionally regulates expression of PLK4.
A) Bar graphs representing the binding of HIF-1 at the PLK4 promoter in MDA-MB-468 cells.
B) Bar graphs representing the binding of HIF-1 at the GAPDH promoter in MDA-MB-468 cells.
C) Bar graphs representing the binding of HIF-1 at the PLK4 promoter in MDA-MB-231 cells.
D) Bar graphs representing the binding of HIF-1 at the PLK4 promoter in MDA-MB-231 cells.
E) Bar graph representing the relative luciferase activity at PLK4 promoter in normoxic and
hypoxic conditions for MDA-MB-231, HCT116 p53-/-, CFPAC and PC3 cells. F) Bar graph
representing the relative luciferase activity at VEGF promoter in normoxic and hypoxic conditions
for MDA-MB-231, HCT116 p53-/-, CFPAC and PC3 cells. * represents p <0.05.

2.5

Discussion

While mitosis-targeting drugs have shown remarkable success in immortalized cell lines and tumor
xenografts, they have failed to deliver their efficacy in human trials. Our current study provides a
rigorous, systematic analysis of the relationship between a universal prognostic factor (mitotic
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index) and a well-known cancer-cell specific trait and a potential prognosticator (CA) in a
spectrum of model systems ranging from cultured cells, preclinical tumor xenografts, patientderived primary cultures and patient tumors. Our data reconfirm that rapid cell division is not as
predominant a trait of human tumors as it is of immortalized cell lines and tumor cell line
xenografts. Since preclinical drug development experiments with antimitotic drugs are most often
performed using immortalized cell lines or xenograft models, a large fraction of cells in these
systems are vulnerable to antimitotic therapy. Therefore, it is not surprising that in human tumors
where the fraction of the mitotically active cells is very low, only a small, insignificant fraction of
cells are vulnerable to antimitotic drugs. In addition, many studies have shown that the median
doubling times for many human tumors are on the order of months or even years, versus only hours
or days for immortalized cell lines and tumor xenografts.[1, 25] The rapid doubling rate of tumors
in preclinical models also explain why antimitotic agents prove very effective in these models but
fail to show much efficacy against patient tumors. Thus, the lack of response of patient tumors to
antimitotic drugs is due to the relative rarity of mitoses and slow doubling rate as highlighted by
our study.

While human cancers including colon, breast, bladder, prostate, gliomas, and pancreas
show profound CA,[26] we found immortalized cell lines are characterized by a much milder
extent of this cell biological trait. The poor concordance between the extent of CA in tumors and
cells in vitro can thus restrict the utility of cultured cells for studying CA mechanisms in vitro as
well as for exploring the potential and promise of CA as a therapeutic target or prognostic
biomarker. We reason that cancer cells seeking to adapt to and thrive in the tumor
microenvironments encounter diverse selection pressures during tumor progression, such as
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varying levels of oxygen. CA drives chromosomal instability[27] and thereby generates karyotypic
diversity, a trait that is highly desirable for tumors seeking a survival advantage; beyond a certain
point however, chromosome instability itself may become a selection pressure that jeopardizes the
viability of cancer cells, which may not be able to maintain a chromosomal composition necessary
for optimal cell growth. It is likely that in continuous cultures, the diminution of CA is due to cells
having achieved a karyotypic composition wherein the persistence of amplified centrosomes could
potentially have deleterious effects. When such a state is attained, CA may itself serve as a
selection pressure, thus explaining the attenuation in the extent of amplification in cultured cells
compared to human tumors.

Based on our findings, it seems possible that CA could be a superior target to mitosis, an
infrequent event in patient tumors, since a third to half of cells in patient tumors exhibit CA
(Figure. 2). Immortalized cell lines, on the other hand, display a much lower degree of CA. This
discordance can in part be explained by the presence of hypoxia in the microenvironment of the
tumor, which is usually absent in vitro. In addition, cells are usually cultured in vitro with excessive
glucose and growth factors compared with the tumor microenvironment, which helps cultured cells
to grow rapidly and thus be more sensitive to antimitotic drugs. Cancer cells dwell within a
complex milieu of normal cells, blood vessels, endogenous small molecules, and secreted factors,
which together comprise the tumor microenvironment. Hypoxia is one of the hallmarks of the
tumor microenvironment, which is critically essential for cancer initiation, progression, metastasis,
and drug resistance.[28, 29] Indeed a major detriment of using cell lines is that the vital interaction
of tumor cells with their microenvironment is inherently omitted. Thus, when cancer cells are
grown in culture dishes in a two-dimensional plane, the oxygen levels between cells stay relatively
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equal, which is an improbable setting within a growing three-dimensional tumor in a patient’s
body. Moreover, the artificial, non-physiological environment in which cells in laboratory cultures
are sustained fails to recapitulate the complex three-dimensional cellular interactions that exist in
vivo. Another major inadequacy of cell culture is its inability to model the effects of physiologic
responses to a tumor, such as the immune response and angiogenesis, two factors known to
strongly influence tumor development.[30] Altogether, our study underscores the remarkable
disparity in CA and mitosis between patient tumors and model systems, which must be carefully
considered when designing experiments to study these phenomena.

Reports indicate that hypoxia, which is known to induce overexpression of HIF1-α,
increases Aurora A/STK15 protein levels, which has been well documented to induce CA.[31-33]
Our study demonstrates that cells grown under hypoxic conditions exhibit higher CA, Aurora A
and PLK4 levels compared with cells grown under normoxic conditions. Although it is possible
that hypoxia may favor the proliferation or survival of cancer cells with extra centrosomes and
therefore favor the maintenance of CA in the population, our results support the notion that hypoxia
induces CA perhaps via promoting overexpression of proteins such as PLK4. Our findings clearly
suggest that HIF-1 directly regulates expression of PLK4 and increase in PLK4 levels in response
to hypoxia results in higher CA in various cancer cells. Based on our studies, we speculate that
hypoxia enhances the metastatic potential of cancer cells by inducing CA through upregulation of
proteins such as Aurora A, PLK4, and Cyclin E, although a more comprehensive study is needed
to investigate this tantalizing research question. Many studies have demonstrated that hypoxia is
associated with an increased capacity for metastasis.[34, 35] We[36] and others[8, 37] have shown

53

that supernumerary centrosomes confer cytoskeletal advantages on the cells that harbor them; this
could increase directional migration and invasiveness and thus enhance metastatic potential.

While these preclinical models (both established tumor cell lines and tumor cell line
xenografts) are far from ideal, they have been widely used given that the rapid doubling times in
such models permit a fast-tracked drug-development timeline. Nonetheless, this perceived
advantage rather puts us at a loss when the doubling time itself is in the spotlight and the drug’s
activity relies on the preponderance of the mitotic population, which hinges on doubling rate. The
brisk doubling times of the preclinical models explain why drugs targeting mitosis proved active
in these models but were ineffective against patient tumors.[1, 2, 25] Our study highlights the
importance of low-passage patient-derived cell line systems as being most representative of the
clinical scenario and thus constituting an invaluable experimental model that could better guide
drug development and clinical trial design.
Centrosome amplification is now well established as a hallmark of cancer. However, the
presence of more than two centrosomes within a cell can be problematic as it may lead to formation
of multipolar spindles leading to “mitotic catastrophe”[4] and cell death. To avoid multipolar
spindle formation and subsequent mitotic catastrophe, cancer cells cluster supernumerary
centrosomes into two polar groups to allow formation of a “pseudobipolar” mitotic spindle and
produce viable daughter cells.[6, 38] Since our study clearly demonstrates that human tumors
display a high frequency of CA, inhibition of centrosome clustering could have afflicted tumor
cells to succumb to mitotic catastrophe and be eliminated. Given that cells with CA are suspected
to have metastatic potential, antagonizing centrosome clustering could prove to be a strategy to
suppress metastasis. Recently, many drugs have been shown to have centrosome declustering,
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including griseofulvin, noscapine and several of its derivatives (e.g., bromonoscapine and reduced
bromonoscapine), the PARP inhibitor PJ-34, and HSET inhibitors like AZ82 and CW069.[9-12]
To discern meaningful activity of these drugs before they are tested in clinical trials as potential
centrosome declustering dugs, it is imperative that we consider the shortcomings of our existent
cell line models and rather develop robust and relevant preclinical models that mimic cellular traits
observed in patient tumors. Our study clearly shows that established tumor cell lines exhibit lower
CA than patient tumors and thus may be inferior model systems for testing centrosome targeted
drugs than early-passage patient-derived tumor cell lines, which exhibit similar CA to patient
tumors.
Undoubtedly the incongruity in CA between patient tumors and established tumor cell lines
depreciates the importance of centrosomes as viable attractive targets and rather overstates mitosis
as a target, perhaps resulting in the drug development process being blindsided. Our findings thus
underscore the critical need to cautiously identify models that resemble patient tumors more
closely in those characteristics/traits that are being targeted and are thus more clinically relevant.
This is the first report to substantiate the previously unrecognized discordance associated with
mitotic frequency and the extent of CA between various model systems. Our study emphasizes the
limitations of in vitro cultures perhaps owing to genomic convergence upon continuous passaging
and highlights the importance of low-passage patient-derived cell line system as most
representative of the clinical scenario and thus a good preclinical model to study the therapeutic
potential of centrosome targeting drugs compared to conventional continuous cell lines. Our study
also underscores the significance of CA as a superior chemotherapeutic target and delineates the
molecular mechanism whereby HIF-1α strongly upregulates PLK4 expression and drives rampant
CA in these tumors. Therefore, our findings indicate that HIF-1α-mediated upregulation of PLK4
tumors drives its distinct tumor biology and establishes a causative link between two biological
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phenomena – hypoxia and CA – that co-occur in many solid tumors. Based upon our findings, we

suggest that low-passage patient-derived tumor cells and tumor xenografts could serve as good
preclinical models for testing these drugs since the degree of CA found in these models closely
resembles that in patient tumors. Taken together, our results suggest that CA could prove to be a
better therapeutic target than mitosis owing to its higher incidence in human tumors, which perhaps
occurs in low oxygen hypoxic tumor environment.
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3

AMPLIFIED CENTROSOMES MAY UNDERLIE AGGRESSIVE DISEASE
COURSE IN PANCREATIC DUCTAL ADENOCARCINOMA

Parts of this chapter have been published verbatim in Cell Cycle 2015 June; 14(17): 2798-809
as “Amplified centrosomes may underlie aggressive disease course in pancreatic ductal
adenocarcinoma.”
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3.1

Abstract
Centrosome amplification (CA), the presence of centrosomes that are abnormally

numerous or enlarged, is a well-established driver of tumor initiation and progression associated
with poor prognosis across a diversity of malignancies. Pancreatic ductal adenocarcinoma (PDAC)
carries one of the most dismal prognoses of all cancer types, and a majority of these tumors are
characterized by numerical and structural centrosomal aberrations; therefore, CA may underlie the
nearly unsurpassed aggressiveness of this disease. In this study, we sought to determine whether
CA was associated with worse clinical outcomes, poor prognostic indicators, markers of epithelialmesenchymal transition (EMT), and ethnic health disparity in PDAC. We also evaluated whether
CA could precipitate more aggressive phenotypes in a panel of cultured pancreatic cancer cell
lines. Using publicly-available datasets, we examined the association between the expression of
genes whose dysregulation drives CA and overall survival and the expression of EMT markers in
PDAC patients. We found that increased expression of these CA-related genes was associated with
worse overall survival and increased EMT marker expression. Quantitative analysis of
centrosomal profiles in pancreatic cancer cell lines and tissue sections uncovered that pancreatic
cell lines exhibited different levels of CA, and markers of CA were associated with the expression
of EMT markers. We induced CA in pancreatic cancer cells and found that CA empowered the
cells with enhanced invasive and migratory capabilities. In addition, we discovered that PDACs
from African American (AA) patients exhibited a greater extent of both numerical and structural
CA than PDACs from European American (EA) patients. Taken together, these findings suggest
that CA may fuel a more aggressive disease course in PDAC patients. Given the prevalence of CA
among pancreatic tumors,
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especially ones from AA patients, future studies should test their susceptibility to centrosome
declustering drugs, which could offer urgently needed targeted therapy with potentially low
toxicity.
3.2

Introduction
Pancreatic cancer is the fourth most fatal cancer in the United States, although it constitutes

only 2.7% of new cancer cases [1]. Greater than 90% of all pancreatic neoplasms derive from
ductal cells, and ~85% of these are invasive PDACs [2]. Over the past 30 years, improvements in
survival for PDAC patients have paled in comparison with improvements for patients suffering
from other cancers. This unsettling trend is expected to continue in the near future, and it is
projected that by 2030 pancreatic cancer will depose colorectal cancer to become the secondleading cause of cancer-related death in the United States [3, 4]. A leading cause for the
exceptionally high mortality of PDAC is its general lack of clinically useful prognostic markers
and therapeutic targets, which contrasts with many other malignancies (such as breast and lung),
in which much greater strides in precision medicine have been made. Surgical resection is the only
treatment to date that appreciably extends survival in PDAC, with a median survival of ~18 months
for patients who undergo complete resection compared with only ~6 months for patients with
unresectable tumors [5]. Gemcitabine is the standard of care for patients with advanced disease,
although it improves survival only by about one month [6]. Therefore, it is critical to identify
prognostic and predictive indicators and clinically actionable drivers of disease aggressiveness in
PDAC. Such an approach has achieved breakthroughs for other highly aggressive, treatmentrefractory cancers, such as melanoma [4], by enabling risk stratification of patients and the
administration of targeted therapies. A deluge of gene expression and proteomic studies has
implicated ~10% of the exome in pancreatic cancer [7], but the size and complexity of these data
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have so far thwarted their integration into an actionable portrait of the disease. Indeed, at present
there is only one FDA-approved biomarker for pancreatic cancer, carbohydrate antigen 19-9;
however, it has low prognostic value before surgery or chemotherapy, so its utility is mostly
limited to post-treatment monitoring of disease progression [8]. Furthermore, only one FDAapproved targeted therapy is available for PDAC, erlotinib (in combination with gemcitabine),
although it improves survival by less than 2 weeks and, thus, is rarely prescribed [4]. Consequently,
there is a critical need for improved prognostic biomarkers and therapeutic targets for PDAC.
Biomarkers and drug targets are generally sought at “omics” levels of late, but a seemingly
overlooked pool of candidates is comprised of organelles. These structures constitute the output of
the cell’s own integration of the staggeringly complex molecular signaling events within it, so
organelles represent particularly comprehensive and clinically significant biomarkers and drug
targets. Investigation of organelle-level variations among PDACs of differing aggressiveness
represents entirely uncharted territory. The centrosome has emerged as a central driver of tumor
aggressiveness across cancer types. CA (the presence of excessively numerous or voluminous
centrosomes) can initiate tumorigenesis, engenders chromosomal instability, and precipitates
invasive tumor behavior [9-11]. In order for cancer cells to avail themselves of the advantages of
CA, however, they must prevent spindle multipolarity during mitosis, lest they succumb to fatal
mitotic catastrophe. As a result, cancer cells deftly cluster supernumerary centrosomes into two
diametrically opposed groups in order to achieve pseudo-bipolar spindle geometry and survive.
The extent of CA correlates positively with aggressiveness across the entire spectrum of cancer
types [12]. Consequently, it is rational to suspect that CA is involved in PDAC, which is nearly
unrivaled in its aggressive behavior among malignancies. Furthermore, a small study focused on
centrosome abnormalities in PDAC revealed a striking difference in the profiles of centrosomes,
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both in terms of their number and size, as compared with normal pancreas [13]. Another study
observed that centrosome abnormalities (defined as supernumerary or structurally aberrant
centrosomes) detected by pericentrin immunofluorescence staining were correlated with nuclear
abnormalities (namely, bi- or multinucleation or the presence of giant nuclei) in a panel of
pancreatic cancer cell lines [14]. These studies lend credence to our rationale that CA may underlie
the more aggressive disease course experienced by PDAC patients and may hold promise as a
prognostic and therapeutic target in PDAC.
To address the above-specified line of inquiry, we investigated the association between CA
and disease aggressiveness in PDAC using publicly available microarray data, with genes whose
dysregulation is known to drive CA serving as surrogates for amplified centrosomes. Intriguingly,
we found that high expression levels of these genes were significantly associated with worse
overall survival and increased expression of EMT markers.

In addition, we performed a

comprehensive quantitative analysis to ascertain whether structural and numerical CA are
associated with clinicopathologic features of PDACs or the ethnicity of PDAC patients. We
discovered that moderately differentiated PDACs exhibited the most extensive CA compared with
well- and poorly differentiated PDACs, although among well-differentiated PDACs CA was
significantly associated with duodenal invasion. CA was not associated with other
clinicopathologic features. Intriguingly, AA PDACs were found to have significantly higher
numerical and structural CA compared with EA PDACs. Finally, to determine whether CA is
causally implicated in pancreatic tumorigenesis, we induced CA in cultured pancreatic cancer cell
lines. We found that supernumerary centrosomes enhanced cell migration and invasion and
upregulated the expression of EMT markers. Collectively, these observations insinuate that CA
may be involved in PDAC aggressiveness.
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3.3

Materials and Methods

3.3.1 Public microarray data analysis
Robust Multi-array Average-normalized expression levels of genes whose dysregulation is known
to drive CA (including AURKA, CCNA2, CCND1, CCNE2, CDK1, CEP63, CEP152, E2F1, E2F2,
E2F3, LMO4, MDM2, MYCN, NDR1, NEK2, PIM1, PIN1, PLK4, RAD6, and STIL) from the
primary PDACs of 42 patients were obtained from GEO series GSE28735. Cutoff Finder [17] was
used to determine optimal cut-points in individual gene expression levels to stratify patients into
two groups based on overall survival using the log-rank test. The same data were used to obtain
Pearson’s correlation coefficients between genes whose dysregulation drives CA (AURKA, CDK1,
STIL, PIM1, PLK4, and NEK2) and EMT markers (PLAUR and MMP3), which were validated
using gene expression data from 39 PDACs from GEO series GSE15471. SPSS software (IBM)
was used for the analyses, with P<0.05 indicating statistical significance.
3.3.2 Clinical tissue samples
Formalin-fixed paraffin-embedded slides of PDAC and normal pancreatic tissue were procured
from Emory hospital. The Emory University Institutional Review Board approved all aspects of
the study.
3.3.3 Immunofluorescence staining, imaging, and scoring of clinical specimens
For immunofluorescence staining all tissue slides were deparaffinized by baking at 67°C for 2 h
followed by 3 xylene washes. Slides were then rehydrated by passing them through a series of
ethanol baths (100%, 95%, 70%, and 50%). Antigen retrieval was performed by incubating slides
in citrate buffer (pH 6.0) in a pressure cooker at 15 psi for 3 min. Tissue samples were then
incubated overnight with primary mouse antibody against γ-tubulin (1:1000 dilution) at 4°C. The
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samples were then washed with 3X phosphate-buffered saline (PBS) before incubating them in
secondary antibody (Alexa-488 anti-mouse) at 37°C for 2 h. Samples were washed with 3X PBS
and then mounted with Prolong-Gold antifade reagent that contained DAPI (Invitrogen). Tissue
samples were imaged using the Zeiss LSC 700 confocal microscope (Oberkochen, Germany), and
images were processed with Zen software (Oberkochen, Germany). The percentage of cells with
CA was quantitated from 10 randomly selected fields, with ~500 cells counted for each sample.
3.3.4 Immunohostochemistry, scoring, and WI calculation for clinical specimens
Deparaffinization and antigen retrieval were performed as described for immunofluorescence
staining. Thereafter, the tissues were immunolabeled using Plk4 and MMP2 antibodies. Enzymatic
antibody detection was performed with the Universal LSAB + Kit/HRP (DAKO, CA, USA). The
staining intensity was scored as 0=none, 1=low, 2=moderate, or 3=high, and the percentage of
cells from 10 randomly selected fields (~500 cells) was determined. The product of the staining
intensity and the percent of positive cells constituted the WI. Pearson’s correlation coefficients
between WIs were sought using SPSS.
3.3.5 Cell culture
MIA PaCa-2, Capan-1, CFPAC-1, and HPAF-II cell lines were grown in Dulbecco's
Modified Eagle's medium supplemented with 10% Hyclone fetal bovine serum and 1%
penicillin/streptomycin. All cell lines were maintained in humidified 5% CO2 atmosphere at 37°C.
3.3.6 Cell lysate preparation, immunobloting, immunofluorescence staining, and confocal
microscopy
Protein lysates were prepared, and immunoblotting was performed as described earlier [51].
Polyacrylamide gel electrophoresis was used to resolve the proteins, which were transferred onto
polyvinylidene fluoride membranes (Millipore). The Pierce ECL chemiluminescence detection kit
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(Thermo Scientific) was used to visualize the immune-reactive bands. β-actin was used as loading
control. For immunofluorescence staining, cells were grown on glass coverslips and fixed with
ice-cold methanol for 10 min. Blocking was done by incubating with 2% bovine serum
albumin/1XPBS/0.05% Triton X-100 at 37°C for 1 h. Coverslips were incubated in primary
antibodies against γ-tubulin and α-tubulin at 1:2000 dilution for 1 h at 37°C. The cells were washed
with 2% bovine serum albumin/1XPBS for 10 min at room temperature before incubating with a
1:2000 dilution of Alexa 488- or 555-conjugated secondary antibodies (Invitrogen; Carlsbad, CA).
Cells were mounted with ProLong Gold Antifade Reagent with DAPI (Invitrogen). Antibodies
against γ-tubulin and α-tubulin were from Sigma (St. Louis, MO); antibodies against Aurora A
and β-actin were from Cell Signaling (St. Louis, MO,USA); antibodies against centrin-2 were from
Santa Cruz Biotechnology (Santa Cruz, CA); and antibodies against Plk4 and MMP2 were from
Abcam (Cambridge, MA, USA). Horseradish peroxidase-conjugated secondary antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA).
3.3.7 Cell migration assay
Monolayers of the aphidicolin-treated and control CFPAC-1 cells were scratched with a
200 µl pipette tip after serum starving for 8 h. Using a 20X objective, images were taken every
hour using the Zeiss Axio Observer. Image J was used to define the edges of the wound and to
measure wound area, and the percent change in the wound area was calculated based on the closure
of wound over time.
3.3.8

Boyden chamber assay
Control and aphidicolin-treated CFPAC-1 cells were collected after 48 h and resuspended

in media at 5 x 104cells/ml. Transmigration assay was carried out in a Boyden chamber system.
The upper wells of the chamber were loaded with 200 µl of cell suspension, and 500 µl media
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containing 20% FBS was added in lower chambers as a chemoattractant. Chambers were incubated
for 12 h at 37°C and 5% CO2. Cells that migrated to the bottom surface of the filter were fixed
with 70% methanol, stained with crystal violet, and counted under a microscope in 10 randomly
selected fields using a 20X objective.
3.3.9

Statistical Methods

Unless otherwise stated in the methods and results, statistical analyses were performed using
Student’s t-test, and the criterion for statistical significance was P<0.05.

3.4

Results

3.4.1 Increased expression of genes that drive CA is associated with worse overall survival in
PDAC
Previous studies have reported an association between CA and chromosomal instability in
PDAC [15, 16]. Furthermore, liver metastases exhibited a greater extent of CA than the primary
tumors in an orthotopic implantation model of PDAC [16]. However, the association of CA with
a more aggressive disease course in PDAC patients has not been explored. As there are currently
no publicly available datasets with information on CA per se, we instead analyzed expression
levels of genes whose deregulation is known to drive CA (including AURKA, CCNA2, CCND1,
CCNE2, CDK1, CEP63, CEP152, E2F1, E2F2, E2F3, LMO4, MDM2, MYCN, NDR1, NEK2,
PIM1, PIN1, PLK4, RAD6, and STIL). Specifically, we tested the associations between Robust
Multi-array Average-normalized expression levels of these genes in primary PDACs from 42
patients and overall survival using Gene Expression Omnibus (GEO) series GSE28735. Survival
over time was estimated using the Kaplan-Meier method. Cutoff Finder, which applies the logrank test to determine an optimal cut-point based on significance [17], was used to stratify patients
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into low- and high-risk groups. High expression levels of nine genes (specifically, AURKA,
CCNA2, CCNE2, CDK1, CEP152, NEK2, PIM1, PLK4, and STIL) were found to be associated
with worse overall survival with P<0.1 Associations with five genes, namely CDK1, NEK2, PIM1,
PLK4, and STIL, were significant (P<0.05), as depicted in Kaplan-Meier plots in Figure 3.4.1
Consequently, CA may be associated with worse overall survival in PDAC. We found that genes
whose dysregulation drives CA and clustering are upregulated in PDACs (n=36) relative to normal
pancreatic tissue (n=12) using the GEO series GSE16515 (Supplemental Figure 3.7.12). We
further found that expression levels of AURKA, CDK1, STIL, PIM1, PLK4, and NEK2 in PDACs
mostly correlate with the expression of the EMT markers PLAUR and MMP3 using GEO series
GSE28735 (Table 3.4.1), which we validated using GEO series GSE15471 (Table 3.4.2). These
results suggest that CA may be associated with increased metastatic potential of PDACs and poor
survival prospects for PDAC patients.

2

All supplemental data, tables, and figures appear in Appendix B for this chapter
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Figure 3.4.1 Kaplan-Meier plots of overall survival based on low or high expression of
genes whose dysregulation drives CA in pancreatic ductal adenocarcinomas.
Expression was categorized as low or high based on whether the value was below or above the
following cut-points in normalized expression levels, given in parentheses here after each gene:
A. CDK1 (2.97), B. NEK2 (3.79), C. PIM1 (5.70), D. PLK4 (3.47), and E. STIL (3.06). HR=Hazard
Ratio
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Table 3.4.1 Correlation between the expression of CA associated gene and EMT markers in GEO
series GSE28735.
Genes whose dysregulation drives centrosome amplification (AURKA, CDK1, STIL, PIM1, PLK4,
and NEK2), that contribute to centrosome structure (CETN2), or that indicate epithelialmesenchymal transition (PLAUR and MMP3). Normalized gene expression levels from breast
tumors in GEO series GSE28735 were used for the statistical analysis.
AURKA

CDK1

STIL

PIM1

PLK4

NEK2

CETN
2

PLAUR

MMP3

Pearson
Correlatio
n
Sig. (2tailed)
N

0.311

0.395

0.305

0.539

0.237

0.359

0.403

0.037

0.007

0.042

0.000

0.117

0.015

0.006

45

45

45

45

45

45

45

Pearson
Correlatio
n
Sig. (2tailed)
N

0.142

0.271

0.506

-0.058

0.248

0.376

0.514

0.353

0.072

0.000

0.705

0.100

0.011

0.000

45

45

45

4
5

4
5

4 45
5

Table 3.4.2 Correlation between the expression of CA associated gene and EMT markers in GEO
series GSE15471
Genes whose dysregulation drives centrosome amplification (AURKA, CDK1, STIL, PIM1, PLK4,
and NEK2), that contribute to centrosome structure (CETN2), or that indicate epithelialmesenchymal transition (PLAUR and MMP3

PLAUR

MMP3

AURKA

CDK1

STIL

PIM1

PLK4

NEK2

CETN2

Pearson
Correlation
Sig.(2tailed)
N

0.567

0.590

0.578

0.436

0.578

0.454

0.414

0.000

0.000

0.000

0.005

0.000

0.004

0.009

39

39

39

39

39

39

39

Pearson
Correlation
Sig.
(2tailed)
N

0.388

0.429

0.256

0.003

0.450

0.472

0.019

0.015

0.006

0.116

0.985

0.004

0.002

0.909

39

39

39

39

39

39

39

We next sought correlations between protein levels of an EMT marker (MMP2) and CA driver
(Plk4) in PDAC samples. To this end, we first immunohistochemically stained 54 PDACs and
uninvolved adjacent normal tissue for Plk4 and MMP2 and calculated weighted indices (WIs). The
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staining intensity was scored as 0=none, 1=low, 2=moderate, or 3=high, and the percentage of
positive cells (i.e., with 1+ staining intensity) from 10 randomly selected fields (~500 cells) was
determined. The product of the staining intensity and the percent of positive cells constituted the
WI. Descriptive statistics regarding patient and clinicopathological characteristics and biomarker
WIs are given in Table 3.4.3. Both Plk4 and MMP2 proteins were overexpressed in PDACs
(Figure 3.4.2). In addition, a strong positive Pearson’s correlation was found between these
markers in PDACs (r=0.460, P<0.001).

Figure 3.4.2 Pancreatic ductal adenocarcinomas exhibit higher expression of Plk4 and
MMP2.
A. Representative micrographs showing immunohistochemical staining for Plk4 (a protein
whose overexpression drives centrosome amplification) and MMP2 (an epithelial-mesenchymal
transition marker) in uninvolved adjacent normal and tumor tissue from grade-matched PDAC
patients. Bi. Box-and-whisker plot depicting the MMP2 weighted index in PDACs and normal
pancreas. Bii. Box-and-whisker plot depicting the Plk4 weighted index in PDACs and normal
pancreas.

Table 3.4.3Descriptive statistics for PDAC patient and clinicopathologic characteristics in the
analysis of MMP2 and Plk4 levels in tumors and matched normal tissue.
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Variable

Level

Race
Tumor Size (cm)

Tumor Size

Grade

MMP2 WI

Plk4 WI

MMP2 WI

Plk4 WI

PNI
LVI

Age at diagnosis

Duodenum
Invasion
Soft
involvement

tissue

AA
CA
<=2
>2
Median
Mean
Maximum
Minimum
St.dev
1
2
3
Median
Mean
Maximum
Minimum
St.dev
Median
Mean
Maximum
Minimum
St.dev
Low (<2)
Moderate (2-6)
High (>6)
Low (<2)
Moderate
(2-6)
High (>6)
Yes
No
Yes
No
Median
Mean
Maximum
Minimum
St.dev
Yes
No
Yes
No

Number

Percentage

23
31
8
46
3
3.55
12
0.25
1.99
10
31
13
6
4.20
9
0
3.07
2
2.11
9
0
2.17
13
34
7
25

42.6
57.4
14.8
85.2

27
2
43
10
26
28
64
62.05
84
35
9.88
20
34
37
17

50.0
3.7
79.6
18.5
48.1
51.9

18.5
57.4
24.07

24.1
63.0
13.0
46.3

37.0
63.0
68.5
31.5
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3.4.2

Amplified centrosomes enhance the motility and invasiveness of pancreatic cancer
cells
Having confirmed an association between a protein whose overexpression drives CA and

a marker of EMT, we were interested in exploring how CA may transform non-invasive pancreatic
tumors into aggressive ones that metastasize. Thus, we examined whether CA can enhance the
motility and invasiveness of pancreatic cancer cells. To this end, we first screened three wellestablished pancreatic cancer cell lines (namely, MIA PaCa-2, CFPAC-1, and HPAFII) by
immunostaining centrosomes (γ-tubulin, green) and microtubules (α-tubulin, red) and
counterstaining nuclei with 4′,6-diamidino-2-phenylindole (DAPI) (blue) (Figure 3.4.3A). We
found that HPAFII cells exhibited the greatest extent of numerical CA (~20% of cells), followed
by MIA PaCA-2 (~15% of cells) and CFPAC-1 (~10% of cells) (Figure 3B). We also evaluated
the expression of centrosome-related proteins in these cell lines using immunoblotting methods.
We found that the cell lines with high CA expressed elevated levels of centrosome structural
proteins (centrin-2 and γ-tubulin) and proteins whose dysregulation is known to drive CA (Aurora
A and Plk4) (Figure 3.4.3C). We next asked if aberrations in centrosome number translate into
aberrations in mitotic spindle geometry. We found that all three cell lines exhibited a significantly
lower proportion of cells with multipolar spindles in comparison with the proportion of cells with
supernumerary centrosomes (Figure 3.4.3B). This discordance corroborates the hypothesis that
cancer cells deal with supernumerary centrosomes by clustering them to form pseudobipolar
spindles. Taken together, our data suggest that cultured pancreatic cancer cells are characterized
by CA, which they are generally successful in managing by executing centrosome clustering.
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Figure 3.4.3 Pancreatic cancer cells with high levels of centrosome amplification (CA)
express high levels of centrosome structural proteins and proteins whose dysregulation
drives CA.
A. Immunofluorescence micrographs showing MIA PaCa-2, HIFA-II, and CFPAC-1 cells in
interphase and mitosis stained for γ-tubulin (green), α-tubulin (red), and nuclei (blue). B. Bar
graph representing the percentage of cells with CA in MIA PaCa-2, CFPAC-1, and HPFA-II cells.
C. Immunoblots depicting the levels of centrosome structural proteins (γ-tubulin and centrin-2)
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and proteins whose dysregulations drives CA (Aurora A, Plk4, and Cyclin E) in MIA PaCa-2,
HPFA-II, and CFPAC-1 cells.
Next, we were curious to learn whether inducing CA via pharmacological means would
enhance the motility of pancreatic cancer cells with lower levels of CA. To this end, we induced
CA in CFPAC-1 pancreatic cancer cells (~10% of which have CA, the lowest level in the lines we
surveyed) by treating them with 25 µm aphidicolin for 48 h. Aphidicolin arrests cells in G1/S phase
by inhibiting DNA polymerase [18, 19]. After treatment ~22% of cells exhibited amplified
centrosomes. We then performed a wound-healing assay, which revealed that pharmacological
induction of CA stimulated migration, as the wound was filled in about half the time taken by
control cells (Figure 3.4.4A and Bi). Thereafter, we examined the invasive capabilities of cells
with supernumerary centrosomes by performing a classical Boyden chamber assay. We observed
that 80% of the CFPAC-1 cells in which CA was induced invaded the Matrigel in 12 h in contrast
with only 53% of control cells (that is, CFPAC-1 cells not treated with aphidicolin) (Figure
3.4.4Bii and C). We confirmed that CA was induced in aphidicolin-treated cells by
immunoblotting for centrin-2 and Plk4 levels (Figure 3.4.4D). In addition, we noted that cells
treated with aphidicolin expressed higher levels of N-cadherin (Figure 3.4.4D), suggesting that
these cells may have attained a more mesenchymal phenotype. In summary, our findings that CA
upregulates N-cadherin levels, invasive capacity, and wound-healing imply that CA may
contribute to epithelial-mesenchymal transition in pancreatic cancer cells.
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Figure 3.4.4 Cells with centrosome amplification (CA) migrate more rapidly in a woundhealing assay.
A. Bright-field micrographs showing the wound-healing capacity of CFPAC-1 control (untreated)
and aphidicolin-treated cells at 0, 12, and 36 h. Bi. Bar graphs representing the percent of
aphidicolin-treated and control (untreated) CFPAC-1 cells in the wound. Bii. Bar graphs
representing the percent of aphidicolin-treated and control CFPAC-1 cells that invaded the Boyden
chamber. C. Brightfield micrographs showing the invasion capacity of CFPAC-1 control and
aphidicolin-treated cells after 24 h. D. Immunoblots of centrosome structural proteins (centrin-2),
a protein whose dysregulation drives CA (Plk4), and epithelial-mesenchymal transition markers
(N-cadherin and MMP2) in CFPAC-1 control and aphidicolin-treated cells.
3.4.3 Amplified centrosomes distinguish AA PDACs from EA PDACs
A previous study of 13 PDACs uncovered that a greater proportion of PDAC cells have
CA, both numerical and structural, than normal pancreas [20]. However, the association of CA
with poor prognostic indicators in pancreatic cancer is unknown. To address this, we examined the
centrosomal profiles of 64 PDACs and sought associations with clinicopathologic parameters
including age, sex, ethnicity, tumor size, grade/extent of differentiation, stage, lymphovascular and
perineural invasion, lymph node metastasis, and surgical margin status. Descriptive statistics
regarding patient and clinicopathologic characteristics are given in Table 3.4.4. Formalin-fixed
tissue sections from the PDACs were immunostained for centrosomes (γ-tubulin) and nuclei were
counterstained with DAPI (Figure 3.4.5A). Centrosome number and volume were quantitated in
tumor areas pre-marked by a gastrointestinal pathologist using confocal microscopy. Tumor cells
with more than two centrosomes or centrosomes greater than 0.56 μm3 in volume were regarded
as having numerical or structural CA, respectively. The volume of 0.56 μm3 was used as a cutpoint because that was the maximum centrosome volume found in normal pancreatic cells using
the 3D volume measurement module from the Zeiss imaging software. The percentage of cells
exhibiting centrosomal aberrations was quantitated from 10 randomly selected fields
(approximately 500 cells) for each sample. The mean volume of the γ-tubulin spots observed in
pancreatic cancer tissues was 1.75 μm3, which was ~9 times greater than the mean volume in
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normal pancreatic cells. Pancreatic tumors also exhibited extensive numerical CA, with ~25-40%
of cells bearing extra centrosomes, unlike normal pancreatic tissue, in which only ~5% of cells
had extra centrosomes. When we compared the extent of CA between tumors of different levels of
differentiation, we found that moderately differentiated tumors exhibited the highest CA when
compared with well- and poorly differentiated tumors (Figure 3.4.5B); however, the results were
not statistically significant, perhaps due to the paucity of well-differentiated tumors in our dataset
(n=6), as PDACs are most often moderately to poorly differentiated. While CA was associated
with duodenal invasion in well-differentiated PDACs (r=0.772, p=0.042), it was not associated
with tumor size, stage, perineural or lymphovascular invasion, or number of positive lymph nodes
in PDACs of any degree of differentiation. In summary, CA clearly differentiates PDACs from
adjacent normal tissue and is associated with duodenal invasion in well-differentiated PDACs.
Table 3.4.4 Descriptive statistics for PDAC patient and clinicopathologic characteristics in the
analysis of centrosome amplification in tumors and matched normal tissue.
Variable

Level
AA
CA
Low (<10%)
Moderate
(10

Race
Centrosomal
amplification

Percentage
46.88
53.13
21.88

High (40%<)
Well
Moderate
Poor
<=2
>2
Median

38
12
6
40
14
10
54
3.1

59.38
15.63
9.38
62.50
21.88
14.49
78.26
-

Mean

3.60

-

Maximum

12

-

Minimum

1

-

St.Dev

1.9

-

Median
Mean
Maximum
Minimum
St.Dev
Median

66
64.4307692
87
35
10.8147788
36.33

-

~40%)

Tumor
Differentiation
Tumor

Tumor in size
(cm)

Age
diagnosis

Number
30
34
14

at

-
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% Centrosome
amplification
Duodenum
Invasion
Soft
tissue
involvement
PNI
LVI

Mean
Maximum
Minimum
St.Dev
Yes
No
Yes
No
Yes
No
Yes
No

36.19
72.22
1.40
18.00
32
32
50
14
55
10
26
38

50
50
50
21.875
85.9375
15.625
40.625
59.375
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Figure 3.4.5Centrosome amplification (CA) in PDACs and normal pancreatic tissue.
A. Representative confocal micrographs depicting centrosomal profiles in well-, moderately, and
poorly differentiated PDACs and adjacent normal pancreatic tissue. Centrosomes were
immunostained (γ-tubulin, green) and nuclei were counterstained with DAPI (blue). B. Bar graph
representation of the percentage of cells showing CA in well-, moderately, and poorly
differentiated PDACs and normal pancreatic tissue samples. ~500 cells were counted in each case.
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Finally, because AA ethnicity is a risk factor for the development of PDAC [21], we were
interested in determining whether centrosomal profiles from AA patients differed from those of
EA patients. Interestingly, when we immunostained moderately differentiated pancreatic tumor
samples from AA and EA PDAC patients (n=20 for each group) (Figure 3.4.6A) and compared
their centrosomal profiles, we found that numerical and structural CA in AA tumors were
significantly higher than in EA tumors (Figure 3.4.6B and C, respectively).

Figure 3.4.6 Centrosome amplification (CA) in PDACs and normal pancreas specimens
from AA and EA patients.
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A. Representative confocal micrographs depicting centrosomal profiles in grade-matched AA and
EA PDACs and adjacent normal tissues. Centrosomes were immunostained for γ-tubulin (green)
and nuclei were counterstained with DAPI (blue). B. Bar graphs representing the percent of cells
showing numerical CA in AA and EA tissue samples. C. Bar graphs representing the percent of
cells showing structural CA in AA and EA PDAC tissue samples. ~500 cells were counted in each
case.
3.5

Discussion

Five-year survival rates in PDAC hover around 5% notwithstanding about a half century of
research into the etiology of its aggressive nature and potential therapeutic interventions [22]. Out
of this burgeoning body of research has emerged an appreciation of the remarkably complex
mutational landscape of PDACs, their extensive intratumor heterogeneity due to chromosomal
instability, and their extraordinary propensity to metastasize [22, 23], although this knowledge has
not translated into considerable improvements in patient outcomes. Chromosomal instability
appears to be an early event in the development of PDAC [24], which no doubt contributes to its
exceptional aggressiveness. Efforts to identify sources of genetic dysfunction in this cancer type
have mostly focused on individual genes or gene signatures without much consideration for
potential organelle-level abnormalities. However, CA is a well-established mediator of
chromosomal instability [25], and the extent of CA correlates with chromosomal instability in
pancreatic cancer cells [26]. Furthermore, CA has been causally implicated in chromosomal
instability, as induction of CA in BJ fibroblasts and RPE1 cells via treatment with cytochalasin D
(a cytokinesis inhibitor) significantly increases the rate of chromosome missegregation [10]. It has
been found that the vast majority of PDACs exhibit CA [15], suggesting that CA is a hallmark of
these tumors. Therefore, it seems likely that in PDAC CA is at least partly responsible for
intratumor heterogeneity, which is associated with adverse outcomes, and it is rational to suspect
that CA is associated with worse clinicopathology and survival rates in PDAC. Our study is the
first to demonstrate that high expression levels of genes whose dysregulation drives CA are
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associated with worse overall survival in this cancer type, although CA itself was not significantly
associated with worse clinicopathology aside from an association with duodenal invasion in welldifferentiated tumors.
In addition to being characterized by genomic complexity and chromosomal instability,
PDAC is also typified by a high propensity to metastasize. At diagnosis 80% of patients have
advanced tumors, almost two-thirds of which have metastasized distantly [27]. Moreover, among
patients who receive a potentially curative resection, ~70-80% will experience a local or distant
recurrence regardless of whether chemotherapy is administered [28]. CA is a primary suspect in
conferral of metastatic abilities to tumors, as induction of CA via overexpression of Plk4 or
treatment with dihydrocytochalasin B (a cytokinesis inhibitor) has been demonstrated to prompt
invasiveness in MCF10A breast epithelial cells and non-transformed keratinocytes [11].
Specifically, CA precipitates the formation of matrix protein-degrading invasive protrusions and
antagonizes intercellular adhesion via augmented microtubule nucleation and Rac1 activation.
Nonetheless, it was previously unknown whether CA contributes to invasiveness or enhanced
migratory capacity in PDAC. In the present study, we discovered that induction of CA via
treatment with aphidicolin enhanced pancreatic cancer cell invasion and migration, suggesting that
CA may promote metastasis in PDAC, which is congruent with our finding that CA was associated
with duodenal invasion in well-differentiated PDACs. Furthermore, we found that induction of
CA upregulated N-cadherin expression, consistent with EMT. The expression of genes whose
dysregulation drives CA mostly correlated with the expression of the PLAUR and MMP3 genes,
and the extent of CA correlated with expression of the MMP2 protein. Furthermore, induction of
CA upregulated MMP3 and N-cadherin protein levels. PLAUR encodes the urokinase-type
plasminogen activator receptor (uPAR), which promotes pancreatic cancer cell migration and
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invasion in vitro and hepatic metastases and retroperitoneal invasion in vivo [29], and amplification
of the PLAUR gene is associated with decreased survival in PDAC [30]. The ligand of uPAR,
urokinase, cleaves plasminogen to plasmin, which then cleaves pro-MMPs to active MMPs that,
together with plasmin, degrade the extracellular matrix to facilitate invasion of tumor cells [31].
The MMP3 protein has been demonstrated to stimulate pancreatic cancer cell invasion [31], and,
similar to the uPAR and N-cadherin proteins, both MMP2 and MMP3 are considered to be EMT
effector proteins [32, 33]. Based on our findings, it appears that CA may encourage EMT, which
is further substantiated by our finding that induction of CA enhances migration and invasion of
pancreatic cancer cells. These findings corroborate the hypothesis that amplified centrosomes
compel metastatic dissemination in PDAC [34].
Previous studies have shown that cancer cells manage the excessive centrosomal load by
forming juxtanuclear supercentrosomal clusters, which they maintain all through interphase and
then disperse transiently in prophase, followed soon by tight reclustering [35]. Centrosome
declustering drugs, such as the non-toxic antifungal griseofulvin and antitussive noscapine,
disaggregate the centrosomal clusters, forcing the mitotic spindle to assume a persistently highgrade multipolar configuration that is incompatible with cell survival [36]. A previous study
discovered that the CFPAC-1 cell line exhibits considerable centrosome clustering, with more than
half of mitoses in cells with CA assuming a pseudobipolar configuration [37], similar to our
findings. Together, these suggest that pancreatic cancer cells tend to cluster their supernumerary
centrosomes. As a corollary, it seems that centrosome declustering drugs could prove
advantageous in PDAC, an intriguing hypothesis that merits testing.
We discovered that AA PDACs exhibited more extensive numerical and structural CA
compared with EA PDACs. The age-adjusted incidence of PDAC is ~30% higher among AA than
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EA [38], and AA race is an established risk factor for PDAC [21]. Various socioeconomic and
lifestyle factors that may contribute to the development of PDAC are more common in the AA
population [21], as are certain K-Ras mutations and possibly strong HER2 expression [39].
Intriguingly, it has been demonstrated that K-RasG12D induces CA in mammary epithelial cells [40]
and head and neck papilloma cells [41]. One study found that this mutation is more prevalent
among AA than EA (47% vs. 34%), although the difference did not reach statistical significance
[39], perhaps due to the relatively small sample size. K-RasG12V, on the other hand, was
significantly more prevalent among AAs in this study, but we are unaware of any data regarding
the impact of this mutation on CA. What might be considered indirect evidence that K-RasG12V
promotes CA is the recent finding by Hu and colleagues that this mutation increases the frequency
of multipolar anaphases and apoptosis following treatment of ED-1 murine lung cancer cells with
seliciclib, a cyclin-dependent kinase inhibitor [42]. CA renders cancer cells vulnerable to
multipolar mitosis [36], so cells undergoing multipolar anaphase might have supernumerary
centrosomes, although this was not directly tested in that study. The relationship between ethnicity
and mutations in genes whose dysregulation is known to drive CA that are common in PDAC (e.g.,
TP53 [43, 44], SMAD4 [41], CDKN2A [45], CHEK2 [46], depicted in Supplemental Figure 3.7.2)
merits investigation. One study found that a greater proportion of AA PDACs displayed strong
HER2 expression than EA PDACs [39], and HER2 overexpression is associated with CA in breast
cancer [47, 48]; thus, HER2 overexpression may contribute to the greater extent of CA we
uncovered in AA PDACs. More research is needed to confirm the CA-promoting role of ethnicityassociated gene amplifications and mutations in PDAC, although it is tempting to speculate that
they underlie the differences in centrosome profiles we observed between AAs and EAs. The
diversity of factors that may confer increased PDAC risk that are associated with AA ethnicity are
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depicted in Supplemental Figure 3.7.3. Although CA is a well-defined risk factor for cancer
aggressiveness [36], the literature reports that AAs with PDAC do not experience worse overall
survival in multivariate analyses accounting for a variety of factors, such as treatment received and
socioeconomic status, as detailed by a recent review of nine relevant studies [49]. This discrepancy
cannot be resolved based on existing data and deserves further exploration. Regardless, it stands
to reason that AA ethnicity might predict therapeutic response to declustering drugs, and clinical
trials testing these drugs clearly should consider ethnicity in their assessment of drug efficacy.
In summary, our microarray analysis suggests that higher levels of certain genes whose
dysregulation promotes CA are associated with worse overall survival, although further study is
needed to confirm that CA itself is indeed associated with worse clinical outcomes. In line with
these in silico results, we found that induction of CA in PDAC cell lines resulted in more
aggressive cellular behavior, such as increased motility and invasiveness. For the most part,
however, we did not find that CA was associated with worse clinicopatholgic features in PDACs
aside from lymphovascular invasion in well-differentiated tumors. A larger sample size is needed
to confirm these immunohistochemical findings, which seem generally to conflict with us in silico
and in vitro findings. It is possible that the relationship between CA and clinicopathologic features
is complex, and some weighted combination of the numerical and structural CA values would be
more strongly associated with clinicopathologic features like the extent of differentiation, tumor
size, and lymph node positivity. Furthermore, we did not consider subtypes in this study, but it is
possible that CA is a prognostic factor only within certain subtypes. Gene expression studies have
shown that PDACs can be divided into three subgroups: classical, quasimesenchymal, and
exocrine-like [50]. It would be intriguing to evaluate whether quasimesenchymal tumors evince
the most extensive CA because this subtype is defined by the expression of genes that promote a
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mesenchymal phenotype, which we found was promoted by induction of CA. Interestingly, the
quasimesenchymal subtype is associated with the poorest overall survival after resection [50]. In
future studies, it will be important to test whether PDACs are susceptible to centrosome
declustering drugs and to identify whether certain subtypes of this cancer have more profound
centrosome abnormalities and thus might be more susceptible to these drugs. Ultimately, our study
establishes CA, a long-standing cancer cell-selective trait, as a quantifiable cell biological property
in PDAC that undoubtedly merits further investigation.
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4.1

ABSTRACT
About 60-80% of ductal carcinoma in situ (DCIS) cases are high-grade (HG) DCIS with an
elevated risk of local recurrence (LR) even after a lumpectomy. Due to the lack of accurate
recurrence risk prediction model’s patients are often under or over treated. Current prognostic
models such as Oncotype DX and VNPI lack consistency and are limited to a specific subset
of patients. Here in this study, we show that the extent of centrosome amplification (CA) in a
DCIS lesion can predict the risk of LR after lumpectomy. By evaluating the severity and
frequency of CA in two different cohorts (n=133 and n=207 respectively) we have developed
a quantitative Centrosomal Amplification Score (CAS) for each tumor sample. Our results
show that the DCIS patients with recurrence exhibited higher CAS and higher CAS was
associated with the risk of developing ipsilateral breast event (HR=7.58 for DC and HR=5.8
for VC, p<0.0001) which stayed significant (HR=8.5, p<0.0001) after taking in account the
other confounding factors like age, tumor size, comedo necrosis and radiotherapy. For the
high and low CAS groups, the 5-year risks of recurrence were 87.5% and 12.5% respectively
(p<0.001). Mixed DCIS cases exhibited higher CAS when compared with pure DCIS
suggesting presence of the CA as early as in premalignant condition which became
significantly higher in the invasive lesions confirming the role of CA in tumor progression.
Thus, our data shows that CAS quantifies the risk of recurrence in DCIS with the highest
concordance and provides a new tool to help tailor the treatment according to individuals risk
of recurrence in DCIS patients.
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4.2

Introduction

About 25% of breast cancers (BCs) are DCIS, a pre-invasive form of BC wherein malignant cells
are confined to the lumen of a mammary duct with no evidence of invasion beyond the epithelial
basement membrane into the adjacent breast stroma. While approximately 60,000 cases of DCIS
are diagnosed in the United States each year, 20%-53% of women with untreated DCIS will
progress to invasive BC over the course of ≥10 years[1]. Since the progressive potential of a DCIS
lesion cannot be reliably determined, surgery (lumpectomy) and radiation is the common course
of treatment, with the addition of hormonal therapy in some cases[2]. Unfortunately, despite a
lumpectomy, ~35% of DCIS patients present with a local recurrence (LR)[3]. The major
challenges in improving the clinical maintenance of the DCIS patients reside in the tailoring of
treatment according to individual risks of recurrence to avoid the undertreatment of cases with
high risk of recurrence and overtreatment of patients with low risk. Therefore, accurate prognostic
markers are required which can improve the recurrence risk stratification for DCIS patients.
Current recurrence predictors such as Van Nuys index[4] and DCIS nomogram[5] (from Memorial
Sloan Kettering) based on commonly used histopathological parameters such as histologic grade,
tumor margins, and age lack consistency and reproducibility in LR risk prediction[6, 7]. In
addition, these tools fail to integrate the molecular predictors, underestimating the heterogeneity
of DCIS lesions. Furthermore, the individual prognostic markers have not been successful in
predicting risk as they are limited to a specific cohort of patients, lacks external validation and fail
to incorporate the histological parameters. Although studies have shown that commercially
available and expensive gene-expression based assay Oncotype DX DCIS score has some value in
predicting recurrence but the key drawbacks of this score are its limited applicability to a set of
patients (ECOG 5194 study) and the poor stratification of high and intermediate- risk patients thus
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leaving the actual prognostic value of this tool questionable[8]. Therefore, a pressing clinical need
for prognostic indices that incorporate clinical, histopathological and molecular biomarkers taking
into account the heterogeneous nature of DCIS lesions persists.

Studies have shown that extensive genetic and phenotypic intratumoral heterogeneity (ITH) is
present in DCIS lesions and greater the ITH present in a pre-invasive lesion, the greater is the
likelihood of LR and invasive BC[9]. Chromosomal instability (CIN) is well-recognized as a driver
of ITH and amplified centrosomes underlie erroneous mitoses and fuel CIN[10, 11]. While normal
cells have one centrosome prior to S-phase and two centrosomes after S-phase, cancer cells display
centrosome amplification[12] (CA) - an abnormal increase in the number and/or volume of
centrosomes. Studies have shown that CA correlates with increased tumor grade, size, metastasis,
and/or recurrence in multiple malignancies[13]. Moreover, studies have shown that within DCIS
precancerous and preinvasive lesions (including DCIS), indicating that CA is an early event in
tumorigenesis[14, 15]. Studies have reported that CA increases with the grade in DCIS and have
higher expression of Aurora-A and Nek2 kinases which play key role in centrosome cycle. Also,
multiple studies have highlighted the role of genes associated with centrosomes including cyclind, cyclin-E, and genes regulating centrosome cycle such as p53, p21 to predict the risk of
recurrence in DCIS[16].

Given the evidence supporting i) the presence of CA in DCIS and ii) that many of the signaling
pathways whose deregulation has been previously implicated in the induction of CA are
deregulated in DCIS it is reasonable to postulate that the organellar-level differences may exist
between recurrent and nonrecurrent DCIS. In this study, we present a novel methodology to
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quantitate both numerical and structural centrosomal aberrations in tumor samples. Our analytical
pipeline allows robust interrogation of the ability of centrosomal overload to predict the risk of LR
after lumpectomy. The algorithm developed quantitates the frequency/prevalence and severity of
CA (numerical and structural) in clinical samples, and computes a score called the centrosome
amplification score (CAS). In this study, we observed that CAS is significantly different for
recurrence and no recurrence DCIS patients and that higher CAS was associated with poorer RFS
in both discovery and validation cohort. CAS score was able to stratify the patients in high risk
and low-risk groups of recurrence with highest concordance (76%; 87.5% of patients with
recurrence were in high CAS group) among that reported for all other available recurrence
predictive tools. Furthermore, when we incorporated the clinical and histological parameters which
are commonly used in the clinics the concordance of CAS increased to 82% thus giving us a tool
which incorporates the contribution of clinical, histopathological and molecular biomarkers all in
one score and can help tailor the treatment according to the risk of recurrence for DCIS patients.
In addition, we observed that the mixed DCIS exhibited higher CAS when compared to the pure
DCIS that confirming role of CA in tumor progression.
4.3

Materials and Methods

4.3.1 Clinical tissue sample
Formalin-fixed paraffin embedded DCIS tissue sections (ICART5 cohort) were procured
from the Nottingham City Hospital DCIS series. Patients were diagnosed between year 1987 to
2012. Samples used in the discovery cohort (n=133) were restricted to pure DCIS cases treated
with breast conserving, rather than complete mastectomy, surgery (BCS). Whereas for the
validation cohort (n=120) pure DCIS cases treated with either lumpectomy or masectomy were
included. DCIS lesions without involvement of invasive component were confirmed by three
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independent pathologists. The mixed DCIS (n=87) cohort consisted of tissue sections from patients
which were presented with coexisting pure DCIS and invasive lesions. The samples were
accompanied by data pertaining to their clinicopathologic variables such as age, Nottingham grade,
TNM stage, Ki67 Index, menopausal status, and information about, treatment (adjuvant and
radiotherapy), overall survival, progression-free survival, recurrence-free survival (RFS) and date
of initial diagnosis, date of surgery, and patient status at last contact. The Institutional Review
Board of Nottingham City Hospital approved all aspects of the study. Methods were carried out in
“accordance” with approved guidelines stipulated in MTAs and DUAs between Nottingham City
Hospital, Nottingham, UK and Georgia State University. Informed consent was obtained from all
subjects.

4.3.2 Immunofluorescence imaging of clinical samples
Centrosomes in formalin fixed paraffin-embedded DCIS tissues were immunofluorescently
stained for γ-tubulin (red) and nuclei (with DAPI). Images of tissue samples were acquired with
Zeiss LSM 700 confocal microscope (using 63x oil emersion lens with numerical aperture of 1.4
and 1.5x optical zoom). All imaging parameters were fixed across all samples. Some imaging
parameters that require special attention include fluorophore saturation, detector saturation, offset,
and sampling. For optimal results, laser power is adjusted to the minimum level wherein
fluorophore emission is saturated. For detector saturation, the gain (master) is adjusted such that
the detector registers the target fluorophores in each channel within full range of detector settings
(8-bit, 12-bit, 16-bit) to prevent over and under saturation that can result in inaccurate data. The
offset was adjusted to minimize the background present in the sample. Given the fact that fine
structural details cannot be compromised, we used 1.5X digital zoom setting that results in a
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sampling size of 0.07 um/pixel, which is the maximum level of detail a detector can detect. The
premarked (by pathologist) DCIS/tumor areas were imaged to obtain at least 10 regions of interest
(ROIs) each containing 20-30 nuclei and associated centrosomes.
4.3.3 Scoring of clinical samples
Next, raw 3D image data was processed using IMARIS Biplane 8.2 3D volume rendering software
to determine volume of each centrosome within each ROI. “Volume rendering” refers to
transforming a 2D image stack for 3D visualization and subsequent analysis. To exclude nonspecific signals, a common background subtraction was applied to all images. This parameter is
determined by first measuring the average diameter of ~100 centrosomes in 10 ROIs, and then
using this measurement as the background subtraction threshold. Automatic detection based on
this measurement helped us to eliminate user bias by providing the same level of background
subtraction to all samples. Surfacing of target objects (centrosomes) helped us to correct point
spread function and to define contours of centrosomes. Next, we applied splitting function where
any clustered centrosomes mistakenly detected as single bodies were split by the software into
individual centrosomes. Finally, data from all optical sections was ordered to enable volume
measurement for each centrosome. The final data of volumes of all centrosomes was then
compared to a maximum intensity projection image and centrosomes for each cell are quantified
based on proximity to their associated nuclei. The number and volume of all centrosomes
associated with each nucleus in the tumor area was recorded.
4.3.4 Analysis
Centrosomes in breast tissues (normal, DCIS or tumor) were categorized into individually
distinguishable centrosomes (iCTRs) and megacentrosomes (mCTRs). iCTRs are defined as
centrosomes that stain positive for γ-tubulin, with centrosomes numbers and boundaries clearly
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distinguishable and volumes that lie within the range of centrosome volumes found in normal
breast tissue stained for γ-tubulin. mCTRs are centrosomes in a neoplastic region that stain positive
for γ-tubulin and whose volume is greater than the upper limit of the centrosome volume range
found in corresponding normal tissue immunostained for γ-tubulin. mCTRs are the centrosomes
with aberrantly large volumes. Volume range for a normal centrosome in breast tissue was
determined by analyzing volumes of both adjacent uninvolved tissue from cancer patients and
normal tissue for disease-free individuals for each cancer type.
4.3.5 Determination of normal volume of centrosomes
To determine the normal range of volume, we analyzed volume of 500 centrosomes for each
sample in adjacent uninvolved tissue from cancer patients (n=40) and in normal tissues (n=40)
from reduction mammoplasties. We evaluated the volume of centrosomes as described in analysis
section. Interestingly we observed that the mean centrosome volume for the adjacent uninvolved
tissue sections was higher when compared to the normal tissues from reduction mammoplasty.
Thus, chose the smallest and largest values for iCTR volume of normal tissues as “normal
centrosome volume range” for breast tissue. Mean volumes of centrosomes in normal breast
epithelial cells ranged from 0.02-0.74 µm3. All centrosomes in each ROI are thus categorized as
iCTRs or mCTRs.
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Figure 4.3.1 Representative immunographs of normal and normal adjacent breast tissue
sections for centrosomes.
Representative H&E images of the ducts of the DCIS recurrence and no recurrence cases. (Images
were captured at 20x magnification). (B) Confocal micrographs showing numerical and structural
CA in recurrence and no recurrence DCIS tissue sections.

4.3.6 Algorithm-based analytics
A cumulative Centrosome Amplification Score (CAS) was computed for each sample on the basis
of the formula: CAStotal =CASi + CASm, where CASi and CASm are scores that describe
numerical and structural CA phenotypes, respectively, in the sample.
Equation 1 for CASi represents how an aggregate value reflecting both frequency and severity of
numerical CA is derived for the sample:
𝑁𝑖 − 𝑅𝑡ℎ 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒(𝑁𝑖 > 𝑅𝑡ℎ )
𝐶𝐴𝑆𝑖 = 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 (
)∗
𝑅
𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 𝛽𝑖
=(

∑𝑁
𝑝𝑖
𝑖=1,𝑁𝑖 >2(𝑁𝑖 − 2) 1
∗ )∗
𝑁
∑𝑖=1 𝐼(𝑁𝑖 > 2)
𝑅
𝛽𝑖
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where: Rth is the threshold for number of centrosomes, which is 2 here. pi is the percentage of cells
with >2 iCTRs; ßi is a scaling factor that may be used to ensure that both CASi and CASm are
given equal weight in the formula for CAStotal; R is the range for normal distribution from 0 to 2,
which is 2 here; Ni is the number of iCTRs in a cell that contains more than 2 iCTRs; N is the total
number of cells analyzed in the sample; i in Ni is used to indicate taking the average over cells
with numerical CA.
The “severity” component of CASi, (i.e., 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 (

𝑁𝑖 −𝑅𝑡ℎ
𝑅

) quantifies how “severe” the

numerical CA is [i.e., the extent to which the numerical CA exceeds the baseline value of 2 in cells
that carry three or more iCTRs (i.e., Ni >2)]. Therefore, cancer cells with 1 and 2 iCTRs do not
contribute to this component. Since cells with larger numbers of iCTRs represent a more severe
numerical CA, a linear measurement was implemented to provide a measure of the number of
iCTRs (above the baseline value of 2) in a given cell by computing the score (Ni - 2) for each cell.
Finally, an average of all these scores is determined. The “frequency” component of the CASi
score (i.e., pi/ßi) provides the scaled frequency of numerical CA in the sample. CASi scaling
factor 𝛽𝑖 value we used here is 0.1 for breast tissue. Equation II for CASm represents how an
aggregate value reflecting both frequency and severity of structural centrosome amplification, is
derived for the sample:

𝑉𝑖𝑚 − 𝑉𝑡ℎ
𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒(𝑉𝑖𝑚 > 𝑉𝑡ℎ )
𝐶𝐴𝑆𝑚 = 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 (
)∗
𝜎𝑉 𝑖𝑚
𝑠𝑐𝑎𝑙𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟 𝛽𝑚
𝑁𝑖
∑𝑁
𝑖=1 ∑𝑚=1(𝑉𝑖𝑚 − 0.735) ∗ 𝐼((𝑉𝑖𝑚 > 0.735) 𝑝𝑚
=
∗
𝜎𝑉 𝑖𝑚
𝛽𝑚
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where: pm is the percentage of cells with mCTRs; 𝑉𝑖𝑚 is the volume of a megacentrosome
associated with a cell nucleus of 𝑚𝑡ℎ centrosome in 𝑖𝑡ℎ nucleus; where a megacentrosome is
defined as a centrosome whose volume exceeds the 𝑉𝑡ℎ critical for that tissue; 𝑉𝑡ℎ critical for
a given tissue is the maximum volume of a normal centrosome in that tissue which was 0.735
for breast tissue; ßm is a scaling factor used to ensure that both CASi and CASm are given
equal weight in the formula for CAStotal. value of ßm used here is 0. 148.. 𝜎𝑉 𝑖𝑚 is the standard
deviation of centrosomes?

For each mCTR (centrosome whose volume exceeds the upper limit of the normal centrosome
volume range for that tissue), a z-score is computed based on the formula below, reflecting the
extent to which the volume of that mCTR exceeds the maximal normal value (i.e., the value for
𝑉𝑖𝑚 − 𝑉𝑡ℎ critical is computed) relative to the baseline (achieved by dividing by the 𝜎𝑉 𝑖𝑚 the
standard deviation):
z=

𝑉𝑖𝑚 − 𝑉𝑡ℎ
𝜎𝑉 𝑖𝑚

Next, this value is multiplied by the number of mCTRs per nucleus. Finally, all these values
are averaged in order to obtain the severity score. The frequency component of CASm has
essentially the same overall mathematical formula as the corresponding term in the CASi
component. In the present form of the algorithm, the components CASi and CASm, contribute
equally to the total CAS score and are thus given equal weight.
4.3.7 Statistical Analysis
The test of group mean differences shown in Box-Whisker Plots is based on nonparametric
Wilcoxon Rank Sum Tests and Kruskal-Wallis Tests depending on the number of groups.
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Recurrence free survival was used as the endpoint for the survival analysis. Log-rank test of
equality over strata was applied to test the differences among the Kaplan Meier survival curves.
Cutoff points selected for all CAS scores in discovery set were kept same for validation cohort as
well. To estimate the effect of related variables on Hazard Ratios(HRs) together with 95%
confidence intervals, we used univariate or multivariate cox proportional hazard regression model.
Statistical analysis was performed using SAS software 9.4 (SAS Institute Inc., Cary, NC).
Statistical significance we claimed was based on p< 0.05 for each test we conducted.
4.4

Results

4.4.1 Traditional histopathological parameters fail to predict recurrence in DCIS patients
from the discovery set
In our discovery dataset, there were 133 (ICART5 cohort) patient samples with sufficient tissue
for CA analysis. Out of these 133 samples 32 patients presented with ipsilateral recurrence. Patient
cohort details are shown in Table 1. The median age of the 133 patients in the discovery group
was 58, and the median follow up was 24 months. Comedo necrosis was present in 111 and no
necrosis in 22 patients. Out of 133 patients, 118 were nuclear grade 3, 10 were nuclear grade 2,
and 5 were nuclear grade 1. 3% of patients had close excision margins (1mm or less). Out of 133
patients, 55 received patients received radiotherapy, and none of the patients were treated with
adjuvant chemo or hormonal therapy. Tumor high grade, the presence of comedo necrosis and
radiotherapy were three clinicopathological parameters which showed significant proportional
differences within the recurrence group and who remained recurrence-free (Table 4.4.1) in the
subgroups. However, when we performed univariate Cox regression analysis none of these
parameters showed any significant association with RFS (Table 4.4.2). Thus, indicating the limited
role of the histopathological parameters in predicting recurrence in this dataset.
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Table 4.4.1 Descriptive statistics of clinicopathological characteristics for DCIS patients
(ICART5 cohort) based on the recurrence status in the discovery cohort.

4.4.2 Recurrent DCIS exhibits higher CAS compared to non-recurrent DCIS
First, we immunofluorescently stained (details in materials and methods section) formalin fixed
paraffin embedded resection samples from DCIS patients (n=133) for centrosomes using an
antibody against γ-tubulin, and co-stained with DAPI for nuclei. As described in the materials and
methods section employing confocal microscopy we imaged the immune-stained slides and
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processed the raw 3D image data using IMARIS Biplane 8.2 3D volume rendering software. Next,
we calculated the centrosome number and volume in ~250 cells of each sample and finally, with
the help of mathematical equation, we integrated the numerical (CASi) and structural (CASm)
aberrations to generate a composite CAS total value for each sample. We observed that the DCIS
cases with recurrence (mean score 1.3055) exhibited significantly higher CASi when compared
with the no recurrence samples (mean score 0.73196) (p=0.0002; Figure.4.4.1C) (Note: values
indicated in the boxplots are based on Wilcoxon’s rank test). As mentioned in materials and
method section CASi is a combination of the severity and frequency of CA. When we looked at
them separately, DCIS cases with recurrence showed higher severity (p=0.09 Figure.4.4.2A) and
significantly higher frequency (p=0.0001 Figure.4.4.2B). Furthermore, when we looked at the
structural amplification the value of CASm was significantly higher (p=0.0280, Figure.4.4.1D) in
recurrence (mean score 1.09586) cases when compared with the no recurrence (mean score
0.80612) cases. Not only this further when CASm was broken in the severity and frequency we
found that DCIS cases with recurrence exhibited significantly higher severity (p=0.0070,
Figure.4.4.2C) and frequency (p=0.0468, Figure.4.4.2D) for structural amplification. Lastly, when
we combined the CASi and CASm to generate the CAS total values as mentioned in materials and
methods section, we observed that the CAS total was significantly higher in the recurrence (mean
score 2.4050) group when compared with the no-recurrence group (mean score 1.5381). Thus,
collectively our data suggests that a significant difference in centrosomal aberrations exist between
the recurrence and recurrence-free DCIS samples.
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Figure 4.4.1 DCIS with ipsilateral recurrence exhibit higher CAS.
(A) Representative H&E images of the ducts of the DCIS recurrence and no recurrence cases.
(Images were captured at 20x magnification). (B) Confocal micrographs showing numerical and
structural CA in recurrence and no recurrence DCIS tissue sections. DCIS tissue sections were
immunostained for centrosomes (γ-tubulin, red) and counterstained with DAPI (blue). Scale bar
(white), 20μm. (C) Representative Beeswarm Box plots for the pure DCIS (n=133) cases with
recurrence (n=32) and no-recurrence (101) for CASi. (D) Representative Beeswarm Box plots for
the pure DCIS (n=133) cases with recurrence (n=32) and no-recurrence (101) for CASm, (E)
Representative Beeswarm Box plots for the pure DCIS (n=133) cases with recurrence (n=32) and
no-recurrence (101) for CAStotal. p<0.05 was considered statistically significant.
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Figure 4.4.2 DCIS with ipsilateral recurrence exhibit higher CAS
Representative Beeswarn Box plots for the pure DCIS (n=133) cases with recurrence (n=32) and
no-recurrence (101) for different CAS values. A) CASi severity distribution, B) CASi frequency
distribution, C) CASm severity distribution, D) CASm frequency distribution. p<0.05 was
considered significant.

Next, we co-immunolabelled 15 DCIS samples with the centrosomes and centrioles respectively
with γ-tubulin and centrin-2 and performed the quantitation as described above. We found that
γ-tubulin foci invariably overlapped with centrin-2 foci in all the samples confirming that the
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structural amplified centrosomes represent enlarged γ-tubulin foci are bona fide centrosomes
and not just fragments of the pericentriolar material. In addition, we observed that there were
no supernumerary centrin-2 foci were present, suggesting that the enlarged γ-tubulin foci
represent structurally augmented centrosomes and not supernumerary centrosomes so tightly
clustered as to be indistinguishable (Fig 4.4.3).

Figure 4.4.3 Representative immunographs DCIS tissue sections immunolabeled for
centrin-2 (red) and γ-tubulin (green) and DAPI (blue) in split form.

4.4.3 CAS can stratify high- grade DCIS patients into subgroups with the high and low risk
of recurrence
Further, when we stratified all the patients into low- and high-CAS groups (threshold used was the
one that minimized log-rank p-value) (Figure. 4.4.4), we observed that high-CASi
(threshold=0.09) DCIS patients were associated with poorer RFS (p<0.001, HR=4.802; for CASisi
p=0.0879, HR=2.77, threshold= 1.09; for CASifi p<0.0001, HR=4.766, threshold= 0.08) when
compared with the low CASi group. Similarly, we observed that high CASm (threshold=0.0877)
group was associated with poorer RFS (p=0.0243, HR=2.396; for CASmsi p=0.0055, HR=5.409,
threshold=.3133, CASmfi p=0.069, HR=2.446, threshold=0.171) when compared with the low
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CASm group. Total CAS (threshold= 1.435) value was able to stratify the high-risk and low-risk
DCIS patients with highest significance and Hazard ratio (p<0.001, HR= 7.185) (Fig4.4.4 and
4.4.5). Interestingly, we observed that 93% of the cases with recurrence were in high CAS group.
This association with CAS stayed significant (p<0.001, HR=8.51) even after accounting for the
confounding factors like comedo necrosis, tumor grade, tumor size, age and the radiotherapy status
of the patient’s Table 4.4.2. As shown in Table 4.4.2 none of the clinicopathological parameters
showed any significant association with the recurrence except the CAS in both univariate and
multivariate analysis.
Furthermore, we performed the concordance analysis using SAS PROC PHREG procedures. This
procedure is based on the Harrell’s concordance index. Herein higher the C-statistics values, the
better the model can discriminate between patients who will present recurrence and patients who
do not. The results from this statistical test indicated that for any patient who has poorer/lower
RFS it would have a probability of 72.6% to be in CAS total high group.

Figure 4.4.4 Higher CAS is associated with poorer RFS in DCIS patients
Kaplan Meier survival curves representing the RFS in DCIS patients: (A) CASi high and low
groups, (B) CASm high and low groups, (C) CASt high and low groups. N is the total number of
patients in each group and R represents the number of patients who showed recurrence. %
calculated represents percentage/proportion of the recurrence patients out of the total number of
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recurrence

patients

in

both

groups.

p<0.05

is

considered

significant.

Figure 4.4.5 Higher CAS is associated with poor RFS in DCIS patients
Kaplan Meier survival curves representing the RFS in DCIS patients: (A) CASi high and low
groups based on the severity component, (B) CASi high and low groups based on the frequency
component, (C) CASm high and low groups based on the severity component, (D) CASm high
and low groups based on the frequency component. N is the total number of patients in each group
and R represents the number of patients who showed recurrence. % calculated represents
percentage/proportion of the recurrence patients out of the total number of recurrence patients in
both groups. p<0.05 is considered significant.
Table 4.4.2 Univariate and Multivariate Cox proportional regression analysis for the risk
of recurrence in DCIS patients treated with lumpectomy comparing the influence of
common clinicopathological variables along with the CAS total model.
Variables

0.001
0.8532

0.935

0.459

1.904

0.6345

Multivariate Analysis
Hazard 95% Hazard
Ratio
Ratio
Confidence
Limits
8.361
2.893
24.16
4
0.837
0.402
1.742

0.3032

1.466

0.708

3.306

0.4269

1.354

0.641

2.858

0.0921

0.317

0.134

0.752

0.0927

0.440

0.169

1.146

Pr > C
hiSq

CAS total
Age
Tumor size
Grade

CASt High
vs low
Age High vs
low
Tumor size
High vs low
Grade High
vs low

Univariate Analysis
Hazard
95%
Ratio
Hazard Ratio
Confidence
Limits
<7.58
2.893
24.164

Pr > Chi
Sq

<.0001
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Comedo
Necrosis
Radiothera
py

Comedo
present vs
absent
Radiotherap
y No

0.0603

2.441

1.149

5.185

0.0714

2.106

0.937

4.733

0.1405

1.959

0.870

4.414

0.3472

1.530

.630

.714

4.4.4 CAS can stratify the DCIS patients in recurrence and recurrence-free group with
higher significance than the Van Nuys Prognostic Index (VNPI)
VNPI is based on clinical and histopathological markers like tumor size, margin width, pathologic
classification (based on nuclear grade and presence/absence of comedo necrosis) and age of the
patients. This index has been used in clinics to decide the treatment strategy for the patients
presented with DCIS. Therefore, to test the performance of this test in our cohort we calculated
VNPI based on the scoring methods described in the literature. Briefly, each of the factors is
assigned a score between 1-3, and the sum total of values for the four parameters is taken as final
score further stratify the patients in high, low and intermediate risk groups of the recurrence.
Herein, we used the binary cutoff score of 8. Next, we performed univariate and Kaplan Meier
Survival analysis to compare the performance of the VNPI index in the discovery cohort (n=100
as VNPI index was available only for 100 patients out of total 133) (Fig 4.4.6A and B). We
observed that there was no significant association of higher VNPI with the poor RFS and that
VNPI was not able to stratify the patients in the high and low-risk for recurrence. In contrast, CAS
for the same patients was able to stratify the patients in high and low risk group and was able to
predict recurrence with higher significance and HRs (CAS- 8.8 vs. VNPI 0.959) (Table 4.4.3).
Moreover, when we performed multivariate analysis taking in account the other confounding
factors like tumor size, presence of comedo necrosis, age and radiotherapy along with VNPI, CAS
presented highest association with RFS with HR=10.41. These findings suggest that the CAS

110

model is better than the traditional VNPI index in predicting the recurrence in DCIS patients.

Figure 4.4.6 Kaplan Meier survival curves representing the RFS in DCIS patients based on
the VNPI and CAS.
N is the total number of patients in each group and R represents the number of patients who
showed recurrence. % calculated represents percentage/proportion of the recurrence patients out
of the total number of recurrence patients in both groups. p<0.05 is considered significant.

Table 4.4.3 Univariate analysis for the risk of recurrence in DCIS patients treated with
lumpectomy comparing the performance of VNPI and CAS models.
Variables
p-value
CAS total
VNPI

High vs low
High vs low

Hazard
Ratio

0.0034
0.9291

Univariate Analysis
95% Hazard Ratio Confidence
Limits
8.847
2.0671
37.93
0.959
0.377
2.436

4.4.5 CAS combined with age, tumor size and comedo necrosis is a superior model for
prediction of recurrence in DCIS patients
To further test the clinical significance of CAS score, we evaluated the associations of CAS with
the clinicopathological parameters used traditionally in clinical practice. In line with the
understanding that CA is associated with the more aggressive phenotype of the disease, we
observed that the CAS association with the recurrence risk (RR) in these subgroup analyses was
similar to that of the overall group of patients. Herein, in the recurrence rate forest plot (Fig 4.4.7)
it is shown that the high age group (red boxes) which is regardless of CAS is at high risk of
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recurrence (0.44) compared to that for overall patients (0.33). When we further stratified this group
in high and low CAS groups we observed that the recurrence rates for the high CAS group (green
boxes- RR-0.73) and low (blue boxes-RR- 0.10) (Fig 4.4.7) suggesting that CAS was further able
to stratify high and low age group in high and low-risk groups as with better RR. Similar trends
were observed for the tumor size, tumor grade, radiotherapy and comedo necrosis.
Thus, collectively these findings suggested that CAS compliments the traditional histopathological
parameters and is able to further stratify the patients in high and low-risk group of recurrence with
better RR. Next, to analyze if the compounded effect of CAS plus other parameters is able to
further stratify the patients’ estimated recurrence rate with more significant RFS difference among
hazard ratios we constructed a multivariate logistic regression model using CASi, CASm,
Age(High/Low), Comedo Necrosis(presence/absence), and Size(Large/Small) to estimate whether
recurrence will happen or not. Here we defined odds as ratio of Recurrence against Recurrence
free and computed the log odds value using following mathematical equation.
Log(Odds)=-3.1807+1.6072*CASi+0.7823*CASm-0.4757*I(age=High)
+0.9535*I(Comedo=present) +0.3230*I(Size=Large)
Here based on log(odds) value we classified patients in recurrence and recurrence free groups.
Wherein if log odds is positive, then we classify that case into recurrence group, and if it is
negative, it falls in into recurrence free group. When we compared our prediction result with true
final recurrence status, we observed 83.02% concordance rate. This multivariate model greatly
improves prediction accuracy compared with the model using CAS as predictor only, which has
74.47% of concordance. Thus, collectively these findings suggest that the CAS compliments the
traditional histopathological parameters and if combined with these clinical parameters is a
superior model.
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Figure 4.4.7 Recurrence rate for the clinically relevant parameters based on CAS total
Forest plot representing the estimates of the 5- year recurrence rate (with 95% confidence interval)
according to the CAS high and low risk subgroups for the clinical and pathological parameters.
Black box represents overall recurrence rate in patients (.39) Red box represents the recurrence
rate presented for the specific clinical parameter regardless of CAS. Green box represents the
recurrence rate in the high CAS group and blue represents recurrence rate in CAS low group in
every specific subgroup.

4.4.6 Recurrent DCIS cases exhibit higher CAS compared to the non-recurrence cases, and
high CAS is associated with worse RFS, in the validation cohort
Next, to confirm the legitimacy of the prediction of CAS and the CAS plus score (CP) model we
tested its performance on an exclusively different cohort of DCIS patients. Our validation cohort
consisted of 120 patient samples out of which 27 patients presented with ipsilateral recurrence.
Patient cohort details are shown in Table 4. The median age of the 120 patients in the discovery
group was 56, and the median follow up was 19 months. Relative to the discovery cohort patients
were equally distributed in subgroups based on Comedo necrosis and grades. Where Comedo
necrosis was present in 67 and no necrosis in 53. Out of 120 Patients, 60 were nuclear grade
high, 37 were grade median and 23 were low grade. 1.7% of patients had close excision margins

113

(1mm or less). Only 14 patients were treated with the radiotherapy out of 120. In this cohort, the
clinicopathological parameters like tumor size, presence of the comedo necrosis and no
radiotherapy were three clinicopathological parameters which showed significant proportional
differences within the recurrence group as well as when compared with the patients who remained
recurrence-free and they were also associated with the RFS.
Employing

the

same

methodology as

mentioned

for

discovery

cohort

we

immunofluorescently stained 120 formalin fixed paraffin embedded resection samples from DCIS
patients to visualize centrosomes and calculated the CAS scores. Similar to the discovery cohort
we observed that regardless of grade DCIS cases with recurrence exhibited significantly higher
CAS total when compared with the no recurrence samples (p<0.0001) (Figure.4.4.8B). Further we
observed similar trends for the other CAS values as we observed in discovery cohort where
significant higher CAS values were noted between the ranked mean score values of CASi
(p<0.0001) and CASm (p<0.0001) including the severity (CASi- p=0.0046, CASm-p=0.0037) and
frequency (CASi- p<0.0001, CASm-p<0.0001) for recurrence group when compared with the no
recurrence group (Figure 4.4.8 and 4.4.9).
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Table 4.4.4 Descriptive statistics of clinicopathological characteristics for DCIS patients
(ICART5 cohort) based on the recurrence status in the validation cohort.
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Figure 4.4.8 DCIS with ipsilateral recurrence exhibit higher CAS in validation cohort
(A) Confocal micrographs showing numerical and structural CA in recurrence and no recurrence
DCIS tissue sections. DCIS tissue sections were immunostained for centrosomes (γ-tubulin, red)
and counterstained with DAPI (blue). Scale bar (white), 20μm. (B) Representative Box-whisker
plots for the pure DCIS (n=120) cases with recurrence (n=27) and no-recurrence 93) for CASi. (C)
Representative Box-whisker plots for the pure DCIS (n=120) cases with recurrence (n=27) and
no-recurrence 93) for CASm. (D) Representative Box-whisker plots for the pure DCIS (n=120)
cases with recurrence (n=27) and no-recurrence 93) for CAS total. p<0.05 was considered
statistically significant.
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Figure 4.4.9 DCIS with ipsilateral recurrence exhibit higher CAS
Representative Box-whisker plots for the Grade matched (grade 3) pure DCIS (n=127) cases with
recurrence (n=30) and no-recurrence (93) for different CAS values. A) CASi distribution, B) CASi
severity distribution, C) CASi frequency distribution, D) CASm distribution, E) CASm severity
distribution, F) CASm frequency distribution. p<0.05 was considered significant.

Furthermore, in line with the findings in discovery cohort, when we looked at the RFS based on
the predefined CAS cutoffs for discovery cohort, we observed that CAS values were able to stratify
patients in high and low risk of recurrence with great significance. As shown in the Fig 8A high
74% of the recurrence patients fall into high CASi group whereas only 23% of the no recurrence
patients fall in this group. 92% of patients from the recurrence-free group are classified in the low
CASm group. Similarly, for CAS total significantly higher proportion of recurrence-free patients
i.e. 73% falls in the low CAS group whereas the significantly higher proportion of recurrence
group, i.e. 66.96% of recurrence falls in the high CAS total group. Though lower than the discovery
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cohort the hazard ratios of CAS total (p<0.001, HR=4.127) on the validation cohort are still higher
than the other clinicopathological parameters (Table 4.4.5). This association stays significant even
after controlling the other confounding factors like age, tumor size, grade, comedo necrosis and
radiotherapy. Thus, the results collectively indicate that the CAS can significantly predict
recurrence in DCIS patients from two different cohorts.

Figure 4.4.10 Higher CAS is associated with poor RFS in DCIS patients
Kaplan Meier survival curves representing the RFS in DCIS patients form validation cohort (A)
CASi high and low groups, (B) CASm high and low groups, (C) CASt high and low groups. N is
the total number of patients in each group and R represents the number of patients who showed
recurrence. % calculated represents percentage/proportion of the recurrence patients out of the
total number of recurrence patients in both groups. p<0.05 is considered significant.

Table 4.4.5 Univariate and Multivariable Cox proportional regression analysis for the risk
of recurrence in DCIS patients treated with lumpectomy comparing the influence of common
clinicopathological variables along with the CAStotal model for validation cohort.
Variables

<0.001

4.127

1.870

9.111

Multivariate Analysis
Hazard
95%
Ratio
Hazard
Ratio
Confidence
Limits
<.0048 3.391
1.451 7.926

0.1289

0.523

0.227

1.207

0.0632

0.392

0.402

1.503

0.0264

1.38

0.134

3.298

0.0172

2.743

1.197

6.284

0.9364

0.969

0.446

2.107

0.8893

1.072

0.4

2.869

0.0144

2.745

1.222

6.165

0.0177

1.215

7.770

0.280

5.845

p-value

CAS total
Age
Tumor
size
Grade
Comedo
Necrosis
Radiother
apy

CASt High
vs low
Age High
vs low
Tumor size
High
vs
low
Grade High
vs low
Comedo
present vs
absent
Radiothera
py No

Univariate Analysis
Haza 95% Hazard Ratio
rd
Confidence
Ratio Limits

p-value

3.073
0.7828

1.226

0.228

5.216

0.7509

1.279
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4.4.7 Higher CAS is observed in the mixed DCIS cases when compared with the Pure DCIS
In our mixed DCIS cohort, there were 87 patient samples with sufficient tissue for CA analysis.
Out of these 87 samples 10 patients presented with ipsilateral recurrence. Patient cohort details are
shown in Table 4.4.6. The median age of the 87 patients in the mixed group was 55 and the median
follow up was 27.7 months. Comedo necrosis was present in 57 and no necrosis in 30. Out
of 87 patients, 32 were nuclear grade 3, 39 were grade 2, and 16 were grade 1. Given the presence
of an invasive component in the mixed DCIS cohort the 40 patients were treated with adjuvant
chemotherapy and 59 were treated with radiotherapy following surgery Table 4.4.6. We stained
the mixed DCIS cases (n=87) for centrosomes using the same methodology as mentioned for
discovery and validation cohorts. We observed that the mixed DCIS samples exhibited
significantly higher CASi (p=0.0043), CASm (p=0.0006) and CAS total (p<0.0001) when
compared to the pure DCIS cases (n=133) (Fig 4.4.11). This suggested that CA has a critical role
in tumor progression.
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Table 4.4.6 Descriptive statistics of clinicopathological characteristics for mixed DCIS
patients (ICART5 cohort) based on the recurrence status.
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Figure 4.4.11 Mixed DCIS exhibit higher CAS when compared with pure DCIS
Representative Box-whisker plots for the mixed DCIS (n=87) and pure DCIS (n=133) cases. A)
CASi distribution, B) CASm distribution, C) CASt distribution. p<0.05 was considered significant.

4.5

Discussion

In the current management of DCIS patients, physicians are faced with the issue of whether to
recommend adjuvant radiotherapy and/or chemotherapy treatment to their patients in addition to
surgery. To aid in this decision, a number of factors are taken into account, including patient age,
tumor margins, grade, and size, but the evidence to support these and other potential features as
prognostic is variable. In the current study, we developed a novel methodology and algorithm to
quantitate both numerical and structural centrosomal aberrations in tumor samples and generated
a recurrence prediction score to help in the treatment decision. Our findings indicate that the
patients with recurrence exhibit higher CAS total when compared with the recurrence free DCIS
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patients. CAS was also associated with poor RFS in DCIS patients and this association was
significant even in multivariable models. CAS total presented an HR of 7.5 in a univariate model
and 8.5 in a multivariate model. These associations of CAS stayed significant in our validation
cohort as well. We further compared the performance of CAS with a known predictive model
VNPI. VNPI is based on clinical and histopathological markers like tumor size, margin width and
pathologic classification (based on nuclear grade and presence/absence of comedo necrosis)[4, 17,
18] incorporates age as the fourth contributing factor for the prediction. When both CAS and VNPI
were factored into multivariable models, only CAS was significantly associated with RFS. This
finding suggests that when CAS is accounted for VNPI no longer holds predictive value.
CAS was further able to stratify the DCIS patients into high and low-risk groups of
recurrence and was able to predict 5-year risk of local recurrence with higher concordance than
what has been proposed by other models, independent of traditional clinical and pathological
factors. These findings stayed significant for the validation cohort as well even though our
discovery and validation cohort had patients with different clinical and pathological parameters
thus indicating the applicability of CAS model is not limited to a specific cohort of patients. Most
of the predictive models which have been used in clinics till now have been proven beneficial for
specific cohort of patients such as Oncotype DCIS score. This test has limited applicability only
to the cases with resection margins of at least 3 mm and low- or intermediate-grade DCIS
measuring 2.5 cm or less, or if HG DCIS 1 cm or less in size, as this is the set of patients from
ECOG 5194 study upon which the test was initially clinically validated[8]. Thus, the global
applicability of this test is limited.
Furthermore, when we further stratified the DCIS patients in the different subgroups based
on the traditional clinical and histopathological parameters the recurrence rate (RR) of CAS high
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group increased. In high age group regardless of CAS the recurrence rate was 44% (33% in overall
patients) When we further stratified this (high age) group in high and low CAS groups we observed
that the recurrence rates for the high CAS group increased to 73% suggesting that CAS was further
able to stratify high and low age group in high and low-risk group. We observed similar trends for
the other clinical and pathological markers such as tumor size and presence of comedo necrosis.
Thus, we generated a combined score where we incorporated the prediction rate from these clinical
and pathological factors. This new score, i.e., CAS plus score increased the concordance for
recurrence prediction from 76.2 for CAS total alone to 82 with CAS plus score. These findings
suggest that with the incorporation of these clinical and pathological parameters the recurrence
prediction increased with a significant number for CAS.
Another major challenge in the management of DCIS is the determination of the accurate
margins. It is now documented that 10-50% of DCIS lumpectomies are followed by a re-surgery
because of "close or positive margins"-in which some tumor is still found on postsurgical
pathologic review in the margins of the removed breast tissue[19]. The positive margin suggests
that some tumor was left behind in the body cavity, and frequently leads to a second surgery. These
re-excisions cause considerable morbidity, as well as emotional, and financial burdens on the
patients. Here in the current study we observed that high CAS was associated with positive margins
and since CAS able to stratify the patients in high and low risk groups of recurrence we suspect
that if CAS based risk profiling is done on the core biopsies it could significantly reduce resurgeries by better predicting who might need a mastectomy to begin with, and for whom resurgery might not be necessary even in the event of close/positive margins.
CAS, as described earlier, is the linear expression of the extent and the frequency of
numerical and structural CA. Centrosome clustering enables chromosomal missegregation
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chromosomes and their unequal distribution to daughter cells resulting in chromosomal instability
(CIN), thus contributing to neoplastic transformation. Given that CIN engenders karyotypic
diversity within tumors, we assert that CAS may perhaps even serve as an indirect measure of ITH
in DCIS. Moreover, our findings also indicate higher levels of CAS in the mixed DCIS cases.
These findings are in line with the previous findings where we and others observed TNBCs the
most aggressive subtype of breast cancer exhibit highest CA among all subtypes[20, 21]. These
findings further substantiate the role of CA in tumor progression and given that CA translates to
the greater risk of malignant transformation, it may help to determine the patient prognosis. An
exciting avenue for future research would be to profile CA in all the stages of tumor progression
starting from the atypical hyperplasia to invasive and metastatic disease to evaluate if CA can
function as a biomarker for tumor evolution.
4.6
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5.1

Abstract

Amplified centrosomes are widely recognized as a hallmark of cancer. Although supernumerary
centrosomes would be expected to compromise cell viability by yielding multipolar spindles that
results in death-inducing aneuploidy, cancer cells suppress multipolarity by clustering their extra
centrosomes. Thus, cancer cells, with the aid of clustering mechanisms, maintain pseudobipolar
spindle phenotypes that are associated with low-grade aneuploidy, an edge to their survival.
KIFC1, a nonessential minus end-directed motor of the kinesin-14 family, is a centrosome
clustering molecule, essential for viability of extra centrosome-bearing cancer cells. Given that
ovarian cancers robustly display amplified centrosomes, we examined the overexpression of
KIFC1 in human ovarian tumors. We found that in clinical epithelial ovarian cancer (EOC)
samples, an expression level of KIFC1 was significantly higher when compared to normal tissues.
KIFC1 expression also increased with tumor grade. Our In silico analyses showed that higher
KIFC1 expression was associated with poor overall survival (OS) in serous ovarian
adenocarcinoma (SOC) patients suggesting that an aggressive disease course in ovarian
adenocarcinoma patients can be attributed to high KIFC1 levels. Also, gene expression levels of
KIFC1 in high-grade serous ovarian carcinoma (HGSOC) highly correlated with expression of
genes driving centrosome amplification (CA), as examined in publically-available databases. The
pathway analysis results indicated that the genes overexpressed in KIFC1 high group were
associated with processes like regulation of the cell cycle and cell proliferation. In addition, when
we performed gene set enrichment analysis (GSEA) for identifying the gene ontologies associated
to KIFC1 high group, we found that the first 100 genes enriched in KIFC1 high group were from
centrosome components, mitotic cell cycle, and microtubule-based processes. Results from in vitro
experiments on well-established in vitro models of HGSOC (OVSAHO, KURAMOCHI),
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OVCAR3 and SKOV3) revealed that they display robust centrosome amplification and expression
levels of KIFC1 was directly associated (inversely correlated) to the status of multipolar mitosis.
This association of KIFC1 and centrosome amplification with HGSOC might be able to explain
the increased aggressiveness in this disease. These findings compellingly underscore that KIFC1
can be a biomarker that predicts an aggressive disease course in ovarian adenocarcinomas.
5.2

Introduction

Ovarian cancer is the sixth most common cancer affecting women worldwide and is the fifth
leading cause of deaths related to gynecological malignancies with less than 40% overall cure rate
[1]. The overall mortality of ovarian cancer has remained largely unchanged over the past decades
even though there is a great advancement in surgical and therapeutic approaches [2]. The standard
treatment for ovarian cancer patients is debulking surgery followed by a platinum- based
chemotherapy (cisplatin and carboplatin) [3, 4]. One of the primary causes of the high mortality
and poor survival in ovarian cancer is the diagnosis at late stages [5]. Despite years of extensive
research, there is still a dearth of reliable biomarkers for early detection, prognosis, and predicting
disease aggressiveness. Since ovarian cancer is a heterogeneous disease with different
histopathological features and clinical behavior, a better understanding of molecular subtypes and
search for clinically-facile prognostic factors that can aid in histological subtyping is imperative.
Greater than 90% of malignant ovarian tumors are epithelial ovarian carcinomas (EOC)
comprising of various subtypes namely serous, endometrioid, clear cell, transitional cell, squamous
cell and mucinous carcinomas [6, 7]. About 70-80% of all cases are serous ovarian cancer (SOC)
among which high-grade serous ovarian cancer (HGSOC) is the most prevalent [8]. Intriguingly,
HGSOC shares similar genomic features with triple negative breast cancer (TNBC) as per reports
from Cancer Genome Atlas (TCGA) Network analysis; in particular, the deregulated pathways
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characterizing HGSOC are very similar to those in TNBC [9]. Several independent studies have
indicated that HGSOC is associated with very high genomic instability and chromosomal
aberrations including intrachromosomal breaks and aneuploidy, which incidentally, also typify and
drive intratumoral heterogeneity in TNBC [10, 11].
Specifically, the most common mutations present in both kinds of tumors (HGSOC and
TNBC) are of p53 and BRCA1/2. It is well established that BRCA1 and BRCA2 tumor suppressor
genes directly preserve genomic stability by regulating DNA repair, p53-mediated cell cycle
checkpoint control as well as centrosome duplication cycle [12-14]. These findings establish the
causative link between BRCA1 and BRCA2 mutations and extensive chromosomal instability
found in HGSOC patients. Furthermore, HGSOC tumors frequently overexpress cyclin E and
Aurora-A, resulting in aberrant activation of the centrosome duplication cycle that induces
centrosome amplification (CA), and eventually genetic instability fueling ovarian cancer
progression [15-17]. CA results in numerous and voluminous centrosomes [18]. Subjectively, the
presence of supernumerary centrosomes sets the stage for the formation of multipolar spindles that
may succumb to a mitotic catastrophe. However, cancer cells avoid this calamitous fate by
clustering their extra centrosomes at the two spindle poles, which allows them to evade cell death
but ultimately engenders low-grade aneuploidy and genetic instability [19-21].
KIFC1, a nonessential kinesin motor protein, also known as HSET, plays a critical role in
clustering of extra centrosomes in cancer cells. Recently several studies have shown that
knockdown of KIFC1 in cancer cell lines containing supernumerary centrosomes causes the excess
centrosomes to be scattered by pole-separating forces that induce spindle multipolarity and cell
death. However, KIFC1 is not required for bipolar spindle assembly in healthy somatic cells [22,
23]. We recently demonstrated that EOC clinical samples harbor extra centrosomes and display
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high levels of centrosome clustering in interphase as well as mitosis. In addition, the study
highlighted that the gene expression levels of KIFC1 are higher in EOC when compared to normal
ovarian tissues in silico and is associated with worse prognosis and survival [24]. To further
understand and validate results of our previous study, we herein evaluated KIFC1 expression in
clinical samples of ovarian cancer by utilizing immunohistochemical staining.

Our results

indicated higher KIFC1 expression in EOC tumor samples when compared to normal tissues.
Furthermore, KIFC1 expression levels in EOC increased with an increase in tumor grade. To
understand better the association of KIFC1 with CA, we examined correlations between expression
levels of KIFC1 and genes driving CA. Intriguingly, higher gene expression levels of KIFC1 was
significantly correlated to expression of CA-driving genes. When GSEA was performed for the
genes enriched in KIFC1-high group, they were also found to be related to centrosome components
and microtubule-based processes. We further validated the correlation by doing quantitative
analysis of CA and extent of clustering in cell lines derived from SOC patients. Our results
indicated that KIFC1 was highly expressed in these in vitro models of SOC and was also associated
to levels of centrosome clustering (mitotic), enabling cells to bypass mitotic catastrophe.
Taken together our findings underscore that KIFC1 is a potential prognostic biomarker in
ovarian adenocarcinomas wherein expression levels of KIFC1 may predict the course of disease
aggressiveness. Work is underway in our laboratory to pin point molecular mechanism to explain
the association of KIFC1 and CA with ovarian cancer aggressiveness and poor patient outcomes.
5.3

Materials and Methods

5.3.1 Cell Culture
The four ovarian cancer cell lines primarily utilized in this study included OVCAR3,
KURAMOCHI, SKOV3, and OVSAHO. The SKOV3 and OVCAR3 cell lines were obtained from
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ATCC and KURAMOCHI, and OVSAHO were obtained from JCRB. All the cell lines were
cultured according to the instructions given by the company.
5.3.2 Immunohistochemistry and scoring
Formalin-fixed paraffin-embedded tissue microarrays (TMAs) for ovarian cancer were obtained
from US, Biomax, Inc. Company provided the ethical statement to confirm that, all the participants
provided their written consents and patient privacy and anonymity was maintained. TMAs were
deparaffinized in a 60°C oven for 20 minutes and placed in 3 consecutive xylene washes.
Rehydration of the slides were carried out by putting them through a series of washes involving
different concentrations of ethanol in water - 100%, 95%, 70%, and 50% - for 3 minutes each. The
antigen retrieval process was done using a pressure cooker and 0.01M citrate buffer with a pH of
6.1. The slides were heated at a temperature of 120°C for 30 minutes. After cooling in ice for 20
minutes, the slides were first subjected to hydrogen peroxide blocking and then protein blocking
(both obtained from ThermoScientific) for 20 minutes and 10 minutes, respectively. Tissues were
incubated with anti-KIFC1 antibody (Abcam) for 1 hour, before incubating with MACH2 HRPconjugated secondary antibody (Biocare Medical) for 30 minutes. Enzymatic antibody detection
using Betazoid DAB Chromogen Kit (Biocare Medical) was followed by nuclear staining with
Myer’s hematoxylin (Dako). The staining intensity was scored as 0=none, 1=low, 2=moderate, or
3=high, and the percentage of KIFC1-positive cells from 10 randomly selected fields (~500 cells)
was determined. The product of the staining intensity and the percent of positive cells constituted
the WI. Statistical analysis was performed using – Tukey’s post hoc test.
5.3.3 Cell staining and imaging
Cells were cultured on coverslips and, after the confluency reached approximately 80%,
the cells were fixed with ice-cold methanol for 7 minutes. The cells were blocked with 5%
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BSA/0.01% Triton X for 45 minutes at room temperature and then incubated at 37°C with
antibodies directed against γ-tubulin and α-tubulin at a dilution of 1:2000 for 30 minutes. The cells
underwent quick washes 5 times with 1xPBS before being incubated with Alexa Fluor 488 antimouse and Alexa Fluor 555 anti-rabbit at a dilution of 1:2000 at 37°C for 30 minutes. After
washing the cells 8 times with 1x PBS briefly, the cells were then incubated with Hoechst 33342
(1:5000 dilution) at room temperature for 10 minutes. The cells were mounted with Prolong-Gold
antifade reagent after being washed with 1x PBS 3 times and observed using Zeiss LSM 700
Confocal microscope (Oberkochen, Germany) and the images were processed with ZEN software
(Oberkochen, Germany).
5.3.4 Immunoblotting
Cell lysates were prepared from 80% confluent cells by scraping with 250ul of 1x lysis prepared
from 10x cell lysis buffer (Cell Signaling). The 1x lysis buffer contained 1mM bglycerophosphate, 20mM Tris-HCl (pH 7.5), 1mM Na2EDTA, 1mM Na3VO4, 150mM NaCl,
1mM EGTA, 2.5mM Na4P2O7, 1ug/ml leupeptin, and 1% Triton. Cell lysates were fractionated
using 10% SDS-PAGE gel. The samples were allowed to run at 70V for 90 minutes. Protein
transfer onto polyvinylidene difluoride (PVDF) membrane was done for 2 hours via the wet
transfer method at 70V. The membrane was then blocked in 5% non-fat, dry milk in 1x TBST for
1 hour at room temperature and probed with the relevant antibodies at a dilution of 1:1000
overnight at 4°C. Primary antibody incubation was followed by incubation with the corresponding
secondary antibody at a dilution of 1: 10,000 for 1 hour at room temperature. SuperSignal West
Pico Chemiluminescent Substrate (ThermoScientific) was directly applied to the membrane for
the subsequent analysis. Cyclin E and Centrin-2 antobodies were obtained from Santa Cruz
Biotech, γ-tubulin from Dako, and KIFC1 and Aurora A antibodies from Abcam.
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5.3.5

In silico analysis

One channel microarray data was downloaded from gene expression omnibus (GEO) database for
primary ovarian cancer samples GSE 9899 [25]. Data was Mas5.0 normalized and was further
taken for processing. Logarithm to the base 2-transformed KIFC1 expression levels from all
ovarian cancer samples (n=284) regardless of histotypes were extracted from GEO database.
Further analysis were carried only on the serous adenocarcinoma samples (n=200). Overall
survival (OS) was calculated as the time interval (in months) from the date of histological diagnosis
to date of death from any cause. KIFC1 was categorized into high and low groups based on the
optimal overall survival cut - points using the log-rank test.
5.3.6 Public microarray data analysis
Robust Multi-array Average normalized expression levels of KIFC1 and genes which drive CA
(CCNA2, CDK1, NEK2, AURKA, MYCN, CCNE2, STIL, LMO4, PLK4, MDM2, CEP63, E2F1,
E2F2, E2F3, CEP152, PIM1, PIN1, CCND1) from the primary serous ovarian carcinoma of 154
patients were obtained from GEO series GSE 9899 To obtain Pearson’s correlation coefficients
between genes whose dysregulation drives CA, SAS software (IBM) was used for the analyses,
with p<0.05 indicating statistical significance.
5.3.7 Gene set enrichment analysis of public microarray data
Publicly available pre-processed gene expression profiles of primary ovarian tumors (n=154 from
Tothill dataset [25], GSE9899; Patients were stratified into two groups by KIFC1 score. Patients
with KIFC1 expressions below the optimal KIFC1 survival threshold where placed in the low-risk
group whereas the above threshold patients where stratified to the high-risk group. GSEA was
performed as indicated in studies by Tamayo, et al. (2005, PNAS 102, 15545-15550) and Mootha,
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Lindgren, et al. (2003, Nat Genet 34, 267-273). False discovery rate q-values.25 were considered
statistically significant.
5.3.8 In silico analysis of KIFC1 gene expression and centrosomal amplification index
(CAI) genes in cell lines
One channel microarray data was downloaded from GEO database for four cell lines with GSM
ids GSM133614, GSM133609, GSM887467 and GSM887488 namely, Ovcar-5, SKOV3,
OVSAHO, and OVCAR3 respectively. Data was Mas5.0 normalized and was further taken for
processing. Logarithm to the base 2 transformed KIFC1 and expression levels from ovarian cell
lines were extracted from the GEO database. PLK4, Aur-A, Aur B, Cyclin E, Centrin, γ-tubulin
and pericentrin genes expression values were added to make centrosomal amplification index.
5.3.9 Statistical analysis
Statistical analyses were performed using two-tailed Student’s t-tests, Anova and Tukey’s post hoc
tests. The criterion for statistical significance for all analyses was p<0.05. Standard errors were
calculated using the general Excel formula where we divided the standard deviation by the square
root of the number of samples. Kaplan-Meier analysis and Cox regression were performed using
SPSS (IBM). Optimal cut-points were identified with the stratification which gave the largest logrank χ2 value.

5.4

Results

5.4.1 KIFC1 is overexpressed in Epithelial Ovarian adenocarcinoma (EOC) clinical samples
We first examined whether KIFC1 is upregulated in human ovarian cancers by analyzing KIFC1
overexpression in EOC clinical samples. To this end, we immunostained paraffin-embedded
formalin-fixed tissue microarrays of EOC (n=120) and normal ovarian epithelial tissue (n=13) for
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KIFC1. The staining intensity was scored as 0=none, 1=low, 2=moderate, or 3=high, and
percentage of positive cells (i.e., with 1+ staining intensity) from randomly selected fields (~500
cells) was determined [18]. The product of the staining intensity and the percent of positive cells
constituted the Weighted

Index

(WI). Descriptive statistics

regarding patient

and

clinicopathological characteristics is given in Table 5.41A, B. In consonance with our previously
published study [24], our immunohistochemical analysis showed overexpression of KIFC1 in EOC
tissues with negligible expression in normal ovarian epithelial tissue (Figure 5.4.1A). We found
that the number of positively-stained nuclei per field in high-grade ovarian cancers (Figure
5.4.1A) was significantly higher compared to low-grade ones. We then compared the nuclear
KIFC1 WI values for normal and tumor samples and also across grades for tumor samples.
Interestingly, we observed that nuclear KIFC1 WI was significantly higher in EOC tissues when
compared to normal tissues (p<0.01). Also, the nuclear KIFC1 WI increased with increasing tumor
grade (Figure 5.4.1Bii) (p<0.05). Among subtypes, we noticed that the number of positivelystained nuclei per field in high-grade serous ovarian cancers (Supplementary Figure. 5.7.1A3)
was significantly higher compared to low-grade serous ovarian cancers (p<0.05). Collectively,
these observations indicate robust KIFC1 overexpression in human ovarian adenocarcinoma and
strong association of KIFC1 expression levels with clinical progression of the disease. These data
suggest that KIFC1 might play an active role in driving the progression of tumors into more
malignant and aggressive forms.
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All supplemental data, tables, and figures appear in Appendix C for this chapter
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Figure 5.4.1High grade epithelial ovarian carcinomas exhibit higher expression of KIFC1
than low-grade adenocarcinomas and uninvolved, adjacent normal tissues.
A. Low magnification (4x) and their corresponding higher magnification (20x) images depicting
KIFC1 expression in normal, low-grade and high-grade EOC tissues. The tissues were stained for
KIFC1 (brown) and nuclei (blue). Scale bar (red) 20 µm. Bi. Box-whisker plot depicting the
weighted index (WI) of KIFC1 expression in normal and tumor tissue. Bii. Box-whisker plot
representing the WI for KIFC1 expression in low and high-grade EOC samples.
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Table 5.4.1 A: Descriptive statistics for patient and clinicopathologic characteristics in the
analysis of KIFC1 levels in tumors and matched normal tissue.
Variable

Age

Grade

Stage

Primary Tumor (T)

Regional Lymph
Nodes(N)

Distant Metastasis

Level

Number

Percentage

20-40

23

19.2

41-60

81

67.5

61<
1

16
32

13.3
26.7

2

36

30

3

46

38.3

Unknown

6

5

I

69

57.5

II

31

25.8

III

12

10

IV

3

2.5

Unknown

5

4.2

T1

72

60

T2

31

25.8

T3

12

10

Unknown
N0

5
103

4.2
85.8

N1

12

10

Unknown

5

4.2

Yes

3

2.5

No

112

93.3

Unknown
Malignant

5
115

4.2
95.8

Metastasis

5

4.2

Tissue Type
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Table 5.4.1 B: Descriptive statistics for Pathological diagnosis in the analysis of KIFC1 levels
in tumors and matched normal tissue.
Variable

Level

Adenocarcinoma
Serous
Adenocarcinoma
Serous Papillary
Adenocarcinoma
Endometrioid
Adenocarcinoma
Metastatic
Adenocarcinoma
Pathological
Metastatic
Diagnosis
Mucinous Adenocarcinoma
Mucinous
Adenocarcinoma
Clear Cell
Carcinoma
Serous Papillary
Carcinoma
Serous Papillary
Cystadenocarcinoma
SD= standard deviation;

Number

Percentage

2

1.7

6

5

3

2.5

10

8.3

4

3.3

1

0.8

11

9.2

4

3.3

32

26.7

47

39.2

5.4.2 Enhanced KIFC1 gene expression is associated with poor survival in HGSOC patients
Having established a significant correlation between KIFC1 expression and tumor differentiation,
we next wanted to determine if there is any association between KIFC1 gene expression and
clinical outcomes (overall survival (OS)) for ovarian cancer patients. To this end, we examined
single channel microarray data from GEO (GSE9899) [25] to compare the expression levels of
KIFC1 among different subtypes. Interestingly, we found that the gene expression levels of KIFC1
were significantly higher in serous ovarian adenocarcinoma (n=154) when compared to all other
subtypes (Borderline serous adenocarcinoma, n=18 and Peritoneal serous adenocarcinoma, n=22)
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(Figure 5.4.2A). Further, we examined grade-wise trends in KIFC1 expression in serous ovarian
adenocarcinoma. We observed a significant increase in KIFC1 expression levels with increasing
grade (Figure 5.4.2B). OS was calculated as the time interval (in months) from the date of
histological diagnosis to date of death from any cause. We then carried out a survival analysis
wherein patients were stratified into high- and low-KIFC1 expressing subgroups using the optimal
KIFC1 expression cut-point (based on the log-rank test). Irrespective of the histological subtypes
(n = 284), those with higher KIFC1 expression had shorter OS (p<0.067) than patients with lower
KIFC1 (Supplementary Figure 5.7.2A). To investigate in-depth, we performed a similar survival
analysis by stratifying serous ovarian adenocarcinoma patients (n= 201) on the basis of site
(primary, n= 154 and metastatic, n= 47) of sample collection. Univariate regression revealed high
KIFC1 gene expression correlated significantly (HR= 2.14, p=0.024) with poor OS in primary
tumors only (Figure 5.4.2C) but not in metastatic ones (data not shown). This association stayed
significant (HR=2.6, p=0.006) during multivariate analysis when potentially confounding factors
like grade and tumor stage were added (Supplementary Figure 5.7.2B). In sum, enhanced gene
expression levels of KIFC1 in primary tumors is strongly associated with poor clinical outcome.
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Figure 5.4.2 KIFC1 is highly expressed in High grade serous ovarian adenocarcinoma and
is associated with poor overall survival.
A. Box-whisker graphs depicting the expression levels of KIFC1 among different subtypes of
ovarian cancer. B. Box- whisker graphs depicting the expression levels of KIFC1 in serous ovarian
adenocarcinoma in different tumor grades. Ci. Kaplan-Meier plots showing overall survival of
HGSOC patients based on low or high expression of KIFC1 gene. Cii. Summary of the number of
censored and uncensored values for the Kaplan-Meier survival analysis.
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Table 5.4.2. Descriptive statistics and clinicopathologic characteristics for patients included
in in silico analysis of KIFC1 expression and overall survival.
VARIABLE

LEVEL

NUMBER

PERCENTAGE

Age (Range)

20-29
30-39
40-49
50-59
60-69
70-79
80-89
Unknown
Primary
Metastasis
Unknown
I
II
III
IV
Unknown
1
2
3
Unknown
Alive
Dead
Unknown
Recurrence
No Recurrence
Unknown

1
4
23
84
54
40
1
1
154
50
4
9
9
126
10
54
6
80
120
2
109
98
1
154
53
1

0.5
1.9
11.1
40.4
26
19.2
0.5
0.5
74
24
1.9
4.3
4.3
60.6
4.8
26
2.9
38.5
57.7
1
52.4
47.1
0.5
74
25.5
0.5

Cancer Site

FIGO Stage

Grade

Survival Status

Recurrence

5.4.3 KIFC1 gene expression correlates with expression of genes related to centrosomal
amplification in serous ovarian cancer
Next, we sought to examine the correlation of KIFC1 and genes driving CA. We analyzed
expression levels of genes including CCNA2, CDK1, NEK2, AURKA, MYCN, CCNE2, STIL,
LMO4, PLK4, MDM2, CEP63, E2F1, E2F2, E2F3, CEP152, PIM1, PIN1 AND CCND1, whose
deregulation is known to drive ca [18, 26-28]. Specifically, we tested the associations between
robust multi-array average-normalized expression levels of these genes in primary soc from 154
patients using gene expression omnibus (GEO) series GSE9899. Higher expression of KIFC1 was
significantly correlated with high expression OF CCNA2, CDK1, NEK2, AURKA, E2F2, MYCN,
STIL, CCNE2, E2F3, LMO4, PLK4, PIN1 AND E2F3 (Table. 5.4.3). These results suggest that
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KIFC1 upregulation and enhanced centrosome clustering in the serous ovarian adenocarcinomas
may enable tumor cells to manage their increased centrosomal load, avert mitotic catastrophe and
promote survival.
Next, we identified the biological processes which are deregulated in the KIFC1 high risk group.
To this end, we probed the publicly-available microarray dataset (GSE9899) and stratified the 154
serous ovarian adenocarcinoma patients from the dataset into KIFC1-high and KIFC1-low groups.
We then identified the gene ontologies of significantly overexpressed genes associated with the
KIFC1-high group utilizing the panther classification system. When pathway analysis was
performed we found that majority of the genes overexpressed were associated to cellular processes
like cell communication, cell cycling, cytokinesis and cell proliferation (Figure 5.4.3ai, ii). We
then validated these results by performing the gene set enrichment analysis (26). We found that
KIFC1 high group was significantly (FDR <0.25 and es p<0.05) enriched in centrosome and cell
cycle gene sets (Figure 5.4.3bi, ii and Supplementary Figure 5.7.3a) (see supplementary table
5.7.1, 2 and 3 for these and all other enriched gene ontologies). The results from GSEA showed
that the top 100 gene sets enriched in KIFC1 high group were among the ones which plays key
roles in, driving ca (NEK2, PLK1, CCNA2), clustering centrosomes (PRC1), microtubule spindle
(KIF11, NUSAP1, NUMA1) etc. Altogether our data shows that the KIFC1-high group had a
preponderance of genes representing all four important mitotic kinases –namely polo-like kinases
(PLK1), aurora kinases (AURKA, AURK B), cyclin dependent kinases (CDK1) and nima related
kinases (NEK1, NEK2). The coordination of progression through mitosis is mainly orchestrated by
protein phosphorylation ensured by these kinases. Thus, it is reasonable to speculate that
overexpression of these kinases results in deregulation of the cell cycle resulting in abnormal
mitosis that generates cells with aberrant centrosomes and abnormal chromosomal content.
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Figure 5.4.3 Gene set enrichment analyses for biological processes associated to KIFC1
high group.
Ai. Biological processes enriched in KIFC1 high group. Aii. Cell cycle processes enriched in
KIFC1-high group. Bi Enrichment plots of centrosome-related genes. Bii. Enrichment plot of
genes associated with cell cycle progression, with red indicating correlation with the KIFC1-high
group and blue the KIFC1-low group.
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Table 5.4. 3. Correlation between KIFC1 expression and expression of genes whose
dysregulation drives centrosome amplification.

GENE

PEARSON CORRELATION

P-VALUE

CCNA2

0.62527

<.0001

NEK2

0.60066

<.0001

E2F1

0.54218

<.0001

CDK1

0.52124

<.0001

E2F2

0.51764

<.0001

AURKA

0.46987

<.0001

STIL

0.397

<.0001

CCNE2

0.36387

<.0001

LMO4

0.36306

<.0001

PLK4

0.34292

<.0001

MYCN

0.31914

<.0001

E2F3

0.31548

<.0001

MDM2

0.24766

0.002

PIN1

0.23016

0.0041

CEP152

0.18128

0.0245

PIM1

0.17826

0.027
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5.4.4 HGSOC cell lines show higher incidence and severity of centrosome amplification
Having confirmed the association between upregulation of KIFC1 gene and CA genes in HGSOC,
we wanted to investigate the CA profile in well-established in vitro cell lines that mimic HGSOC.
To this end, we first screened four well-established cancer cell lines (namely, KURAMOCHI,
OVCAR3, OVSAHO and SKOV3 by immunostaining centrosomes (γ-tubulin, green) and
microtubules (α-tubulin, red) and counterstaining nuclei with DAPI (blue) Figure 5.4.4A.
Employing confocal microscopy we imaged 10 areas of interest (at least 500 cells were counted
per cell type). Cells with abnormal number (more than two) of gamma tubulin spots were
considered as cells with amplified centrosomes. We found that KURAMOCHI exhibited the
highest percentage of cells with amplified centrosomes (~38%) followed by OVSAHO (~24%),
OVCAR3 (~15%) and SKOV3 (~9%) (Figure 5.4.4B). In a recent molecular profiling study by
Domcke et al., KURAMOCHI and OVSAHO were selected as the representative cell lines for
HGSOC [29]. Thus, our findings here parallel previous studies that recognize CA as a biomarker
of aggressive tumors. Furthermore, we validated our results by evaluating the expression levels of
centrosome-related proteins by performing immunoblotting assays. We found that the cell lines
with high CA (KURAMOCHI and OVSAHO) expressed higher levels of centrosome structural
proteins (densitometry values for centrin-2 relative to loading control β actin (KURAMOCHI 0.291445, OVSAHO - 0.432561) and proteins whose dysregulation is known to drive CA (for
Cyclin-E and Aurora A, KURAMOCHI- 0.194213 and 0.256828, OVSAHO- 0.428814, 1.664283
respectively) (Figure 5.4.4C). Our next step was to investigate if aberrations in centrosome
numbers among the different cell lines had any bearing on the mitotic spindle geometry.
Interestingly, we found that the percentage of multipolar mitotic cells in three cell lines
(OVSAHO, SKOV3 and OVCAR3) was lower (by ̴ 2-fold) in comparison with the proportion of
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cells with supernumerary centrosomes (Figure 5.4.4B). This difference in the proportion of cells
with CA and multipolar spindles clearly supports the hypothesis that ovarian cancer cells cluster
supernumerary centrosomes to form pseudobipolar poles. But as the results here indicate that
KURAMOCHI showed significantly more multipolar mitoses when compared to the other ovarian
cancer cell lines we tested, we evaluated if there existed variability in the level of clustering
molecules that help cancer cells to deal with supernumerary centrosomes by corralling them to
form pseudobipolar spindles [24]. To this end, we performed immunoblotting to evaluate
expression level of centrosome clustering protein KIFC1 in cell lysates obtained from the ovarian
adenocarcinoma cells (KURAMOCHI, OVCAR3, OVSAHO and SKOV3). We found that all the
three cell lines with pronounced centrosomal clustering expressed higher levels of KIFC1
(SKOV3- 0.342396, OVCAR3- 0.204796 and OVSAHO- 0.452534) whereas negligible KIFCI
expression was noted in KURAMOCHI (0.145452). It is noteworthy to mention that a recent report
shows that KURAMOCHI is the only cell line that did not induce tumorigenesis in vivo [11]. This
finding resonates with our notion that centrosome clustering is essential for the viability of cancer
cells with extra centrosomes and therefore determines their tumorigenicity.
The in vitro findings were validated in silico by probing publically-available microarray
dataset using Gene set. We interrogated publically-available microarray dataset of ovarian cancer
cell lines (GSM133614, GSM133609, GSM887467 and GSM887488). We calculated a
cumulative gene expression-based centrosome amplification index (CAI) by adding logtransformed, normalized gene expression for both structural centrosomal proteins (CETN2
(centrin-2), TUBG1 (γ-tubulin), PCNT2 (pericentrin)), and genes implicated in centrosome
amplification (PLK4 (polo-like kinase 4) and CCNE1 (cyclin E) genes) (Supplementary Figure
5.7.4 Ai). The analysis showed that CAI genes are expressed in all cell lines but is highest in
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OVSAHO. In addition, we evaluated gene expression levels of KIFC1 and found that the gene
expression levels of KIFC1 was higher in cancer cell lines in comparison to normal ovarian surface
epithelial cells (Supplementary Figure 5.7.4 Aii). Taken together, our results indicated that CA
and KIFC1 levels are associated with HGSOC cell lines.

Figure 5.4.4 HGSOC cell lines show higher incidence and severity of Centrosome
amplification.
A. Confocal microscopic images showing the presence of centrosome amplification and clustering
in ovarian cancer cell lines. Centrosomes and microtubules were visualized by immunostaining
for γ-tubulin (green) and α-tubulin, respectively, and DNA was stained using DAPI (blue). Scale
bar (white) 5 µm. B. Bar graphical representation of percent cells showing centrosome
amplification and multipolar mitosis in human ovarian cancer cell lines. 500 cells were counted in
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each case. C. Immunoblots showing the levels of KIFC1 and centrosomal markers in ovarian
cancer cells lines (KURAMOCHI, OVCAR3, OVSAHO, and SKOV3).

5.5

Discussion

Ovarian cancer in the advanced stage remains the deadliest gynecologic malignancy. One of the
major causes of the low five-year survival is the diagnosis at later stages after it has already
metastasized beyond the pelvis [30]. While extensive literature contains information on the
different kinds of biomarkers for ovarian cancer, risk predictive or prognostic markers that are
utilized in clinical settings are few and far between. Generally, most researchers focus on single
prognostic markers which may be insufficient for complete prognostic information, and also most
of them have very low clinical utility. A combination of multiple factors needs to be considered
simultaneously to more accurately predict a patient’s prognosis. Presence of heterogeneity in
ovarian cancer is another key factor to be considered in prognosis as many ovarian cancer studies
have failed to take into account differences in the histological subtype which clearly pose
prognostic and therapeutic challenges [30, 31]. Essentially, these unique attributes and challenges
can be addressed by personalizing treatments based upon the unique biomarker profiles of
individual patients. Thus, a comprehensive understanding of risk predictive or prognostic factors
with regard to histological subtype is imperative to devise relevant treatment strategies specific for
the particular group of patients or tumor subtypes.
Chromosomal instability (CIN) is the main cause of complex genomic alterations in
tumorigenesis. Since CA engenders CIN, the role of CA driven karyotypic diversity is well studied
in several malignancies including pancreatic ductal adenocarcinoma, TNBC and colon cancer [18,
20]. Several studies have highlighted the presence of supernumerary centrosomes in ovarian cancer
suggesting that CA is a hallmark of ovarian cancer [32-34]. Recently, we also demonstrated the
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presence of amplified centrosomes in EOC [24]. Supernumerary centrosomes in cancer cells tend
to cluster to manage the centrosomal load and thus escape from the perils of mitotic catastrophe.
KIFC1 is well studied for its role in clustering supernumerary centrosomes [22, 23]. In our
previous study, we emphasized the role of KIFC1 in tumor progression of EOC at the gene
expression level [24]. In the present study we have validated those findings by immunostaining
ovarian cancer tissue samples for KIFC1. Our findings show that KIFC1 expression increases
with the grade in EOC. Among the various subtypes that comprise EOC, we found that KIFC1
expression was highest among high-grade SOC samples. This helped us to focus our study on
HGSOC, which is a more prevalent and aggressive form of ovarian cancer. This strong relationship
of KIFC1 with HGSOC suggests that KIFC1 may be directly involved in tumor development and
in driving aggressiveness by allowing the cancer/poorly differentiated cells to escape mitotic
catastrophe and thrive. Moreover, data from our GSEA analysis showed that BIRC5 gene, which
codes for the protein Survivin, that performs dual roles in promoting cell proliferation and
preventing apoptosis [35, 36], was among the first 20 enriched genes in KIFC1-high group. Thus,
KIFC1 overexpression not only protects cancer cells from undergoing mitotic catastrope but also
endows them with low-grade aneuploidy, as a form of genomic instability, and high levels of
survival signaling that together facilitate tumor evolution and disease progression. This finding
was bolstered by results obtained from in silico analysis wherein we found that primary tumors
with higher gene expression of KIFC1 were associated with poor survival; by contrast, while
samples collected from the metastatic sites showed similar expression levels of KIFC1 as in
primary sites, high KIFC1 expression in metastatic sites was not significantly correlated to poor
survival. This differential effect of high KIFC1 expression strongly suggests that elevated KIFC1
in primary sites perhaps helps tumor cells present in the primary sites to acquire karyotypic
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diversity (through CIN), which is more likely to lead to successful metastasis and poor survival. It
is possible that once metastasis commences, high KIFC1 levels in the metastatic clones provides
little further survival advantage for the cancer cells; alternatively, once metastasis occurs, the
survival difference between KIFC1-high and KIFC1-low patients is no longer so marked. Further
studies are required to gain more insights into these intriguing issues.
Given the direct association of CA with KIFC1 in the present study, we examined the
association of KIFC1 with CA-associated genes. Our in silico analysis indicated that in primary
SOC samples KIFC1 expression was positively correlated to the expression of genes which drive
CA. CCNA2, NEK2, and AURKA were among the top 10 genes which were highly correlated to
KIFC1 expression. Role of NEK2, CCNA2, and AURKA as potential targets in ovarian cancer
has been recently highlighted by a detailed systematic bioinformatic study [37]. Besides, this
enrichment analysis showed that the KIFC1-high group was enriched in genes implicated in cell
cycle regulatory processes, especially genes participating in G2-M transition and the spindle
assembly checkpoint (MAD2, BUB1). Several studies in past have reported MAD1 and MAD2
overexpression in different malignancies, and association of this overexpression with aneuploidy
and poor overall survival [38-40]. Thus, our findings from the GSEA and Pathway analysis
suggests that KIFC1 overexpression drives overexpression of genes that control mitotic
checkpoints (Supplementary Table 5.7.2), which by generating aneuploidy, accelerate tumor
progression and evolution of more aggressive phenotypes.
In line with these in silico findings, we found that cell line derived from HGSOC displayed
robust CA, and the proteins which are known to drive CA were also highly expressed. Some recent
studies on molecular profiling of ovarian cell lines have demonstrated that OVSAHO represents
most of the characteristics (KRAS, p53 and BRCA1 and 2 mutations) of HGSOC [29] and is
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considered to be most aggressive cell line among all. From our study, we found that OVSAHO
cells expressed the highest levels of KIFC1 and in spite of presence of interphase supernumerary
centrosomes it showed significantly low level of multipolar mitosis. These findings clearly indicate
that strong association of CA and clustering with KIFC1 overexpression, which leads to CIN,
could be the underlying cause of aggressiveness in these cells. Testing effects of centrosome
declustering drugs on these cells could prove to be advantageous.
In conclusion, our results indicate that HGSOC overexpresses KIFC1, which is associated with
poor overall survival suggesting a causative link between KIFC1 and tumor aggressiveness. These
findings highlight KIFC1 as a potential biomarker to predict disease aggressiveness KIFC1 may
also serve as a cancer-selective therapeutic target for high-grade serous ovarian adenocarcinoma
patients.
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KIFC1 AS A NOVEL THERAPEUTIC TARGET FOR P53 MUTANT
COLORECTAL CANCER
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6.1

Abstract
Loss or mutation of p53 gene is the most frequent genetic lesion in late-stage colon cancers.

The optimal management of p53 mutant colorectal cancer (CRC) remains a significant therapeutic
challenge owing to its resistance to 5-fluorouracil, the first-choice chemotherapy drug for CRC.
Thus, the search for novel therapeutic targets for the treatment of p53 mutant CRC is highly
warranted. We report here that p53 negatively regulates expression of KIFC1 (a centrosome
clustering protein), which can serve as a potential therapeutic target for p53 mutant CRCs. To test
this hypothesis, we first immunohistochemically stained 203 CRC tissue samples for p53, KIFC1,
and FOXM1 and calculated their weighted indices (WIs) for nuclear staining. Further, we
quantitated the protein levels of KIFC1 and FOXM1 by immunoblotting. For determining the
mechanistic relationship of KIFC1 and p53, overexpression (OE) of p53 and ChiP assays were
performed. Finally, inhibited KIFC1 by pharmacological and genetic methods to elucidate the role
of the KIFC1 inhibition on the vitality of p53-/- CRC cells. Our results indicated that p53-/- and
p53 mutant CRC [p53 null n=82, p53mutant n=40, and WT n=81] exhibited significantly
(p<0.001) higher expression of KIFC1 and FOXM1 when compared with the p53 WT CRC tissue
samples and was associated with worse overall survival (HR=4.249, p=<0.001)). p53-/- cells
showed increased expression of KIFC1 and FOXM1. OE of p53 in p53-/- cells decreased the
expression of FOXM1 and KIFC1 indicating the negative regulation of KIFC1 via FOXM1 which
was further strengthened by ChiP assay (FOXM1 interaction with KIFC1 promoter was
significantly higher p=0.037 in p53-/- cells when compared with p53 WT cells). Inhibition of
KIFC1 using shRNA, CW069 (a known KIFC1 inhibitor) and griseofulvin (a known centrosome
declustering drug), led to increased multipolarity followed by cell death only in p53-/- CRC cells.
Collectively our results indicate that p53 negatively regulates expression of KIFC1 via FOXM1
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and contributes to poor outcomes in p53 mutant CRCs. Thus, KIFC1 may serve as a potential
therapeutic target for p53 mutant CRCs.
6.2

Introduction

Colorectal cancer (CRC) is one of the leading causes of cancer morbidity and mortality in the
United States. Studies indicate that the multistep progression from normal intestinal epithelial
tissue to metastatic neoplasm in CRC results from impairment of multiple regulatory mechanisms
involving major signaling pathways that regulate important cellular functions [1, 2]. Inactivation
of tumor suppressor genes such as those encoding adenomatous polyposis coli (APC) [3, 4] and
p53 [5]; and oncogenic activation of KRAS and BRAF have been shown to be crucial for the
pathogenesis of CRC [6]. The mutations in p53 or its loss of function mainly occur at the transition
from adenoma to cancer, and the frequency of alterations in the gene increases with the
corresponding progression of the lesion [7]. p53 is a stress-inducible transcription factor, which
regulates a large number of diverse downstream genes to exert regulative function in multiple
signaling processes [8]. p53 mutation occurs in approximately 40%-50% of sporadic CRC, and
the status of p53 mutation is closely related to the progression and outcome of sporadic CRC [8,
9].
Studies have shown that CRC cells carrying p53 mutation often develop resistance to the apoptotic
effects of 5-fluorouracil (5-FU is the first-line adjuvant therapeutic agents used CRC therapy) [10],
both in vitro [11, 12] and in vivo [13-18]. Resistance to chemotherapy represents the major
obstacle for the improvement of survival of nearly 50% of CRC patients and the current therapies
to target mutant p53 are not effective as different mutations affect p53 function differently and
different agents may be required to target different mutations. Thus, identification of molecules or
pathways that can be targeted in p53 mutant CRC might help in improving the patient outcome.
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Studies have shown that p53, has been linked to the regulation of centrosome duplication
and centrosome amplification (CA) is a consequence of mutation of p53 [19-21] in multiple
cancers. In cancer cells, excess centrosomes cluster into two polar groups during mitosis, giving
rise to pseudo-bipolar spindles. Merotelic attachment of individual kinetochores to more than one
spindle pole is a frequent occurrence. Such inappropriate attachments can cause CIN in the
resulting two, three, or more daughter cells via missegregation of whole chromosomes and/or the
separation of parts of chromosomes via the stress placed on chromosomes by microtubule
attachments and their misguided forces, rendering the chromosomes unstable and liable to break
[22]. Further, clustered supernumerous centrosomes are inherited by progeny cells, leading to a
perpetuation of CIN in progeny cells. Numerical and structural CA has been reported in CRCS
and researchers have reported CA and chromosomal instability in several CRC cell lines
suggesting a link between CA and CIN in CRCs. In another study, it was reported that inactivation
of p53 in CRC cells HCT116 lead to a 3.5-fold increase in tetraploidization. Also, p53 is involved
in centrosome clustering and thus preventing cells to undergo mitotic catastrophe. Therefore, loss
of p53 leads to both induction of CA and generation of CIN in CRCs.
KIFC1, also known as HSET, is a nonessential kinesin motor protein, that plays a crucial
role in centrosome clustering in cancer cells [23, 24]. Knockdown of KIFC1 was shown to induce
multipolar spindle defects and cell death in mitotic cancer cell lines containing extra centrosomes
[24] whereas it had no effect on cell division in a variety of diploid control cell lines [24]. In cancer
cells, the role of KIFC1 becomes indispensable due to the presence of supernumerary centrosomes.
This differential dependence of cancer cells on KIFC1 for viability makes KIFC1 a cancer-cell
selective therapeutic target. We and others have shown that KIFC1 is elevated in several cancer
types [25-28], including colon cancer. To further understand the regulation and expression of
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KIFC1 in CRCS herein this study we evaluated KIFC1 expression in clinical samples of p53
mutant, WT and null CRCs and observed higher expression of KIFC1 with p53 mutation/loss and
was associated with poor overall survival in patients. Furthermore, to understand better the
association KIFC1 and p53 mutation/loss we performed invitro assays to disseminate role of
upstream molecules of KIFC1 in indirect regulation through p53. We observed the FOXM1
member of the Forkhead Box (Fox) family of transcription factors positively regulates expression
of KIFC1 in p53 null CRC cells. Studies have also shown that p53 negatively regulates expression
of FOXM1[29]. Thus, collectively suggesting that p53 negatively regulates expression of KIFC1
in CRCs via FOXM1. Furthermore, we showed that suppression of KIFC1 via pharmacological
(CW069 known inhibitor) genetic (siRNA) induces multipolarity in p53-/- CRC cells resulting in
increased cell death. Lastly, we presented that CRC cells with p53 mutation show higher sensitivity
to griseofulvin (GF), and treatment with GF causes extensive multipolarity followed by mitotic
catastrophe in these cells suggesting GF might be triggering centrosome declustering by inhibiting
KIFC1. Collectively our study shows that KIFC1 can serve as a novel therapeutic target in p53
null/mutant CRCs.
6.3

Material and Methods

6.3.1 Clinical samples
203 formalin-fixed paraffin-embedded (FFPE) CRC resection samples (full-face sections) with
information on all clinicopathologic parameters and clinical outcomes were obtained from Emory
University Hospital, Atlanta, USA. All aspects of the study including protocols, sample
procurement, and study design were approved by IRBs of Emory University Hospital.
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6.3.2 Cell culture
All the cell lines used in the study were obtained from American Type Culture Collection (ATCC).
The colon cell lines utilized in this study included HCT 116 wild type (WT) and HCT 116 p53
null. were grown in McCoy’s 5A media supplemented with 10% Hyclone Fetal Bovine serum and
1% penicillin/streptomycin. All cell lines were maintained in humidified 5% CO2 atmosphere at
370 C.
6.3.3 Lysate preparation and immunoblotting
Whole cell protein lysates were prepared from ~80% confluent cells with 250ul of 1x RIPA cell
lysis buffer (Cell Signaling). The 1x lysis buffer contained 1 mM b-glycerophosphate, 20 mM
Tris–HCl (pH 7.5), 1 mM Na2EDTA, 1 mM Na3VO4, 150 mM NaCl, 1 mM EGTA, 2.5 mM
Na4P2O7, 1 ug/ml leupeptin, and 1% Triton. Lysis buffer was supplemented with 10% protease
inhibitor to prevent protein degradation. Equal amounts of protein (30ug) was loaded and
fractionated using 10% SDS-PAGE gel. Pierce ECL kit (Thermo-Scientific) was used for detection
of immune-reactive bands corresponding to the respective primary antibody. β-actin was used as
loading control.

6.3.4

Immunofluorescence staining, imaging, and scoring of clinical specimens

Formalin-fixed paraffin-embedded tissue slides were deparaffinized in xylene (three changes)
followed by serial rehydration in ethanol baths (100%, 95%, 70% and 50%). Antigen retrieval was
done by heating slides in a pressure cooker in citrate buffer (pH 8.5) at psi 15 for 30 min. Blocking
was performed by incubating the slides with the 100mM glycine for 30 min. Tissue samples were
then incubated with primary mouse antibody against γ -tubulin at 1:1000 dilution at room
temperature for 1 h, followed by washing 3X with PBS. The samples were then incubated with
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secondary antibody (Alexa-555 anti-mouse) at 1:2000 dilution for 2 h, at 37 °C followed by
washing 3X with PBS. Next, the tissue samples were incubated with Hoechst 33342 (1:5000) at
room temperature for 10 minutes. Finally, coverslips were mounted with Prolong-Gold Antifade
Reagent with DAPI (Invitrogen). Tissue samples were imaged using the LSM 700 Confocal
microscope (Oberkochen, Germany) and the images were processed using the Zen software
(Oberkochen, Germany). The percentage of cells with CA was quantitated from 10 randomly
selected fields, with ~ 200 cells counted for each sample.
6.3.5

Immunohistochemistry and scoring

Samples were processed in the same way till antigen retrieval as mentioned above in
Immunofluorescence section. Following antigen retrieval, slides were cooled down by keeping
them in ice for 20 minutes. Slides were subjected to two blocks- firstly with hydrogen peroxide
block for 20 minutes to quench endogenous peroxidase activity, secondly with protein block for
10 minutes. Slides were incubated with primary antibodies for p53 (Santa Cruz) and KIFC1
(Abcam) for 1 hour. MACH2 HRP-conjugated secondary antibody was applied for 30 minutes
followed by chromogen visualization by DAB (Biocare Medical). Finally, slides were
counterstained with Myer’s hematoxylin (Dako), dehydrated with serial washes in ethanol
followed by xylene and mounted. A relative intensity score was represented as 0 = none, 1 = low,
2 = moderate, or 3 = high. The product of intensity and frequency was measured as a weighted
index (WI) for both the nucleus and cytoplasm.
6.3.6 Immunocytofluorescence staining
Cells were cultured on coverslips and, after the confluency reached approximately 80 %, cells were
fixed with ice-cold methanol for 7 min. The cells were blocked with 5 % BSA/0.01 % Triton X
for 45 min at room temperature and then incubated at 37 °C with antibodies directed against γ-
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tubulin and α-tubulin at a dilution of 1:2000 for 30 min. Cells were washed 5 times with 1x PBS,
followed by incubation with anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 555 at 370 C
for 30 minutes. Next, cells were washed briefly for 8 times with 1x PBS, followed by staining with
Hoechst 33342 used at a dilution of 1:5000 for 10 minutes at room temperature. Finally, cells were
washed with 1x PBS for 3minutes and, mounted with Prolong Gold antifade reagent.
Immunofluorescence imaging was carried out using the Zeiss LSM 700 confocal microscope
(Oberkochen, Germany) and images were analyzed using the Zen software (Oberkochen,
Germany).
6.3.7 p53 overexpression and KIFC1 knockdown
HCT 116 WT and null cells were grown to 70% confluency and transfected using Lipofactamine
2000 according to manufacturer’s instructions. KIFC1 gene knockdown in HCT116 null cell was
achieved using KIFC1 siRNA (Origene). The non-targeting universal scrambled siRNA was used
as the negative control in both the cell lies. 24 hours post transfection, whole cell protein lysates
were prepared for immunoblot assay. HCT 116 null cells were grown to 70% confluency and
transfected using Lipofactamine 2000 according to manufacturer’s instructions. For this, 6 ul of
lipofectamine was added to 4ug of p53 overexpression vector and the mixture was slowly added
to the cells. GFP tagged p53 vector was a generous gift from Dr. Tylor Jacks (Addgene plasmid
#12091). 24 hours post transfection, whole cell protein lysates were prepared for immunoblot
assay.
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6.4
6.4.1

Results
p53-mutant CRCs show poorer overall survival (OS) compared to p53-wild-type CRCs

203 formalin-fixed paraffin-embedded FFPE) CRC resection samples (full-face sections) were
stained immunohistochemically (IHC) for p53 (Figure. 6.4.1A) and were scored by two
independent pathologists without prior knowledge of the patients’ pathologic/outcome data.
Samples wherein <80% but >1% of cells stained positive for p53 were considered p53 wild type
(WT) (n=81), those wherein ≥80% of cells stained positive for p53 were considered p53-mutant
(M) (n=40), and those where in <1% cells were stained for p53 were considered as p53-null (N)
(n=81). Multiple studies have provided evidence where p53 IHC staining can be used as a
surrogate for the mutational analysis in the diagnostic workup of the various carcinomas. KaplanMeier survival analysis suggested that p53-null CRC patients have the worse prognosis than p53mutant and p53-WT. Also, p53 mutant CRCs were associated with worse OS than p53 WT CRCs.
(HR=4.249, p=<0.001) (Figure. 6.4.1B). These findings were supported by our in silico findings
GSE41258) where the p53-mutant (n=93) CRC was associated with poorer OS (HR=1.46,
P=<0.05) (Figure. 6.4.1C) than p53-WT CRCs.
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Figure 6.4.1 p53-mutant CRCs show poorer overall survival (OS) compared to p53-wildtype CRCs
A) Representative micrographs of p53 IHC staining in CRC tissue samples. (B) Kaplan-Meier
plots of OS based on p53 status in clinical tissue samples. (C) Kaplan-Meier plots of OS based
on p53 status in in silico data.
6.4.2

p53-mutant CRCs exhibit higher centrosome amplification than p53-WT CRCs

Studies have shown that p53 mutations in various tumor types are associated with CA. To study
this we visualized amplified centrosomes in 40 CRC samples (n=20 p53-WT and n=20 p53mutant) employing multicolor confocal immunofluorescence microscopy. Centrosomes were
labeled by anti-γ-tubulin (green) antibody, and centrosomal aberrations were determined by
quantifying percentage of cells bearing abnormal numbers of γ-tubulin foci (more than two). We
found that the number of cells/500 cells harboring extra centrosomes was higher in p53-mutant
CRCs when compared with to p53-WT CRCs (p=0.086) (Figure. 6.4.2.1 A, B). In line with this,
we observed that p53-null colon cancer cell line (HCT116 p53-null CRC cells) exhibited notably
higher CA (~40%) as compared to p53-WT (~10%) cells (Figure. 6.4.2. A, B). Furthermore,
protein levels of proteins associated with CA were also elevated in p53-null cells when compared
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with the p53-WT CRC cells (Figure. 6.4.3 C). Thus, these findings indicate that p53null/mutant
CRCs exhibit higher CA when compared to the WT CRCs.

Figure 6.4.2 p53-mutant CRCs exhibit higher centrosome amplification than p53-WT
CRCs
(A) Representative confocal images showing the presence of CA in p53-mutant and WT CRC
tissue. (B) Box whisker graph representing the distribution of % numerical CA in p53-WT and
p53-mutant CRC tissue sections

Figure 6.4.3 HCT 116 p53-/- CRC cells exhibit higher centrosome amplification than WT
cells
(A) Confocal micrograph showing the presence of CA in HCT-116 p53-null CRC cells and
HCT-116 p53-WT cells. Scale bar, 5 µm. (B) Degree of CA in p53-null and p53-WT CRC cells.
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(C) Immunoblots showing expression of the CA associated proteins in p53-null and p53-WT
CRC cells.
6.4.3

p53-mutant CRCs exhibit higher expression of the centrosome clustering kinesin,
KIFC1

In cancer cells that harbor supernumerary centrosomes, KIFC1 is required for proper spindle
assembly [23], where it promotes centrosome clustering and suppresses multipolar spindle
formation and cell death [24]. Thus, given the association of high CA with p53-mutant status in
CRCs, we suspected that KIFC1 levels may perhaps be elevated in these samples in order to cope
with the increased centrosomal load. Therefore, serial sections from the 203 CRC tissue samples
that were stained for p53 (see 6.3.1.) were stained for KIFC1. Scoring was performed for both the
intensity of staining (0 = none,1 = low, 2 = moderate, 3 = high) and the percentage of cells with
any positivity (i.e., staining of 1+). KIFC1 WIs were calculated as the product of the nuclear
staining intensity and percentage of positive cells. P53-null (p53-/-, n=82) and p53-mutant CRC
(n=40) exhibited significantly (p<0.001) higher expression of KIFC1 when compared with the
p53-WT CRC (n=81) tissue samples (Figure. 6.4.4 A, B). Similarly, we observed that the p53null CRC cells exhibited higher expression of KIFC1 (immunoblotting) when compared with the
p53-WT CRC cells (Figure. 6.4.4 C).
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Figure 6.4.4 p53-mutant CRCs exhibit higher expression of the centrosome clustering
kinesin, KIFC1
A) Representative micrographs of p53 and KIFC1 IHC staining in p53 null/ mutant and p53-WT
CRC tissue samples. B) Box whisker graph representing the KIFC1 expression in p53-null, p53mutant and p53-WT CRC tissue samples. C) Immunoblots showing expression of KIFC1 in p53null and p53-WT CRC cells.
6.4.4 FOXM1 expression is correlated with KIFC1 and is higher in p53-mutant when
compared with the WT
Serial sections from 203 CRC tissue samples used in Section 6.3.1 were IHC- stained for FOXM1
and WIs for nuclear staining was calculated. We observed that expression of FOXM1 was
significantly higher in p53-mutant and p53-null group when compared with the p53-WT CRCs
(Figure 6.4.5). In addition, expression of FOXM1 was strongly correlated with KIFC1 expression
(r=1.3, p=<0.05). We also observed that p53-null CRC cells expressed higher levels of FOXM1
when compared with p53-WT CRCs.
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Figure 6.4.5 Box whisker graph representing the FOXM1 expression in p53-mutant and
p53-WT CRC tissue samples.

6.4.5

FOXM1 and KIFC1 expression was decreased by p53 overexpression (OE) in p53-null
cells and FOXM1 binds to the promoter of KIFC1 with higher binding affinity

Next, we transiently transfected the pEGFP-P53 construct into HCT116 p53-null CRC cells. Given
a transfection efficiency of ~70%, we observed that FOXM1 and KIFC1 expression decreased in
HCT 116 p53-null CRC cells with OE of p53, when compared with the control vector (Figure.
6.4.6A). Literature has reported that KIFC1 promoter has binding sites for FOXM1. In line with
this, our in silico analysis using publily-available TRANSFAC dataset showed that KIFC1
promoter regions contain two FOXM1 binding motif sites suggesting that KIFC1 is a potential
target gene of FOXM1 (data not shown). Additionally, our ChIP results indicated a significantly
higher (p=0.037) binding of FOXM1 to the KIFC1 promoter in p53-null CRC cells when compared
with the p53-WT CRC cells (Figure. 6.4.6B). Thus, collectively indicating that p53 negatively
regulates expression of KIFC1 via FOXM1.
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Figure 6.4.6 FOXM1 regulates expression of KIFC1 in p53-/- CRC cells
A) Immunoblots showing decreased expression of KIFC1 and FOXM1 after overexpression of
p53 in HCT116 p53-null cells. B) Bar graph representing FOXM1 interaction with KIFC1
promoter in HCT 116 p53-null and p53-WT CRC cells.
6.4.6

Inhibition of KIFC1 using siRNA led to increased multipolarity only in p53-/- colon
cancer cells

Given that KIFC1 was significantly upregulated in p53-mutant and p53-null CRC cells, we were
prompted to examine the effects of depletion of cellular pools of KIFC1 in CRC cells. We
performed transient siRNA transfections using pools of KIFC1 siRNA duplexes in p53-null and
p53-WT CRC cells. KIFC1 depletion induced centrosome declustering and significant spindle
multipolarity (Figure. 6.4.7A) in p53-null HCT116 cells. p53-WT HCT 116 cells, however,
maintained bipolarity upon KIFC1 RNAi (Figure. 6.4.7B), indicating that KIFC1 is a potential
cancer-selective therapeutic target for p53-null/mutant CRC.
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Figure 6.4.7 Bar graph representing % bipolar and multipolar cells in KIFC1 KD and CV
(A) p53-WT (B) p53-null CRC cells.
6.4.7 Griseofulvin induces multipolarity and downregulates expression of KIFC1
Griseofulvin (GF) is an antifungal drug which has recently been shown to inhibit proliferation of
various types of cancer cells and to inhibit tumor growth in nude mice. Studies have shown that
Griseofulvin inhibits microtubule dynamics, which leads to spindle tension causing centrosome
declustering, multipolar mitosis and cell death. Thus, we suspected that Griseofulvin might be
leading to centrosome declustering via inhibition of KIFC1 activity in p53-mutant CRCs. To this
end, we tested efficacy of Griseofulvin in CRC cells. We observed that Griseofulvin induced
extensive centrosome declustering and mutlipolarity (~85% of mitotic cells were multipolar) in
p53-null CRC cells when compared with the p53-WT CRC cells (~30% of mitotic cells were
multipolar). Furthermore, the extent of multipolarity and cell death induced by Griseofulvin was
far superior to that of a known KIFC1 inhibitor CW069 (Figure. 6.4.8A-C). Further, we performed
intensive in silico modeling and observed that Griseofulvin (similar to CW069) docks onto a
pocket within the motor-domain that houses the ATP-binding site of KIFC1 (Loop-5) with similar
(-0.24 for CW069 and 0.25 for Griseofulvin) mean ligand efficiency. The predictive free energy
(∆G) for this binding is -6.0 Kcal/mole (Figure. 6.4.8A, C).
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Figure 6.4.8 Griseofulvin induces multipolarity and downregulates expression of KIFC1
A) Confocal micrographs showing rampant multipolarity after treatment with CW069 and
Griseofulvin (GF). B) Bar graphs representing % bipolar and multipolar cells in CW069- and
GF-treated in p53-WT and p53-null CRC cells.
6.4.8 Griseofulvin inhibits the ATPase activity of KIFC1
Since KIFC1 is a kinesin-like microtubule motor protein, it contains a conserved motor domain
that catalyzes ATP hydrolysis and generates a minus end-directed mechanical force along the
microtubule. We, therefore, asked if Griseofulvin can inhibit the ATPase activity of KIFC1 in
vitro. Employing the Kinesin ATPase ELIPA assay kit (Cytoskeleton Inc.) containing a kinesin
heavy chain motor domain protein (KIF5B) (as a positive control) and microtubules as a substrate
for kinesin activity, our results indicated that Griseofulvin inhibits KIFC1’s ATPase activity to a
similar degree as CWO69 (Figure. 6.4.9B). Thus, Griseofulvin inhibits the motor activity of
KIFC1 and induces centrosome declustering.
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Figure 6.4.9 Griseofulvin inhibits the ATPase activity of KIFC1
A) Distribution of binding energies of GF and CW069 from docking simulation. (B) Bar graph
representing percentage inhibition of KIFC1 activity by GF and CW069 at 50 and 100µm. (C)
Binding efficiency values of the CW069 and GF at loop 5 on KIFC1.
6.5

Discussion

In this study we showed that the expression of KIFC1 is significantly higher in p53 mutant/null
CRCS when compared to the p53 WT CRCs and is associated with poor overall survival. Further,
we evaluated the role of upstream regulators of KIFC1 to understand better the association KIFC1
and p53 mutation/loss. We observed the FOXM1 member of the Forkhead Box (Fox) family of
transcription factors positively regulates expression of KIFC1 in p53 null CRC cells. Studies have
also shown that p53 negatively regulates expression of FOXM1[29]. Thus, collectively suggesting
that p53 negatively regulates expression of KIFC1 in CRCs via FOXM1. Moreover, we showed
that inhibition of KIFC1 via pharmacological (CW069 known inhibitor) and genetic (siRNA)
methods induced multipolarity specifically in p53-/- CRC cells resulting in increased cell death.
Finally, we observed that HCT116 p53-/- CRC cells were significantly higher sensitivity to GF
when compared that of HCT116 p53WT CRC cells, and treatment with GF induced extensive
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multipolarity followed by the mitotic catastrophe in the p53 null CRC cells. This suggests that GF
might be triggering centrosome declustering by inhibiting KIFC1.
In conclusion, our results indicate that p53 null/mutant CRCs overexpresses KIFC1 which is
associated with poor overall survival suggesting a causative link between KIFC1 and tumor
aggressiveness. Taken together our findings underscore that KIFC1 is a potential cancer selective
therapeutic target for p533 null/mutant CRCs.
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MULTINUCLEATED POLYPLOIDY DRIVES RESISTANCE TO DOCETAXEL
CHEMOTHERAPY IN PROSTATE CANCER

Parts of this chapter have been published verbatim in British Journal of Cancer 2017; Apr 25;
116(9:1186-1194 as “Multinucleated polyploidy drives resistance to Docetaxel chemotherapy
in prostate cancer.”
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7.1

Abstract
Docetaxel is the only FDA-approved first-line treatment for castration resistant prostate

cancer (CRPC) patients. Docetaxel treatment inevitably leads to tumor recurrence after an initial
therapeutic response with generation of multinucleated polyploid (MP) cells. Here we investigated
role of MP cells in clinical relapse of CRPC. Herein, prostate cancer (PC-3) cells were treated with
docetaxel (5 nM) for 3 days followed by a wash-out and samples were collected at close intervals
over 35 days post drug-washout. The tumorigenic potential of the giant MP cells was studied by
implanting MP cells subcutaneously as tumor xenografts in nude mice. Docetaxel-induced
polyploid cells undergo mitotic slippage and eventually spawn mononucleated cells via
asymmetric cell division or neosis. Both MP and cells derived from polyploid cells (CDPCs) had
increased survival signals, were positive for CD44 and were resistant to docetaxel chemotherapy.
While MP cells were tumorigenic in nude mice, these cells took a significantly longer time to form
tumors compared to parent PC-3 cells. Generation of MP cells upon docetaxel therapy is an
adaptive response of apoptosis-reluctant cells. These giant cells ultimately contribute to the
generation of mononucleated aneuploid cells via neosis and may play a fundamental role
precipitating clinical relapse and chemoresistance in CRPC.
7.2

Introduction

Despite significant advances in research, diagnosis, and clinical practice, prostate cancer still
remains the second most commonly diagnosed cancer and the sixth most common cause of cancerrelated death among men worldwide [1]. Androgen-deprivation remains the mainstay of the first
line treatment for both primary and metastatic prostate cancer. Initially majority of the patients
respond well to this treatment but eventually the tumor progresses to castration-resistant prostate
cancer (CRPC) which is the major cause of mortality [2]. Docetaxel was approved by the
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European Medicine Agency and the US Food and Drug Administration in 2004 for the first-line
treatment of patients with CRPC and is now the only standard of care in this setting [3, 4]. While
this clinical regimen prolongs overall survival in CRPC patients, the cancer unfortunately recurs
(clinical relapse) inevitably after an initial illusionary therapeutic response. Currently, there is a
lack of mechanistic knowledge underlying this tumor cell “replenishment” after docetaxel
treatment which inevitably leads to tumor recurrence and translates to only a modest increase in
overall survival. The present study explores this therapy-relapse paradox that inescapably results
in tumor recurrence shortly after a therapy response.
The formation of giant multinucleated polyploid (MP) cells after therapeutic
intervention with either taxane-based chemotherapy including docetaxel or DNA damaging
agents has been well described. Studies have reported that some tumor microenvironmental
factors including hypoxia are also responsible for the generation of MP cells. Studies have also
shown that hypoxia-mimicking CoCl 2 treatment induces formation of polyploid cells that
contributes to expansion of a cell subpopulation with stem cell characteristics [5, 6].
These polyploid cells can be a result of DNA over-replication [7], abrogated mitotic checkpoint
[8] or failed cytokinesis [9]. It was long assumed that these giant polyploid cells do not survive
and die due to “mitotic catastrophe” subsequent to multipolar cell division. But, recent evidence
indicated that while most polyploid cells succumb to cell death, a small percentage of them
survive and produce viable progeny [10, 11]. A study also found that colon cancer cells treated
with DNA damaging agent cisplatin generated giant polyploid cells, a subset of which were able
to engender viable clones via asymmetric cell division; furthermore, this phenomenon was
recapitulated in an in vivo xenograft model of colon cancer treated with cisplatin [ 1 2 ] . Another
study revealed that when PC-3 cells were treated with docetaxel, it led to growth arrest and
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formation of multinucleated cells and the generation of docetaxel-resistant progeny [13]. A very
recent study has reported the cabazitaxel, a second line chemotherapy in CRPC treatment, also
leads to chemoresistance by inducing severe multinucleation in prostate cancer cells [14].
Altogether, these data suggest that polyploid cells that were once presumed to be either destined
for terminal growth arrest or cell death may actually represent a “transition state” for generation
of viable clones.
The current study a i m e d to analyze the long-term effects of post docetaxel exposure
on prostate cancer cells. Our study shows that most of the prostate cancer cells exposed to
docetaxel undergo cell death following mitotic arrest. However, a small percentage of the cells
“slip out” of mitosis to form giant MP cells. Most of these MP cells succumbed to cell death, but
a small fraction survived for several weeks, eventually giving rise to small mononucleated cells
via an asymmetric cell division process called neosis. We further show that these MP cells
have tumorigenic potential in nude mice and that both MP cells and cells derived from
multinucleated polyploid cells (CDPC) are chemoresistant and were positive for cancer stem cell
marker CD44. In conclusion, the formation of MP cells after docetaxel treatment suggests an
escape process that is involved in tumor relapse and chemoresistance following an initial
illusionary therapeutic response.
7.3

Material and Methods

7.3.1 Cell culture and treatment schedule
PC-3 and DU145 cells were obtained from American Type Cell Culture (ATCC) and were grown
in RPMI medium supplemented with 10%

fetal bovine serum (FBS) and 1%

penicillin/streptomycin. Cells were maintained in humidified 5% CO2. All experiments were
performed using 5nM of docetaxel unless stated otherwise.
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7.3.2 Flow cytometry
Cells were harvested at different time intervals, washed twice with ice-cold PBS, and fixed in
70% ethanol for at least 24 h. Cell pellets were then washed with PBS followed by RNase A (2
mg/ml) addition and staining with anti-MPM-2 primary antibody and Alexa-488 conjugated
secondary antibody. Propidium iodide (0.1% in 0.6% Triton X-100 in PBS) was added for 45
min in dark followed by analysis on a FACS Canto flow-cytometer (BD Canto) using FlowJo
software.
7.3.3 Immunofluorescence
Cells were grown on glass coverslips for immunofluorescence microscopy and were fixed and
blocked as described previously [40] . Coverslips were incubated in primary antibodies (1:2000
dilution) against γ-tubulin and α-tubulin at 1:2000 dilution for 1 h at 37°C, washed with 1XPBS
for 10 min at room temperature, and then incubated in 1:2000 Alexa 488- or 555-conjugated
secondary antibodies (Invitrogen; Carlsbad, CA). Cells were washed 5x with PBS and then
mounted with Prolong-Gold antifade reagent that contained DAPI (Invitrogen).
7.3.4 Microscopy
Immunofluorescently stained cells were imaged utilizing the Zeiss LSC 700 confocal microscope
(Oberkochen, Germany) and were processed with Zen software (Oberkochen).
7.3.5 Time lapse imaging
Giant MP cells were isolated and plated 12 days after docetaxel removal. Cells were imaged for
7 days using time-lapse microscopy at 40x magnification on Zeiss Axio Observer 5A
(Oberkochen, Germany). Differential Interface Contrast Images were captured at multiple points
every 2 h for 7 days and were processed with Zen software (Oberkochen, Germany).
Magnifications and details related to imaging are provided in individual sections.
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7.3.6

Lysate preparation and immunoblotting

Cells were cultured to ~80% confluence and after treatments as mentioned in individual sections
protein lysates were prepared as described previously [41]. Polyacrylamide gel electrophoresis
was used to resolve the proteins, which were transferred onto polyvinylidene fluoride membranes
(Millipore). The immune reactive bands were visualized by using Pierce ECL
chemiluminescence detection kit (Thermo Scientific). Primary Antibodies, Phospho-Bcl2 (Thr
56) human, Bcl-XL (54H6), Survivin (71G4B7), Beclin-2 and CD44 (156-3C11) were obtained
from Cell Signaling. -actin (SC47778 from Santa Cruz Biotechnology) was used as loading
control. All relative band intensities were quantitated by densitometry and were normalized
against β-actin values using ImageJ.
7.3.7

Cell migration assay using Boyden Chambers

A total of 10,000 cells suspended in RPMI medium containing 0.5% FBS were added to the
upper well of the Boyden chamber. The lower chamber was filled with RPMI medium
containing 10% FBS. After 48 h, cells that had migrated to the bottom surface of the filter were
fixed with 70% methanol, stained with crystal violet, and counted under a microscope in ten
randomly selected fields at a magnification of 20x.
7.3.8 MTT assay
MTT assay was used to measure metabolic activity suitable for analysis of proliferation rates
between PC-3, giant MP, and CDPC. Approximately 10,000 cells of each cell type were seeded
into each well of a 96-well microplate. The assay was performed over a six-day period with
incubation times at 24 h, 48 h, 72 h, 96 h, 120 h, and 144 h. At the end of each incubation period,
10μl of MTT (Sigma-Aldrich, Germany) at 5mg/ml in PBS was added into each well after removal
of the culture medium and incubated for 4 h under the same conditions. After the incubation,
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100μl of DMSO was added to dissolve the formazan crystals. Absorbance was measured at 570nm
using a 96-well microplate reader.
7.3.9

In Vivo Tumor growth

A total of 50,000 PC-3 cells or giant MP cells (cells that were treated with 5nM docetaxel and
harvested one day after drug removal) were subcutaneously injected in the right flank of 6-week
old male BALB/c nude mice (Harlan Laboratories, Indianapolis, IN). Tumors were measured
every week using a digital Vernier Caliper. The two longest perpendicular axes in the x/y plane
of each xenograft tumor were measured to the nearest 0.1 mm. The depth was assumed to be
equivalent to the shortest of the perpendicular axes, defined as y. Tumor volume was calculated
using the formulae xy2/2 as is standard practice. All animal experiments were performed in
compliance with Georgia State University (GSU) Institutional Animal Care and Use
Committee (IACUC) guidelines. All animal protocols (including description of experiments
and experimenters) were approved by GSU IACUC.
7.3.10 Statistical analyses
Unless otherwise stated in the Methods and Results sections, statistical analyses were performed
using two-tailed Student’s t-tests. The criterion for statistical significance for all analyses was
p<0.05.

7.4
7.4.1

Results
Docetaxel induces formation of giant multinucleated polyploid (MP)cells

To corroborate the fact that docetaxel treatment causes mitotic arrest prior to cell death, we
examined the cell cycle events post docetaxel treatment. To this end, we treated PC-3 cells with
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5nM docetaxel for 72 h and then stained them for MPM-2 antibody (mitotic cell marker) by flow
cytometry. As shown in Figure7 . 4 . 1A, there was an induction of mitotic arrest 24 h post
docetaxel treatment. Using immunofluorescence confocal microscopy, we noticed large number
of mitotically-arrested cells (Figure.7.41B) displaying aberrant multipolar spindles 24 h after
docetaxel treatment. On the other hand, DMSO treated control cells showed normal bipolar cell
division (Figure 7.4.1B). Following this, a disappearance of the M-phase population and an
emergence of apoptotic cells (sub-G1 population) was observed at 48 h after docetaxel
treatment (Figure 7.4.1D).
We next investigated if docetaxel in addition to causing mitotic arrest and cell death
induces other phenotypic changes. At 72 h post-treatment, there was an emergence of G1/G2interphase cells, which in addition to being much bigger in size were also multinucleated
compared to parent PC-3 cells (Figure 7.4.1B). Also, we observed that there was a significant
drop in the percentage of MPM-2 positive cells from ~11% at 48 h to 1% at 72 h and a
simultaneous increase in MPM-2 negative population from ~26% at 24 h to 42% at 72 h
(Figure.7.4.1A, D). Most likely, these large multinucleated cells resulted from a mitotic exit, that
is, cells slipping out of mitosis without cell division. Since cells have failed to successfully
progress through mitosis to execute cytokinesis, they have twice or more the amount of DNA as
compared to parent PC-3 cell in the G1 phase of the cell cycle (Figure.7.41C). We termed these
pseudo-G1 like cells as giant multinucleated polyploid (MP) cells. Almost 95% of the surviving
cells after 3 days of docetaxel treatment were giant MP cells. Taken together, these observations
clearly suggest that, upon docetaxel treatment a small percentage of cells slip out of mitosis
resulting in the formation of giant MP cells. The induction of giant MP cells was not limited
to PC-3 cells but was also formed in two other cell lines: DU-145 (androgen dependent prostate
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cancer cell line) and MDA-MB-231 (triple negative breast cancer cell line) (Supplementary. Figure
7.7.14).

Figure 7.4.1Docetaxel induces formation of giant multinucleated polyploid cells.
4

All supplemental data, tables, and figures appear in Appendix D for this chapter
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A) Cell-cycle histograms of doubly-stained PC-3 cells treated with docetaxel at 5 nM
concentration for different time points showing mitotic arrest and slippage at different time points.
B) Representative immunofluorescent confocal micrographs of PC-3 cells treated with docetaxel
for 24 h and 72 h indicating mitotic arrest and emergence of giant multinucleated polyploid cells
respectively. Centrosomes and microtubules were immunolabeled for γ-tubulin (green) and αtubulin (red), respectively, and DNA was counterstained with DAPI (blue). Scale bar (white) 5
µm. C) Cell-cycle histogram of docetaxel treated PC-3 cells showing emergence of polyploid
population. D) Bar-graphs showing the percentage of sub-G1 and mitotic population resulting from
5nM docetaxel treatment. E) Bar-graphs showing the percentage of giant multinucleated polyploid
cells 72 h after docetaxel treatment.
7.4.2 Giant MP cells undergo asymmetric cell division via neosis
Having established that docetaxel treatment induces the formation of giant MP cells we next
followed the fate of these giant MP cells for the consequent 35 days after docetaxel removal.
To accomplish this, we collected cells every 3rd day post drug removal and, employing confocal
microscopy we visualized the morphology of PC-3 cells. Microtubules were immunolabeled for
α-tubulin (red)and DNA was counterstained with DAPI (blue). For the first 15 days post drug
removal we did not observe any remarkable changes in cell morphology. After 15 days in culture
we started observing the formation of small mononucleated cells in the vicinity of giant MP cells
(Fig 2A). The number of mononucleated cells further increased by day 25 (Figure.7.42A and
E). At later time points (day 35) following the removal of docetaxel, sparse colonies of small,
tightly-packed, mononucleated cells were observed in the culture dish (Figure.7.42A and E).
We next examined the origin of these mononucleated cells at day 15 after removal of docetaxel.
To this end, starting at 12 days after docetaxel removal, we isolated and plated 3 giant MP cells
per well by serial dilution and followed them for 7 days using time lapse imaging. We observed
asymmetric cell division pattern in giant MP cells through a process known as neosis [15-17].
Small mononucleated daughter cells were seen budding from the giant MP cells from the
branches of the giant MP cells (Figure.7.4.2B). To confirm the presence of DNA in the
budding cells, we stained the giant MP cell along with the budding cells with Hoechst 33342
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and used it in combination with differential interference contrast (DIC) microscopy. Using this
method, we were able to detect the presence of DNA in the budding daughter cells (Supplementary
Figure. 7.7.2). We named these budding cells as cells derived from multinucleated polyploid
cells (CDPC). Furthermore, by using confocal microscopy, we demonstrated that the DNA was
transported within the branches of the giant MP cells (Figure.7.4.2C). These results demonstrate
that giant MP cells produce daughter cells through a process of budding also known as neosis
where the branches of the giant MP cells can serve as vessels for DNA transport.

Figure 7.4.2 Giant MP cells undergo asymmetric cell division via neosis.
A) Confocal micrographs of docetaxel treated PC-3 cells. Cells are stained with α-tubulin (red)
and DNA (blue) and showed emergence of small mononucleated cells on different days (D) after
drug removal. Scale bar (white) 5 µm. B) Time lapse images of giant MP cells generating small-
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sized daughter cells via budding (black arrows) over a 7-day period. Scale bar (black) 5 µm. C)
Confocal immunographs of cells stained with α-tubulin (red) and DNA (blue) showing transport
of DNA from the branches of the giant MP cells (white arrows). D) Line graph representing the
total number of small sized nucleated cells and giant MP cells at different days after drug
removal.
7.4.3

Giant MP cells and CDPC are chemoresistant

After establishing that giant MP cells can survive and can form small mononucleated cells via
neosis, we next determined their response to docetaxel treatment. For this purpose, PC-3, CDPC
and giant MP cells were treated with 5nM of docetaxel for 48h. Cell death was estimated by
measuring the expression of cleaved caspase-3 and cleaved PARP. Interestingly, we observed
increased levels of cleaved caspase-3 staining in PC-3 cells after 48 h of docetaxel treatment
(Figure.7.43A). This was further substantiated by increased protein expression of cleaved PARP
and cleaved caspase-3 by immunoblotting (Figure.7.43B and Supplementary Table 7.7.1). On the
other hand, CDPC and giant MP cells showed lower expression of both cleaved caspase-3 and
cleaved PARP after docetaxel exposure, suggesting that these cells were resistant to docetaxel
treatment.
Next, we evaluated the sensitivity of PC-3, CDPC and giant MP cells to various
concentrations of docetaxel (5nM, 10nM and 20nM) using MTT assay. PC-3 cells exhibited
a dose dependent increase in cell death 48 h after docetaxel treatment when compared with, both
CDPC and giant MP cells (Figure 7.4.3C). In addit ion , we assessed the expression of antiapoptotic and survival proteins in both CDPC and giant MP cells and compared them to the
parental cells. The expression of anti-apoptotic proteins like Bcl-2, pBcl-2 and Bcl-XL were much
higher in giant MP cells (day 1 to day 25 in figure 3D and Supplementary Table 2) and CDPC
(day 35) as compared to parental PC-3 cells (Day0). Similarly, survival protein like survivin and
beclin-2 were also higher in giant MP cells and CDPC compared to parent PC-3 cells. Taken
together, these results suggested that both giant MP cells and CDPC exhibited a completely
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different response to docetaxel treatment as compared to the parental cells owing to the increased
expression of anti-apoptotic and survival proteins. We also observed that the giant MP and CDPC
cells were positive for CD44 which a cancer stem cell marker is (Supplementary Fig 7.7.3E and
Supplementary Table 7.7.4).

Figure 7.4.3Giant MP cells and CDPC are chemoresistant.
A) Confocal images of cleaved caspase-3 staining (red) on docetaxel treated PC-3 cells. B)
Representative Immunoblot images of cleaved caspase-3 and cleaved-PARP for docetaxel
treated cells. Actin was used as the loading control. C) Graphical representation of cell survival
using MTT assay. Cells were treated with 3 different concentrations of docetaxel and MTT
assay was done 48h after docetaxel treatment. D) Western blots of anti-apoptotic and survival
proteins in at different days after docetaxel removal. D0 are control PC-3 cells while cells on
D35 are CDPCs.
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7.4.4

Giant MP cells and CDPC show differential ability to migrate and proliferate as
compared to parent PC-3 cells

We next examined the ability of the giant MP cells and CDPC to migrate and proliferate and
compared it to the parent PC-3 cells. Transwell migration assay was used to compare the
migratory ability of CDPC and giant MP cells with that of the parent PC-3 cells. At 48 hours,
the mean number of parent PC-3 cells that had migrated across the membrane was 9-fold higher
than the giant MP cells and 2-fold higher than the CDPC cells (Figure 7.4.4A and B). The MTT
assay showed the giant MP cells showed no signs of proliferation over a six-day period. On the
other hand, the proliferation rate of CDPC was similar to that of the parent PC-3 cells over the
six-day period (Figure.7.4.4C). Surprisingly, the mesenchymal marker vimentin was much higher
in CDPC and giant MP as compared to the parent PC-3 cells (Figure.7.4.4D and Supplementary
Table 7.7.3). We speculate that the giant MP cells use this mesenchymal phenotype to transport
DNA through the branches in order to produce small mononucleated cells via neosis
(Figure.7.4.2D). These results suggest that giant MP cells have slow proliferation and low rates
of invasion and tumor formation compared to the parent PC-3 cells, suggesting that giant MP
cells are less aggressive or malignant than that of parental cells.
We next wanted to see if the CDPCs have a different genetic profile as compared to the
parent PC-3 cells. We measured the degree of aneuploidy in the CDPC and parent PC-3 cells
using fluorescent in situ hybridization (FISH) (Figure.7.4.4E). The average number chromosomes
in the parent PC-3 cells were 83 as compared to 82 in the CDPC (Figure.7.4.4F). We next
calculated the percent aneuploidy in parent PC-3 and CDPCs by counting the number of cells that
had either < 80 or > 86 chromosomes. Using this method, the percent aneuploidy in parent PC-3
cells was 12% compared to 18% in CDPC. Taken together the degree of aneuploidy in CDPC
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was comparable to that of the parent PC-3 cells (eg: chromosomal translocation). Since there was
a high number of translocations/duplications/etc. in the parent PC-3 cells, making many of the
chromosomes unidentifiable, we were not able to measure the degree of structural
chrom os om al abnormalities in the PC-3 and CDPC cells. These results suggested that the
degree of aneuploidy in the parent PC-3 and CDPC was not very different.

Figure 7.4 .4 Phenotypic changes in CDPC and giant MP cells.
A) Bright-field microscopic images of cells stained with crystal violet showing invasion capacity
of PC-3, CDPC and giant MP cells. B) Bar graph representing the number of migrated cells in a
Boyden chamber. C) Cell proliferation assay over a 7-day period using MTT assay. D)
Representative immunoblots of Vimentin in PC-3, giant MP and CDPC’s. E, F) Graphical
representation of the percent aneuploidy and number chromosomes respectively using FISH
analysis. A total of 50 cells were counted.
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7.4.5

Giant MP cells have tumorigenic potential

To test the tumorigenicity of giant MP cells, we collected the giant MP cells 3 days after
docetaxel treatment. A total of 50,000 PC-3 or giant MP cells were injected into the right flank
of the nude mice (n=6). As shown in Figure.7.4.5A, 6/6 mice (100%) injected with PC-3 cells
formed tumors while only 2/6 mice (33%) injected with giant MP cells formed tumors in the nude
mice. We also measured the kinetics of the tumor growth over a period of 60 days. Measurable
tumors started to form as early as 15 days post inoculation in mice injected with parent PC-3
cells. On the other hand, measurable tumors were started to form only after 28 days’ post
inoculation in mice injected with giant MP cells. The rate of tumor growth was also much higher
in mice injected with PC-3 cells compared to mice that were injected with giant MP cells
(Figure.7.4.5C). At the end of 60 days, the tumor weight of mice injected with PC-3 cells was 3
times higher than the tumors formed by giant MP cells (Figure.7.4.5B, C)). These results
suggested that even though the giant MP cells have tumorigenic capacity the rate of tumor
formation is much slower than the parent PC-3 cells.
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Figure 7.4.5Giant MP cells have tumorigenic potential.
A) Bar graph representing the number of animals forming tumors after injecting either PC-3 or
giant MP cells. B) Bar graph representing the tumor weight. C) Tumor growth monitored (by
Vernier calipers) and presented as tumor volume in cubic millimeter over a period of 60 days.

7.5

Discussion

Docetaxel, a member of the taxane class of antimicrotubule agents is the only FDA-approved
chemotherapeutic agent for CRPC. In many clinical situations, tumors will initially respond
successfully to docetaxel but subsequently relapse and become progressively more malignant.
This is mainly because of the intermittent dosing schedule followed for docetaxel administration.
This intermittent dosing regimen allows tumor regrowth between treatment schedules resulting
in only a partial regression of the prostate tumor mass. Our current study very elegantly
demonstrates that the formation of giant MP cells due to docetaxel treatment is the culprit cell
population responsible for cancer relapse. We describe here that the formation of giant MP cells
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is mainly a result of mitotic slippage. It is well known that the mitotically slipped cells can
undergo a second round of DNA replication without undergoing mitosis leading to formation of
giant MP cells [18] . This phenomenon is known as endoduplication [19, 20]. Several reports
suggest that p53 is an important component of ploidy checkpoint and its overexpression can lead
to endoduplication of cell [21]. Also, generation of resistant giant multinucleated cells has
been reported in p53 mutated tumor cells [22]. Since PC-3 cells lack p53 [23], endoduplication
and subsequent formation of giant MP cells may be attributed to the loss of p53 gene.

These giant MP cells can not only survive for a long period of time but could give rise to small
mononucleated, actively proliferating cells that can later cause the tumor to relapse. Here, the
giant MP cells undergo a novel type of cell division that involves nuclear budding followed by
intracellular cytokinesis to produce mononucleated daughter cells that “bud off” from the giant
MP cell, a phenomenon known as neosis or reductive cell division. Previous studies have also
shown that giant MP cells can form small daughter cells through this process of neosis [10, 12,
16, 17, 24, 25]. These mononucleated daughter cells have previously been reported to be highly
error -prone which increases the rates of genomic instability and contributes to tumor regrowth
[26].
We further show that giant MP cells and cells generated from them (CDPC) are
chemoresistant. The fact the giant MP cells are chemoresistant was not surprising. It is well
known that tumor cells in patients’ bodies are present in different phases of the cell cycle (G1,
S, G2 and M) and conventional chemotherapy kills only the most vulnerable phase of the cell
cycle but spares the others [ 2 7 ] . In other words, the cell death upon administration of the
chemotherapeutic agent depends upon the “cytotoxicity window” of the drug [27]. In
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particular, extensive literature reports that the high “cytotoxicity window” of docetaxel
corresponds to late S and G2 phase of the cell cycle [28, 29]. Studies have convincingly
demonstrated that cells are variably sensitive to docetaxel when treatment is applied to cells
synchronized in different phases of the cell cycle It is now well established that docetaxel is
almost totally lethal against S -phase cells but is only partially toxic against cells in G1 phase
of the cell cycle. Since these giant MP cells are pseudo-G1 like cells, these cells are very
unlikely to die upon docetaxel treatment. We also speculate that the chemoresistance of CDPC
cells could be attributed in part to high expression of antiapoptotic (cIAP-1, cIAP-2, XIAP and
survivin, clusterin) [30] proteins and survival proteins (Bcl-2, Bcl-XL) [31, 32]. It is also likely
that CDPCs have altered expression of drug transporter proteins thus making them less
susceptible to docetaxel toxicity.[33-36]

These cells also express cancer stem cell (CSC) marker CD44. This CSC marker plays a
critical role in regulating the properties of CSCs like, tumor initiation, self-renewal and
chemoradioresistance [37]. Our findings are in line with a previous study which reported that
docetaxel resistant prostate cancer cells exhibit increased stemness compared to their parental
counterpart [38]. Thus, targeting CSCs seems to be potential mechanism to combat the resistance
and relapse developed after docetaxel treatment. In line with this a recent study showed that
Napabucasin (BBI608) a cancer cell stemness inhibitor suppresses the prostate cancer growth and
makes the prostate cancer cells sensitive to docetaxel by killing the prostate cancer stem cells that
were resistant to docetaxel [39]. Thus, we speculate that the docetaxel treatment leads to clonal
selection of highly aggressive phenotype with stem cell like phenotype and this in part is
responsible for the chemotherapy failure.
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Finally, we show evidence that giant MP cells have tumorigenic potential in nude mice.
The giant MP cells take a significantly longer time to form the tumor as compared to the parent
PC-3 cells. This is because the giant MP cells first need to produce the mononucleated daughter
cells which then subsequently proliferate to form the tumor. This result is in concordance to the
fact that tumor relapse always occurs after a significant delay usually ranging from a couple of
months to sometimes years.
Taken together, our studies show that generation of giant MP cells that were once
presumed to be either destined for terminal growth arrest or cell death may actually represent
a “transition state” for generation of viable clones. These cells may play an integral part in tumor
relapse and generation of chemoresistance. Strategies preventing the formation of giant MP cells
and understanding the molecular mechanism of neosis will help us identify key targets to prevent
tumor relapse.
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8

CONCLUSIONS

In the collection of the studies described in this dissertation we have presented centrosome
amplification and clustering as important risk predictors of tumor aggressiveness and progression
that can serve as a surrogate of intra tumor heterogeneity (ITH). Since there are no cost-effective
readily quantifiable markers available for ITH these studies presented here highlight the role of
CA as a more comprehensive biomarker which can work as a clinically adaptable readout of ITH.
High CA is associated with increased tumor grade and has been shown to impart
aggressive phenotypes, such as invasive behavior and enhanced cell migration in pancreatic ductal
adenocarcinoma (PDAC) and the genes that drive CA are associated with worse overall survival
in this cancer type. Thus it is reasonable to suspect that CA is associated with worse
clinicopathology and survival rates in PDAC and can serve as an independent prognostic marker
for which there are no prognostic and predictive biomarkers available. In addition we also observed
that the African American (AA) PDACs exhibited higher CA when compared to the European
Americans (EA), AA PDACs have ~30% higher incidence and more aggressive disease course
than EA PDAC patients[1], perhaps in part because their tumors display elevated mutations in
genes whose dysregulation is known to drive CA that are common in PDAC (e.g., TP53 [2, 3],
SMAD4 [4], CDKN2A [5], CHEK2 [6],). The relationship between ethnicity and mutations in these
genes needs to be further investigated.
Moreover, in DCIS where high levels of ITH is present and in order to predict the
recurrence, there is a pressing clinical need for prognostic indices that can take into account the
heterogeneous nature of DCIS lesions. Current recurrence predictors based on commonly used
histopathological parameters such as histologic grade, tumor margins, and age lack consistency,
reproducibility fails to integrate the molecular predictors, underestimating the heterogeneity of
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DCIS lesions[7]. Deregulation of numerous pathways have been shown to result in CA; this
phenotypes thus integratively captures information about deregulation of multiple pathways and
the ITH-generating potential inherent in a tumor thus, the extent of CA can be used a predictor in
recurrence in DCIS. The major challenge of using CA as a biomarker is that there are no clinicallyfacile methods to quantify CA in tumor cells. In order to quantify CA and investigate its utility as
a predictive biomarker for recurrence in DCIS, we have pioneered a novel semi-automated
platform that integrates immunofluorescent confocal microscopy with digital image analysis
algorithms and yields a quantitative centrosomal amplification score (CAS) by evaluating the
severity and extent of numerical and structural centrosomal aberrations in a clinical sample. We
observed that the clinical samples with the higher risk of recurrence exhibited high CAS values
thus indicating a great extent of CA and consequently higher degree of ITH compared to samples
with a lower CAS value. Also, CAS was able to stratify the DCIS patients in high risk and low
risk of recurrence in a multivariable model. Not only this when the performance of CAS was
compared to another known predictor tool Van Nuys index, the performance of CAS was
significantly better in prediction than the other model. Thus, CAS offers a comprehensive and a
quantitatively precise measure of aberrant centrosomal status in DCIS lesions and with its ability
to predict recurrence in these lesions provides us a new tool to help tailor the treatment according
to individuals risk of recurrence in DCIS patients and avoid the over and under treatment of these
patients. Furthermore, we observed that mixed DCIS cases which have the invasive component in
them exhibited higher CAS compared to pure DCIS thus indicating that CA is associated with the
greater risk of malignant transformation and thus its quantitation may help to determine which
tumor will metastasize or become chemoresistant. Further studies are required to gain more
insights into these intriguing issues.
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Since centrosome amplification and clustering are cancer cell-specific phenomena,
centrosome-clustering proteins may also serve as attractive prognostic markers and theranostic
targets. The presence of higher KIFC1 in HGSOC and its association with poor overall survival
and aggressive phenotype predict that the patients with high KIFC1 levels experience high
mortality. In this study, we observed that primary tumors exhibited higher expression of KIFC1
gene expression and was associated with poor overall survival by contrast, while samples collected
from the metastatic sites showed similar expression levels of KIFC1 as in primary sites, high
KIFC1 expression in metastatic sites was not significantly correlated to poor survival. This
differential effect of high KIFC1 expression strongly suggests that elevated KIFC1 in primary sites
perhaps helps tumor cells present in the primary sites to acquire karyotypic diversity (through
CIN), which is more likely to lead to successful metastasis and poor survival. It is possible that
once metastasis commences, high KIFC1 levels in the metastatic clones provides little further
survival advantage for the cancer cells; alternatively, once metastasis occurs, the survival
difference between KIFC1-high and KIFC1-low patients is no longer so marked, an interesting
question for future studies. Another intriguing avenue for future research would be to test whether
HGSOC patients would benefit from the centrosome declustering drugs.
The non essential role of the KIFC1 in normal somatic cells and its crucial requirement for
the viability of cancer cells, together makes KIFC1 an ideal cancer selective drug target. This
proposition is bolstered by the observation that KIFC1 expression was significantly higher in the
mutant p53 CRCs and that the depletion by pharmacological and genetic methods in CRC cells
induced robust spindle multipolarity and subsequent apoptosis specifically in p53 null colorectal
cancer cells without minimal toxicity to the WT cells, a mechanistic insight that can guide rational
drug design as resistance to chemotherapy represents the major obstacle for the improvement of
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survival of nearly 50% of CRC patients. Since, the current therapies to target mutant p53 are not
effective as different mutations affect p53 function differently and different agents may be required
to target different mutations.[8] The identification of molecules or pathways that can be targeted
in p53 mutant CRC might help in improving the patient outcome. A major challenge faced in
development of the targeted therapies for cancer is the fundamental disconnect between preclinical
data and clinical results. Although the number of drugs entering in clinical trials is very high when
compared to other diseases as in a span of 10 years ~30% (~3000)drugs which entered in clinical
trials are for cancer but only 13.8% (~200) made it from the phase I to the testing approval [9].
This high rates of failure of therapies in the clinics is due to the lack of appropriate preclinical
models which can recapitulate all the features of individuals tumor and show accurate efficacy
rates. The preclinical models (both established tumor cell lines and tumor cell line xenografts) are
far from ideal, they have been widely used given that the rapid doubling times in such models
permit a fast-tracked drug-development timeline. Nonetheless, this perceived advantage rather
puts us at a loss when the doubling time itself is in the spotlight and the drug’s activity relies on
the preponderance of the mitotic population, which hinges on doubling rate. The brisk doubling
times of the preclinical models explain why drugs targeting mitosis proved active in these models
but were ineffective against patient tumors.[10-12] Our study highlights the importance of lowpassage patient-derived cell line systems as being most representative of the clinical scenario and
thus constituting an invaluable experimental model that could better guide drug development and
clinical trial design . We performed a rigorous, systematic analysis of the relationship between a
universal prognostic factor (mitotic index) and a well-known cancer-cell-specific trait and a
potential prognosticator (CA) in a spectrum of model systems ranging from cultured cells,
preclinical tumor xenografts, patient-derived primary cultures and patient tumors. Our data
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reconfirm that rapid cell division is not as predominant a trait of human tumors as it is of
immortalized cell lines and tumor cell line xenografts which explains the lack of response of
patient tumors to antimitotic drugs. Thus, to discern meaningful activity of drugs before they are
tested in clinical trials, it is imperative that we consider the shortcomings of our existent cell line
models and rather develop robust and relevant preclinical models that mimic cellular traits
observed in patient tumors. As highlighted by our study the role of centrosome declustering drugs
in tumor suppression and progression the study of these drugs in the early-passage patient-derived
tumor cell lines, which exhibit similar CA to patient tumors remains a uncharted territory and thus
can be an intriguing question for future studies.
A new era of precision medicine has dawned in oncology with the recent advances in
cancer genomics—an era in which a patient’s tumor can be characterized extensively for mutations
and other molecular abnormalities, and treatment can be based mainly on the identified molecular
changes (not just the type of cancer)[13, 14]. As defined by the National Cancer Institute precision
or personalized medicine is “A form of medicine that uses information about a person’s genes,
proteins, and environment to prevent, diagnose, and treat disease”[15]. It further elaborates that
“In cancer, personalized medicine uses specific information about a person’s tumor to help
diagnose, plan treatment, find out how well treatment is working, or make a prognosis.” Thus, the
biomarkers described herein constitute precision medicine because they can assist oncologists in
prognostication and planning treatment. Collectively all the findings presented in this dissertation
highlight the role of CA as a surrogate of ITH. Where it was presented that majority of the tumors
exhibit CA and centrosome clustering and that clustering of supernumerary centrosomes during
mitosis causes chromosome missegregation; thus, CA and centrosome clustering collectively fuel
karyotypic diversification and, thus, ITH. Therefore, I envision that CA and centrosome clustering
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these two factors may yield a reliable and comprehensive “ITH index” which can identify patients
which are likely to exhibit heterogeneity and associated aggressive disease features with the
increased need for aggressive treatment. Furthermore, the inclusion of the histopathological
features and features associated with tumor microenvironment in the developed CAS score might
help to develop models which can predict metastasis, which is the next question I intend to address
in my post-doctoral research. I am also interested in investigating the process by which CA leads
to the malignant transformation as the disease progresses which may help in limiting the extent of
ITH at an early stage, thus rendering it relatively manageable.
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APPENDICES
Appendix A: Supplementary Data for chapter 2
Detailed Description of Centrosome Amplification Quantitation
To evaluate the number of centrosomes in tumor samples per cell, we immunostained centrosomes
in tissues (normal and tumor for respective cancer types) with anti-γ-tubulin antibody and
counterstained nuclei with DAPI. We imaged these tissue slides at low magnification (20x)
employing LSM 700 confocal microscope to capture images of 10 fields of view that encompass
several nuclei and centrosomes (Supplementary Figure. 2.7.1). For each field we selected a region
with 30-35 clearly distinguishable nuclei and defined it as region of interest (ROI) by drawing a
boundary around the outer edges of outermost nuclei in the ROI. Next, we quantified the number
and volume of γ-tubulin foci in each ROI at higher magnification (63X objective). In our study,
nuclei associated with more than two centrosomes were deemed to have “numerically” amplified
centrosomes and nuclei associated with structurally abnormal centrosomes were accounted to have
“structurally” amplified centrosomes. Centrosome amplification (CA) was calculated as a
percentage by adding percent cells harboring more than two γ-tubulin foci and percent cells
harboring γ-tubulin foci with volume greater than upper range of mean centrosomal volumes found
in respective normal tissues (Supplementary Figure. 2.7.1). Since centrosomes pass through a
duplication cycle that involves large volume changes, we needed to define a “normal range” for
centrosomal volumes using both adjacent uninvolved tissue from cancer patients and normal tissue
for disease-free individuals for each cancer type. To determine the normal range, we analyzed
volumes of centrosomes (500 centrosomes for each sample) in adjacent uninvolved tissue from
cancer patients (20 samples for each cancer type) and in normal tissues (20 normal tissue samples
for breast, pancreas and bladder). Normal tissue samples were obtained from Biomax Inc. in the
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form of commercial tissue microarrays. We evaluated the volume of centrosomes by using the
three-dimensional measurement module in the Zeiss imaging software. Mean volumes of
centrosomes in normal breast, pancreatic and bladder epithelial cells ranged between 0.22-0.76
µm3, 0.20-0.56 µm3, and 0.20-0.74 µm3, respectively. The various centrosomal phenotypes
observed in hypoxic conditions are represented in Supplementary Figure. 2.7.2 and 2.7.3. The
presence of CA was confirmed via immunoblotting for CA-associated proteins as shown in
Supplementary Figure.2.7. 4.

Figure 2.7.1 Schematic showing the steps followed for quantitation of CA in the cancer
tissues, normal tissues and their corresponding cultured cell lines.
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Figure 2.7.2 Different configurations of Centrosome amplification observed in MDA-MB
468 after hypoxia induction by treating them with CoCl2.
Representative confocal micrographs of cells with centrosome amplification (dispersed
represents cells with widely distributed centrosomes in the interphase, clustered represents cells
with supernumerary centrosomes assembled together in the interphase but distinguishable, and
PCM represents abnormally large centrosomes due to PCM accumulation).
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Figure 2.7.3 Different configurations of centrosome amplification observed in MDA-MB
231 cells immunolabeled for centrin-2 (green) and γ-tubulin (red) after treatment with
CoCl2.
Representative confocal micrographs of cells with centrosome amplification (dispersed
represents cells with widely distributed centrosomes in the interphase, clustered represents cells
with supernumerary centrosomes assembled together in the interphase but distinguishable, and
PCM represents abnormally large centrosomes due to PCM accumulation). 200 cells were
counted in each condition.
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Figure 2.7.4 Representative immunographs of MDA-MB 231 immunolabeled for centrin-2
(green) and γ-tubulin (red) after treatment with CoCl2 in split form.
B: Split confocal images of dispersed centrosome amplification. C: Split confocal images of the
clustered CA. D: Split confocal images of structural amplification with PCM accumulation.
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Figure 2.7.5 Immunoblots showing the levels of hypoxia and centrosomal markers in cells
treated with CoCl2 and cultured under hypoxia.
A : Immunoblots showing the levels of hypoxia and centrosomal markers in MDA-MB-231 and
MDA-MB-468 cells treated with 100µM of CoCl2 for 24 h. B. Immunoblots showing the levels
of hypoxia and centrosomal markers in MDA-MB-231 and MDA-MB-468 cells exposed to
hypoxia for 48 h.

Figure 2.7.6 Immunoblots showing the levels of hypoxia and centrosomal markers in HIF1α KO and OE cells.
A. Immunoblots of HIF-1α and centrosomal proteins in MDA-MB-231 and MDA-MB-468
transfected with empty vector or degradation-resistant HIF-1α. B. Immunoblots of HIF-1α and
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centrosomal proteins in MDA-MB-231 and MDA-MB-468 transfected with Cas9-sgRNA (HIF1α) construct or control vector (pSpCas9-2A-GFP).

Figure 2.7.7 Quantitation of CA in cells treated with DMOG and MG132
A. Representative confocal micrographs of centrosome amplification in MDA-MB-231 cells
treated with DMOG and MG132. Representative confocal micrographs of centrosome
amplification in MDA-MB-231 transfected with empty vector or degradation-resistant HIF-1α
and with HIF-1α gene KO. B. Immunoblots showing the levels of hypoxia and centrosomal
markers in cells treated with 1mM DMOG for 24 h. Immunoblots showing the levels of hypoxia
and centrosomal markers in cells treated with 5µM of MG132 for 5 h. C. Quantitation of
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centrosome amplification per microscopic examination for DMOG and MG132 treated and
untreated MDA-MB-231 and MDA-MB-468 cells.

Enrichment of centrosomal gene expression in tumors with a hypoxia-high gene expression
signature
We validated our in vitro findings of a correlation between CA and hypoxia in silico by
probing the publicly-available Kao[1] and Jonsdottir[2] microarray datasets using Gene Set
Enrichment Analysis (GSEA).[3] Essentially, our goal was to determine whether breast tumors
that are enriched in hypoxia-associated transcripts also show a correlational enrichment in
centrosomal transcripts. Publicly available pre-processed gene expression profiles of primary
breast tumors (n=327 for the Kao dataset, GSE20685; n=94 for the Jonsdottir dataset, GSE46563)
were used for GSEA. Within each dataset, patients were stratified into two groups by a hypoxia
score, the reduced hypoxia metagene previously shown to have prognostic ability in multiple
cancers.[4, 5] As previously defined, hypoxia scores were calculated as the median expression of
26 genes that are upregulated in response to hypoxia. Scores  median were categorized as
“hypoxia low” and scores > median were categorized as “hypoxia high.” For the Kao dataset,
Affymetrix probes with the “x_at” extension was removed unless no other probe was available
(e.g., as with ALDOA). For the Jonsdottir dataset, Illumina probes with the “A” designator were
preferentially used. When multiple probes were present, their median expression was used in score
calculation. GSEA was performed with 1000 permutations, and false discovery rate q-values<0.05
were considered statistically significant.
Using the kao dataset, we collapsed features into gene symbols, resulting in 20,606 genes
being available for gsea using curated gene sets from molecular signatures database[6] v5.0,
including those from the gene ontology (go) consortium (for analysis of cellular components and
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biological processes) and reactome [7] v53 (for pathway analysis), along with gene sets that we
defined based on empirical evidence from the literature. We validated that the hypoxia-high group
was differentially enriched in hypoxia-associated genes by performing gsea with the full hypoxia
metagene as shown in supplementary Figure. 2.7.7 (also see supplementary table 2.7.1 for study
details and supplementary table 2.7.2 for the ranked gene list; n=44 after filtering). We then
performed GSEA to identify gene ontologies associated with the hypoxia-high group, which we
found was significantly enriched in microtubule-organizing center and centrosome components,
which were among the top-20 enriched cellular components (see supplementary table 1 for these
and all other enriched gene ontologies). The hypoxia-high group was also enriched in cell cyclerelated processes, which constituted the top-ranked gene ontology among biological processes.
Cellular pathway analysis using reactome terms identified mitosis as the third-most enriched
pathway, with various other cell cycle-related pathways also significantly enriched. Cellular
pathway analysis revealed an enrichment in genes associated with the recruitment of centrosome
proteins and complexes. Intriguingly, the hypoxia-high group was also enriched in genes involved
in the cellular pathway associated with loss of ninein-like protein (nlp), a γ-tubulin-binding protein,
from mitotic centrosomes. It is known that plk1 and nek2 phosphorylate nlp at the onset of mitosis,
resulting displacement of nlp from the centrosome, which is associated with centrosome
maturation (involving the recruitment of γ-tubulin ring complexes and other pericentriolar material
components) and a concomitant increase in microtubule-nucleating capacity. Plk1 or nek2
overexpression results in premature nlp dissociation from centrosomes and also induces ca.[8]
Although hypoxia-high breast tumors were clearly found to be enriched in centrosomal
components and pathways, we wanted to more specifically test the hypothesis that they are
enriched in gene ontologies related to CA per se. No high-throughput screen of CA-associated
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genes has been performed to inform construction of a CA gene set; nevertheless, the literature
reports that CA is associated with hormone receptor-negative and node-positive breast cancer.[9]
Thus, we analyzed enrichment of centrosome-associated genes (namely, experimentally
identified human centrosomal proteins in the MiCroKiTS[10] database; n=540 genes) in hormone
receptor-positive node-negative patients, rationalizing that this gene set has a high likelihood of
representing CA. We found that 77 of these genes were enriched in hormone receptor-negative
node-positive breast carcinomas. Next, we performed GSEA using these 77 genes as a gene set,
which we found was significantly enriched in the hypoxia-high group, as shown in Supplementary
Figure. 2.7.7B (also see Supplementary Table 2.7.3 for the ranked gene list). Many genes
implicated in CA (such as AURKA, CCNA2, CCNE2, CEP152, NEK2, PLK4, and STIL) or
amplified centrosome clustering (such as KIFC1, the top-ranked hit, along with BIRC5 and
TACC3) from the literature are among the enriched genes from this set. Because CA drives
chromosomal instability (CIN), we wondered whether hypoxia-high cases were also enriched in
CIN-associated genes. To this end, we performed GSEA with genes from the CIN25 signature, net
overexpression of which has prognostic significance in various types of cancer.[11] We found this
set was highly enriched in the hypoxia-high group (Supplementary Table 2.7.1). Collectively,
these results suggest that hypoxic breast tumors are enriched in CA- and CIN-associated genes.
Enrichment of centrosomal gene expression in tumors with a hypoxia-high gene expression
signature regardless of mitotic activity
Many CA-associated proteins do not exclusively localize to the centrosome; some also
localize to the mitotic spindle. Thus, it could be argued that, rather than having a greater extent of
CA, the hypoxia-high group merely has more mitotic cells than the hypoxia-low group. To test
this hypothesis, we analyzed the Jonsdottir dataset, which contains gene expression profiles and

214

mitotic activity indices for 94 breast tumor specimens from lymph node-negative patients. To
begin, we validated that the hypoxia-high group was enriched in hypoxia-associated genes. We
performed GSEA with the full hypoxia metagene and found significant enrichment
(Supplementary Table 2.7.1), which also underscores the robustness of this 26-gene hypoxia
signature across platforms and breast cancer datasets. We then performed GSEA using the 77
potentially CA-associated genes (that is, those that were enriched in the hormone receptor-negative
node-positive breast carcinomas from the Kao dataset) and found significant enrichment in the
Jonsdottir dataset as well (Supplementary Table 2.7.4). This is especially interesting because the
Jonsdottir patients are also all node-negative, indicating this gene set captures a phenotype that is
not wholly dependent on nodal status. There was substantial overlap in the potentially CAassociated genes enriched in the Jonsdottir and Kao hypoxia-high groups. Next, we did find that
the hypoxia-high group was associated with a high mitotic activity index (MAI; >10 mitotic figures
per 10 fields of vision) based on the Mann-Whitney test (p=0.01). Nonetheless, when we
performed GSEA on the MAI-low group (n=60) using hypoxia scores as the phenotype, we still
found that the hypoxia-high group was enriched in potentially CA-associated genes
(Supplementary Table 2.7.5). Thus, even among tumors with relatively low mitotic activity,
hypoxia-high tumors show enrichment in potentially CA-associated genes, minimizing the
probability that we are merely capturing proliferation-associated genes with our gene set.
Combined with our in vitro data, these in silico data substantiate the hypothesis that hypoxia is
associated with CA in patient breast tumors.
Finally, we were interested to determine whether hypoxia-associated CA, as determined
by gene expression levels, predicts worse outcomes and, if so, whether its predictive ability
depends on mitotic activity. To this end, we created a score based on the top ten CA-associated
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genes enriched in the hypoxia-high samples of the Jonsdottir dataset (from Supplementary Table
2.7.4). Specifically, we defined the hypoxia-associated CA score as the median expression of those
top 10 genes. Kaplan-Meier analysis and Cox regression were performed using SPSS Statistics
version 21 (IBM). For multivariate Cox regression analysis, all potential predictors were entered
into the full model and then eliminated stepwise based on an α=0.10 elimination criterion. Optimal
cut points based on distant-metastasis-free survival (DMFS) were found using X-tile[12] per the
highest Χ2 value following dichotomization. We found that stratifying patients based on a cutpoint
of 317 resulted in the CA score having the best predictive ability using the 94 node-negative breast
cancer patients of the Jonsdottir dataset (p=0.020; Supplementary Figure. 2.7.6C). Univariate Cox
regression revealed that a high hypoxia-associated CA score (i.e., >317) was associated with worse
DMFS (HR=2.87; p=0.026), which was upheld in multivariate regression adjusting for all
available potentially confounding covariates (including tumor size, Nottingham grade, estrogen
and human epidermal growth factor receptor 2 statuses, and mitotic activity index). In fact, only
this score remained in the final model. When hypoxia score was added to the Cox regression
analysis, the effect of CA score on DMFS was more pronounced (HR=3.39, p=0.011). Only the
CA score and hypoxia score remained in the final model, though the hypoxia score was no longer
significant (HR=2.22, p=0.066). When the analysis was repeated without the CA score in the full
model, however, the hypoxia score was a significant predictor of DMFS (HR=2.45, p=0.047), as
was mitotic activity (HR=2.88, p=0.0.17), with no other variables in the final model. These results
raise the tantalizing possibility that the ability of the hypoxia score to predict DMFS results from
its association with CA. Even more intriguing is the idea that hypoxia might upregulate CA to
drive metastatic dissemination, an exciting avenue of future research.
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Figure 2.7.8 Gene-set enrichment and Kaplan-Meier analyses based on hypoxia- and
centrosome amplification-associated genes.
A. Enrichment plots of hypoxia metagene components available in the Kao dataset and B. genes
potentially associated with centrosome amplification (CA), with red indicating correlation with
the hypoxia-low group and blue the hypoxia-high group. C. Plots of Kaplan-Meier product limit
estimates of distant metastasis-free survival of patients in the Jonsdottir dataset stratified by
hypoxia-associated CA score (low vs. high), p=0.020 by the log-rank tesst. TTDM=time to distant
metastasis. Di. Number of distant metastases and censored cases by centrosome amplification
score. Dii. Mean distant metastasis-free survival time by centrosome amplification score.
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Figure 2.7.9 Representative immunoblots
A. Immunoblots of HIF-1α in MDA-MB-231 and MDA-MB-468 transfected with empty vector
or degradation-resistant HIF-1α. B. Immunoblots of VEGF in MDA-MB-231 and MDA-MB-468
cells treated with 100µM of CoCl2 for 24 hrs.

Figure 2.7.10 Representative immunoblots showing the levels of HIF-1α in nuclear and
cytoplasmic lysates of MDA-MB-231 and MDA-MB-468 cells treated with 100µM of CoCl2
for 24 hrs.
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Table 2.6.1 Gene Set Enrichment Analyses for specified Gene Ontologies.
Reactome pathways, literature-based gene sets, and self-defined gene sets. GO and Reactome
IDs (for curated gene sets) and publication details (for literature-based gene sets) are given in
parentheses. ES=Enrichment Score; NES=Normalized Enrichment Score; NOM=nominal;
FDR=False Discovery Rate; FWER=Family-Wise Error Rate

Gene Set

Size
after
Filterin
g

ES

ES

NOM pvalue

FDR qvalue

FWER pvalue

Ran
k at
Max

Hypoxia
Metagene (Buffa
et al., 2010)
Microtubule
Organizing
Center
(GO:0005815)
Centrosome
(GO:0005813)

44

-0.77

-2.04

<0.001

<0.001

<0.001

3686

57

-0.54

-2.06

<0.001

4.5E-03

0.03

1531

49

-0.54

-2.01

<0.001

0.01

0.05

1531

Cell cycle
(GO:0007049)

285

-0.61

-2.33

<0.001

3.1E-03

0.02

2632

Cell Cycle Mitotic
(Pathway:6927)
Recruitment of
Mitotic
Centrosome
Proteins and
Complexes
(Pathway:380270)

271

-0.67

-2.29

<0.001

4.2E-03

0.01

2316

54

-0.46

-1.89

0.02

0.02

0.01

2313

Loss of NLP from
Mitotic
Centrosomes
(Pathway:380259)
Centrosomal
Genes
Upregulated in
ER/PR+ NodeTumors

47

-0.46

-1.85

0.02

0.02

0.40

2313

77

-0.82

-1.88

<0.001

<0.001

<0.001

2630

CIN25 Genes
(Carter et al.,
2006)
Jonsdottir Entire Dataset

23

-0.89

1.69

<0.001

<0.001

<0.001

1297

Kao- Entire
Dataset

219
Hypoxia
Metagene (Buffa
et al., 2010)
Centrosomal
Genes
Upregulated in
ER/PR+ NodeTumors

47

-0.81

-1.55

0.01

0.01

0.003

5057

77

-0.81

-1.56

4.0E-03

4.0E-03

2.0E-03

4008

47

-0.75

-1.49

0.04

0.04

0.02

5163

77

-0.85

-1.72

<0.001

<0.001

<0.001

1813

Jonsdottir - MAILow Only
Hypoxia
Metagene (Buffa
et al., 2010)
Centrosomal
Genes
Upregulated in
ER/PR+ NodeTumors

Table 2.6.2 Rank-ordered list of filtered hypoxia metagene components with associated rank
metric scores, enrichment scores (ES), and whether each gene is part of the core enriched genes
(i.e., the leading-edge subset) in the hypoxia-high group of the Kao dataset
GENE SYMBOL

RANK IN
GENE LIST

RANK METRIC SCORE

RUNNING ES

CORE
ENRICHME
NT

ALDOA

10185

-0.001037822

-0.4951352

No

ANKRD37

12004

-0.013171702

-0.5810628

No

LRRC42

13846

-0.026962586

-0.6655041

No

MCTS1

15337

-0.04007807

-0.73039776

No

MIF

15612

-0.042822175

-0.7356349

No

CHCHD2

15748

-0.044233657

-0.7338455

No

LDHA

16016

-0.047092326

-0.7379356

No

GAPDH

16182

-0.049089462

-0.73668796

No

GPI

16921

-0.058381788

-0.76155204

Yes

SEC61G

17016

-0.059670471

-0.75485283

Yes

UTP11L

17344

-0.064875908

-0.75850195

Yes

HK2

17604

-0.069081984

-0.75804955

Yes

TUBB6

17812

-0.072616458

-0.7544006

Yes

PSMA7

17838

-0.073151112

-0.7417994

Yes

17903

-0.074541941

-0.7308322

Yes

PGK1

18012

-0.076205611

-0.72169065

Yes

BNIP3

18017

-0.076291725

-0.70747495

Yes

P4HA1

18145

-0.07900098

-0.69872946

Yes

SLC25A32
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MAD2L2

18230

-0.080925092

-0.68752927

Yes

CORO1C

18285

-0.082037203

-0.67465997

Yes

ENO1

18319

-0.082770482

-0.6606309

Yes

TPI1

18340

-0.083269544

-0.64587533

Yes

SLC16A1

18401

-0.084655896

-0.63280326

Yes

YKT6

18405

-0.084711224

-0.6169486

Yes

DDIT4

18565

-0.088841394

-0.6079007

Yes

MRPL15

18878

-0.098103359

-0.60454416

Yes

MRPL13

19107

-0.106322989

-0.59554994

Yes

AK3L1

19315

-0.114598989

-0.5839712

Yes

NDRG1

19351

-0.11648801

-0.56367075

Yes

NP

19458

-0.121711895

-0.5458365

Yes

SLC2A1

19484

-0.12285845

-0.52384645

Yes

MRPS17

19534

-0.126033917

-0.50242376

Yes

ACOT7

19727

-0.138207912

-0.48565617

Yes

PFKP

19803

-0.144859448

-0.46194214

Yes

HIG2

19898

-0.152798504

-0.4376526

Yes

PSRC1

19910

-0.154252052

-0.4090519

Yes

ADM

20066

-0.17373921

-0.38377362

Yes

CA9

20175

-0.192664087

-0.35263497

Yes

CTSL2

20338

-0.228577107

-0.31733918

Yes

SHCBP1

20490

-0.299957722

-0.2680258

Yes

CDKN3

20524

-0.333389521

-0.20665893

Yes

KIF20A

20528

-0.337646633

-0.14302899

Yes

KIF4A

20545

-0.356419325

-0.07648543

Yes

ANLN

20585

-0.420125276

9.73E-04

Yes

Table 2.6.4 Rank-ordered list of potential centrosome amplification-associated genes with
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the core
enriched genes (i.e., the leading-edge subset) in the hypoxia-high group of the Kao dataset.
GENE SYMBOL

RANK IN GENE
LIST

TRIM22

9257

PRKAA1

RANK METRIC
SCORE

RUNNING ES

CORE
ENRICHMENT

0.005535

-0.45051

No

10390

-0.0025

-0.50547

No

MAP1B

11819

-0.01194

-0.57415

No

GIMAP5

12039

-0.01341

-0.58383

No

FYN

12842

-0.01913

-0.62148

No

ODF2L

13067

-0.02089

-0.63085

No

RASSF5

14099

-0.02883

-0.67894

No
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PRKD3

14243

-0.02992

-0.6837

No

MARCKS

14472

-0.03196

-0.69244

No

LIMK1

14658

-0.03361

-0.69897

No

SYK

14810

-0.0351

-0.70373

No

HAP1

15154

-0.03818

-0.71762

No

PIM1

16282

-0.05017

-0.76881

No

FIGN

16589

-0.05401

-0.77973

No

LIMK2

16953

-0.05886

-0.79306

No

BRSK1

17048

-0.06002

-0.79321

No

PRKCQ

17094

-0.06075

-0.79091

No

SMURF2

17543

-0.06803

-0.80771

No

SOCS1

17796

-0.07242

-0.81464

No

NEK6

17977

-0.07552

-0.81783

Yes

CRYAB

18091

-0.07784

-0.81758

Yes

RUNX3

18196

-0.08005

-0.81673

Yes

SPHK1

18224

-0.0808

-0.81208

Yes

SASS6

18240

-0.08116

-0.80682

Yes

SLC16A1

18401

-0.08466

-0.80836

Yes

GNAI1

18457

-0.08613

-0.80467

Yes

TSKS

18806

-0.09576

-0.81455

Yes

WASF1

18833

-0.0967

-0.80867

Yes

PLEKHG6

19038

-0.10343

-0.81097

Yes

PDE7A

19279

-0.11301

-0.81431

Yes

LCK

19344

-0.11619

-0.80885

Yes

NDRG1

19351

-0.11649

-0.80054

Yes

CCNA1

19406

-0.1191

-0.79437

Yes

CENPJ

19444

-0.12114

-0.78722

Yes

LMO4

19518

-0.12512

-0.78154

Yes

PSMD3

19615

-0.13063

-0.77656

Yes

VAC14

19642

-0.13237

-0.76805

Yes

CDC25B

19705

-0.13691

-0.76096

Yes

CHEK2

19769

-0.14153

-0.75357

Yes

RANBP1

19788

-0.14291

-0.74389

Yes

GPSM2

19923

-0.15544

-0.73894

Yes

CKAP2

19951

-0.15892

-0.72852

Yes

CEP152

19990

-0.16318

-0.71831

Yes

MCM5

19996

-0.16407

-0.70644

Yes

GMNN

20040

-0.16928

-0.69603

Yes

EIF4EBP1

20052

-0.17204

-0.68385

Yes

TACC3

20230

-0.20252

-0.67752

Yes

FANCA

20250

-0.20734

-0.66313

Yes
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BRCA2

20291

-0.21723

-0.64903

Yes

SGOL1

20325

-0.22475

-0.63403

Yes

STIL

20384

-0.24633

-0.61866

Yes

ESPL1

20406

-0.25368

-0.60095

Yes

CHEK1

20417

-0.2561

-0.58252

Yes

TROAP

20421

-0.25745

-0.56365

Yes

CCNB1

20430

-0.26098

-0.54476

Yes

PTTG1

20441

-0.26845

-0.52542

Yes

CRABP1

20449

-0.27154

-0.5057

Yes

CCNA2

20464

-0.28031

-0.48567

Yes

KIF15

20467

-0.28398

-0.4648

Yes

MAD2L1

20468

-0.28479

-0.44376

Yes

CENPF

20471

-0.28903

-0.42251

Yes

AURKA

20480

-0.29411

-0.40117

Yes

KIF11

20487

-0.29864

-0.3794

Yes

HMMR

20503

-0.31248

-0.35705

Yes

CDC25C

20510

-0.32075

-0.33365

Yes

CCNE2

20511

-0.32077

-0.30996

Yes

NEK2

20517

-0.32682

-0.28606

Yes

CDKN3

20524

-0.33339

-0.26172

Yes

KIF14

20548

-0.35903

-0.23632

Yes

PLK1

20550

-0.35933

-0.20983

Yes

KIF18A

20556

-0.37178

-0.18261

Yes

ASPM

20557

-0.37248

-0.1551

Yes

TTK

20560

-0.37723

-0.12733

Yes

CEP55

20561

-0.37875

-0.09935

Yes

BIRC5

20577

-0.40346

-0.07028

Yes

CDC20

20586

-0.42014

-0.03964

Yes

KIFC1

20603

-0.54844

9.75E-05

Yes

Table 2.6.5 Rank-ordered list of potential centrosome amplification-associated genes with
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the core
enriched genes (i.e., the leading-edge subset) in the hypoxia-high group of the entire Jonsdottir
dataset.
GENE
SYMBOL

RANK IN
GENE
LIST

RANK
METRIC
SCORE

RUNNING
ES

CORE
ENRICHME
NT

MAP1B

9927

0.027879

-0.2694731

No

GIMAP5

11620

0.018845

-0.3146127

No

NEK6

14304

0.006694

-0.3874912

No

TSKS

20675

-0.02045

-0.5602645

No

223
LCK

21643

-0.0252

-0.585253

No

GNAI1

21692

-0.02545

-0.5851359

No

MARCKS

25609

-0.04594

-0.6894773

No

SYK

25673

-0.04634

-0.6885981

No

WASF1

25818

-0.04722

-0.689881

No

FIGN

26288

-0.05058

-0.6998489

No

SMURF2

26579

-0.05269

-0.704811

No

CCNB1

26876

-0.05483

-0.7098172

No

TRIM22

28230

-0.06621

-0.7430442

No

SLC16A1

28325

-0.06714

-0.7418446

No

BRCA2

29320

-0.07824

-0.764595

No

RASSF5

29744

-0.08353

-0.7714585

No

PRKAA1

30331

-0.0924

-0.7822752

No

HAP1

30451

-0.09399

-0.780252

No

ODF2L

30904

-0.10177

-0.7868843

No

FYN

31621

-0.1156

-0.7999487

No

PRKD3

31760

-0.11896

-0.7970437

No

PSMD3

32154

-0.12857

-0.8005617

Yes

SOCS1

32256

-0.13107

-0.7959673

Yes

CRABP1

32696

-0.14402

-0.7998746

Yes

CCNA1

32921

-0.15105

-0.7975177

Yes

SASS6

33107

-0.15692

-0.7937663

Yes

BRSK1

33320

-0.16365

-0.7903748

Yes

CHEK2

33524

-0.17026

-0.7863668

Yes

RUNX3

34028

-0.19051

-0.7894138

Yes

LIMK1

34450

-0.20953

-0.789155

Yes

KIF14

34790

-0.22531

-0.7857721

Yes

SPHK1

34813

-0.22655

-0.7736645

Yes

TACC3

34830

-0.22751

-0.7613397

Yes

PRKCQ

34832

-0.22752

-0.7486046

Yes

ESPL1

34847

-0.22799

-0.7361981

Yes

FANCA

34935

-0.23268

-0.7255213

Yes

CDC25C

34988

-0.23525

-0.7137451

Yes

VAC14

35284

-0.25222

-0.7076517

Yes

HMMR

35293

-0.25279

-0.6936903

Yes

PLEKHG6

35543

-0.27288

-0.6851819

Yes

CDC25B

35587

-0.27725

-0.6708041

Yes

PLK1

35601

-0.27839

-0.655543

Yes

EIF4EBP1

35641

-0.28117

-0.6408358

Yes

CRYAB

35712

-0.28594

-0.6267073

Yes

MCM5

35760

-0.29006

-0.61172

Yes
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CKAP2

35792

-0.29443

-0.5960506

Yes

ASPM

35799

-0.29504

-0.5796646

Yes

KIF11

35823

-0.29804

-0.5635741

Yes

CCNE2

35873

-0.30251

-0.5479429

Yes

GMNN

35987

-0.31268

-0.5334887

Yes

CENPJ

35995

-0.31324

-0.5161092

Yes

NEK2

36018

-0.31532

-0.4990226

Yes

CEP55

36028

-0.31635

-0.4815231

Yes

CDKN3

36053

-0.31868

-0.4643022

Yes

PIM1

36092

-0.32313

-0.4472143

Yes

BIRC5

36106

-0.32495

-0.4293416

Yes

KIF18A

36150

-0.3296

-0.4120271

Yes

MAD2L1

36155

-0.33

-0.3936251

Yes

CENPF

36214

-0.33744

-0.3762802

Yes

PTTG1

36249

-0.34282

-0.3579785

Yes

TROAP

36260

-0.3446

-0.3389218

Yes

KIF15

36303

-0.35197

-0.3203251

Yes

CEP152

36317

-0.35415

-0.3008146

Yes

SGOL1

36319

-0.35452

-0.2809555

Yes

TTK

36354

-0.3624

-0.2615553

Yes

CDC20

36396

-0.36887

-0.2419837

Yes

CCNA2

36406

-0.37126

-0.221404

Yes

KIFC1

36418

-0.37251

-0.2008091

Yes

LIMK2

36451

-0.37996

-0.1803693

Yes

AURKA

36460

-0.38249

-0.1591323

Yes

PDE7A

36488

-0.38882

-0.1380591

Yes

GPSM2

36559

-0.4058

-0.1172072

Yes

NDRG1

36567

-0.40833

-0.0944937

Yes

RANBP1

36571

-0.40905

-0.0716305

Yes

LMO4

36595

-0.41683

-0.0488768

Yes

STIL

36597

-0.41794

-0.02546

Yes

CHEK1

36684

-0.50451

4.92E-04

Yes

Table 2.6.6 Rank-ordered list of potential centrosome amplification-associated genes with
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the core
enriched genes (i.e., the leading-edge subset) in the hypoxia-high group of the mitosis-activityindex-low cases of the Jonsdottir dataset
GENE
SYMBOL
CRABP1

RANK IN
GENE
LIST
1247

RANK
METRIC
SCORE
0.196209

RUNNING
ES
-0.022491

CORE
ENRICHM
ENT
No

225
SYK

4586

0.083097

-0.108734

No

MAP1B

4941

0.077617

-0.113828

No

GNAI1

6693

0.05668

-0.158298

No

PRKCQ

7260

0.051505

-0.170718

No

CCNA1

11454

0.025851

-0.283677

No

GIMAP5

12204

0.022238

-0.302817

No

LIMK1

13681

0.015818

-0.342184

No

TSKS

14283

0.013139

-0.35782

No

HAP1

14837

0.010819

-0.372281

No

NEK6

15431

0.008267

-0.387985

No

LCK

16809

0.002983

-0.425406

No

RUNX3

18761

-0.004223

-0.478425

No

WASF1

19448

-0.006835

-0.496752

No

SMURF2

20802

-0.012268

-0.532971

No

SOCS1

21207

-0.014023

-0.543175

No

CRYAB

23902

-0.025877

-0.615206

No

PRKD3

24183

-0.027193

-0.621249

No

SLC16A1

24424

-0.028282

-0.626136

No

FANCA

24474

-0.028508

-0.625795

No

TRIM22

26151

-0.036923

-0.66938

No

ODF2L

26970

-0.041393

-0.689276

No

LMO4

27255

-0.042918

-0.694502

No

VAC14

28281

-0.049818

-0.719554

No

FIGN

28767

-0.053333

-0.729655

No

MARCKS

28812

-0.053722

-0.727692

No

EIF4EBP1

30948

-0.074622

-0.781589

No

CHEK2

31454

-0.081308

-0.790588

No

RASSF5

32122

-0.091782

-0.803394

No

FYN

32229

-0.093444

-0.800785

No

PRKAA1

33495

-0.122161

-0.828128

No

SPHK1

33904

-0.13265

-0.831455

No

BRCA2

34464

-0.152763

-0.837721

No

PIM1

34891

-0.169697

-0.839357

Yes

BRSK1

35120

-0.181113

-0.834915

Yes

LIMK2

35200

-0.184675

-0.826196

Yes

PDE7A

35419

-0.198272

-0.82047

Yes

PLEKHG
6
PSMD3

35542

-0.20546

-0.811701

Yes

35718

-0.219175

-0.80357

Yes

GMNN

35762

-0.222346

-0.791649

Yes

NDRG1

35901

-0.235135

-0.781568

Yes

RANBP1

35918

-0.236222

-0.768093

Yes
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MCM5

35984

-0.242655

-0.755576

Yes

PLK1

36105

-0.258397

-0.743634

Yes

SASS6

36241

-0.277588

-0.730971

Yes

CEP152

36386

-0.312943

-0.716472

Yes

CENPF

36392

-0.313983

-0.698116

Yes

CDC25B

36411

-0.319583

-0.679785

Yes

STIL

36430

-0.324553

-0.661162

Yes

ASPM

36438

-0.326208

-0.642141

Yes

AURKA

36476

-0.341741

-0.623024

Yes

KIF14

36482

-0.342514

-0.602988

Yes

BIRC5

36494

-0.345894

-0.582916

Yes

CCNB1

36500

-0.348213

-0.562544

Yes

KIF18A

36520

-0.356315

-0.542078

Yes

TACC3

36528

-0.35818

-0.521174

Yes

HMMR

36541

-0.363636

-0.500085

Yes

CKAP2

36568

-0.374923

-0.478713

Yes

MAD2L1

36570

-0.37601

-0.456595

Yes

SGOL1

36580

-0.38294

-0.434287

Yes

CCNE2

36581

-0.383755

-0.411685

Yes

KIFC1

36583

-0.383929

-0.389101

Yes

CCNA2

36587

-0.38714

-0.366382

Yes

GPSM2

36588

-0.388246

-0.343516

Yes

CDKN3

36616

-0.40076

-0.32065

Yes

CDC20

36621

-0.406762

-0.296802

Yes

ESPL1

36626

-0.410511

-0.272734

Yes

CHEK1

36627

-0.412625

-0.248432

Yes

TTK

36633

-0.414843

-0.224136

Yes

CEP55

36647

-0.434241

-0.198916

Yes

TROAP

36665

-0.460532

-0.172257

Yes

KIF11

36671

-0.467194

-0.144878

Yes

CDC25C

36678

-0.47623

-0.116993

Yes

KIF15

36679

-0.477443

-0.088874

Yes

NEK2

36683

-0.486579

-0.060298

Yes

PTTG1

36691

-0.501135

-0.030975

Yes

CENPJ

36699

-0.530558

8.18E-05

Yes
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Appendix B: Supplementary Data for Chapter 3

Supplementary Figure 3.7.1 Heat maps of genes whose dysregulation drives centrosome
amplification and clustering.
Heat maps of genes whose dysregulation drives centrosome amplification and clustering are
upregulated in pancreastic ductal adenocarcinoma (N=36) relative to normal pancreas (N=16).
Heat map generated with Oncomine Gene Browser.

Supplementary Figure 3.7.2 The proportion of gene-level non-silent somatic mutations in
The Cancer Genome Atlas pancreatic adenocarcinoma dataset (N=144).
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Supplementary Figure 3.7.3 Risk factors for the development of PDAC that are associated
with African American ethnicity
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Appendix C: Supplementary Data for Chapter 5

Supplementary Figure 5.7.1 High grade serous ovarian carcinomas exhibit higher
expression of KIFC1. A. Box-whisker plot representing the weighted index for KIFC1
expression in low and high-grade SOC tissues.
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Supplementary Figure 5.7.2 Kaplan-Meier plots of overall survival based on low or high
expression of KIFC1 gene in ovarian cancer patients regardless of histotypes.
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Supplementary Figure 5.7.3 Gene set enrichment analyses for biological processes
associated to KIFC1 high group. A. Enrichment plot of genes associated to microtubule-based
processes, with red indicating correlation with the KIFC1-high group and blue the KIFC1-low
group.

Supplementary Figure 5.7.4 HGSOC cell lines show higher expression of genes, driving
Centrosome amplification, and KIFC1 in silico. Ai. Bar graph representing Log Base 2
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KIFC1expression in ovarian cell lines (Ovcar5, OVCAR3, OVSAHO, and SKOV3). Aii Bar
graph representing Log Base 2 Centrosome amplification index expression in ovarian cell lines
(OVCAR5, OVCAR3, OVSAHO, and SKOV3).

Table 5.7.1 Descriptive table for univariate and multivariate analysis.
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Table 5.7.2 Rank-ordered list of filtered genes comprising centrosome components with
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the
core enriched genes (i.e., the leading-edge subset) in the KIFC1-high group.
GENE
SYMBOL

RANK IN
GENE LIST

RANK
METRIC SCORE

TOP2A

25

0.334119827

KIF15

31

0.329936087

BIRC5

33

0.328538954

NEK2

49

0.306233615

PLK1

69

0.277375519

CTAG2

133

0.232606009

ESPL1

163

0.211262807

317

0.161001891

SAC3D
1
NDE1

394

0.147750571

BRCA2

470

0.137022048

CROCC

841

0.106630601

AZI1

1055

0.095914356

CKAP5

1293

0.087143637

RUNNIN
G ES

CORE
ENRICHMENT

0.0778286
0.1556403
8
0.2333162
1
0.3050340
7
0.3697302
0.4216944
6
0.4702634
2
0.5009095
7
0.5321666

Yes

0.5609342
0.5681608
3
0.5804899
3
0.5895765
4

Yes

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes

Table 5.7.3 Rank-ordered list of filtered genes associated to mitotic cycle components with
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the
core enriched genes (i.e., the leading-edge subset) in the KIFC1-high group.
GENE
SYMBOL

RANK
IN GENE LIST

KIF23

7

KIF2C

16

NCAPH

19

KIF15

31

RANK
METRIC SCORE

RUNNING
ES

0.38020667
4
0.34368071
0.34149092
4
0.32993608
7

0.02617827
8
0.04975993

CORE
ENRICHMENT

Yes
Yes

0.07348197

Yes

0.09595834
5

Yes
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BIRC5

33

TPX2

43

BUB1

45

ANLN

47

PRC1

48

NEK2

49

CDKN3

52

CDC6

54

UBE2C

58

TTK

59

NUSAP
1

65

CENPF

68

PLK1

69

CDC7

72

CENPE

76

AURKA

77

FBXO5

86

CDC25
C

93

BUB1B

106

KIF11

126

CCNA2

128

CDCA5

131

RCC1

157

ESPL1

163

ZWINT

185

CDK2
CDKN2
A

201

STMN1

238

CIT

255

207

0.32853895
4
0.31242573
3
0.31174606
1
0.30931574
1
0.30758470
3
0.30623361
5
0.30384364
7
0.30182740
1
0.29473295
8
0.29472723
6
0.28140944
2
0.27754867
1
0.27737551
9
0.27584514
0.27514043
5
0.27472376
8
0.27031439
5
0.26497542
9
0.25538018
3
0.23612600
6
0.23533037
3
0.23478570
6
0.2154641
0.21126280
7
0.20219287
3
0.19581379
0.19183807
1
0.18024593
6
0.17556032
5

0.11882581
6

Yes

0.14017852

Yes

0.16187464

Yes

0.18340124

Yes

0.20485595

Yes

0.22621644

Yes

0.24731249

Yes

0.26831678

Yes

0.28872848

Yes

0.30928636

Yes

0.328671

Yes

0.34793293

Yes

0.3672805

Yes

0.3864236

Yes

0.4054687

Yes

0.4246313

Yes

0.44309548

Yes

0.46128497

Yes

0.47851205

Yes

0.49405414

Yes

0.5104201

Yes

0.5266992

Yes

0.54050696

Yes

0.55499876

Yes

0.5680762

Yes

0.5810018

Yes

0.5941387

Yes

0.6052456

Yes

0.61670965

Yes

236

KNTC1
MAD2L
1
CDKN2
D

264

0.17323194
4

0.6284021

Yes

305

0.16407761

0.6378927

Yes

0.6479683

Yes

0.65819

Yes

0.66625553

Yes

0.67494035

Yes

0.6833162

Yes

0.6909405

Yes

0.696788

Yes

0.70517176

Yes

0.7060298

Yes

0.7131949

Yes

0.7185633

Yes

0.7221773

Yes

0.71569943

Yes

0.71276724

Yes

0.7141451

Yes

0.71104246

Yes

0.70828867

Yes

0.7127867

Yes

0.7130398

Yes

0.71550256

Yes

0.72035104

Yes

0.72499233

Yes
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KIF22

343

E2F1

390

SKP2

420

MAD2L
2

450

DBF4

488

CDKN2
C

553

POLD1

564

POLE

710

DDX11

726

PKMYT
1

774

SMC4

852

PIN1

1119

TBRG4

1304

ASNS

1397

SMC1A

1575

PPP5C

1741

CDC25
B

1758

CDC27

1859

POLA1

1913

BTG3

1918

GSPT1

1927

0.15915641
2
0.15704949
2
0.14784903
8
0.14482110
7
0.14039075
4
0.13522075
1
0.12865872
7
0.12719699
7
0.11385873
0.11322832
9
0.10988337
5
0.10574237
3
0.09343647
2
0.08683542
9
0.08419103
2
0.07948930
6
0.07608585
8
0.07569229
6
0.07366871
8
0.07242853
9
0.07231188
6
0.07214269
8
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Table 5.7.4 Rank-ordered list of filtered genes associated microtubule-based processes with
associated rank metric scores, enrichment scores (ES), and whether each gene is part of the
core enriched genes (i.e., the leading-edge subset) in the KIFC1-high group.
GENE
SYMBOL

RANK
IN GENE LIST

RANK
METRIC SCORE

RUNNING
ES

CORE
ENRICHMENT

KIF23

7

0.380206674

KIF2C
KIF4A
PRC1
TTK
NUSAP
1
KIF11
RCC1
STMN1
TUBG1
KIF1A
KIF1B
NLGN1
YKT6
MAP1S
CKAP5
SNAP29
SMC1A
CENPJ

16
32
48
59

0.34368071
0.329859108
0.307584703
0.294727236

0.06844783
6
0.13023852
0.18918754
0.24410658
0.29694292

65

0.281409442

0.34761333

Yes

126
157
238
542
577
729
846
972
976
1293
1408
1575
1691

0.236126006
0.2154641
0.180245936
0.129438803
0.125762284
0.112902582
0.106165938
0.098996036
0.098900363
0.087143637
0.083875522
0.079489306
0.076832272

0.38741168
0.42493314
0.45364717
0.46230626
0.4834036
0.496475
0.51003253
0.5218544
0.5396018
0.5399754
0.54959744
0.5558929
0.56419194

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes
Yes
Yes
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Appendix D: Supplementary Data for Chapter 7

.

Supplementary Figure 7.7.1: MDA-MB-231 and DU-145 cells showing formation of giant MP
cells 72 h after treatment with 5nM docetaxel (DTX).
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Supplementary Figure 7.7.2: DIC and Hoechst 33342 images showing presence of DNA
(black arrows) in cells budding from the giant MP cells.

Supplementary Figure 7.7.3: Immunoblots of CD44 at different days after docetaxel
removal. C are control PC-3 cells while cells on D0 are cells collected 72 h post docetaxel
treatment.

Supplementary Figure 7.7.4: Representative immunofluorescent confocal micrographs of
PC-3 cells treated with docetaxel (5nM) for 24 h and 72 h indicating mitotic arrest and
emergence of giant multinucleated polyploid cells respectively.
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Centrosomes and microtubules were immunolabeled for γ-tubulin (green) and α-tubulin (red),
respectively, and DNA was counterstained with DAPI (blue). Scale bar (white) 5 µm

Supplementary Table 1: The quantification of Western Blot densitometry values in relation
to loading control β-actin for Fig 3B (calculated using Image-J software).
Cell type
Giant MP Giant MP +
PC-3 PC-3 +
CDPC CDPC +

Cleaved PARP
0.027111272
0.440467057
0.070632216
1.035792334
0.027747402
0.746083581

Cleaved Caspase
0.02259534
0.57760081
0.054661554
1.586356511
0.049495095
0.827335698

Supplementary Table 2: The quantification of Western Blot densitometry values in relation to
loading control β-actin for Fig 3D (calculated using Image-J software).
Days after
drug removal

Beclin-2

Survivin

Bcl-XL

P-Bcl2

Bcl2

0

0.941251727

0.803824128

0.941123482

0.065360381

0.055159161

1

2.822945541

0.981694271

0.803645446

1.195198385

0.804328047

5

3.713716836

0.781451901

0.972501709

1.130220819

1.209606137

10

0.433636748

1.074286244

0.434295141

0.461309892

0.34912065

15

0.138397195

0.697108731

1.073126657

0.585133676

0.916490447

25

0.074917074

1.469521135

1.339419773

1.17057988

0.517625674

35

0.072369018

1.383199964

1.237650405

1.10612344

0.26394166

Supplementary Table 3: The quantification of Western Blot densitometry values in relation to
loading control β-actin for Fig 4D (calculated using Image-J software).
PC-3
Giant MP

Vimentin
0.194946108
1.683074943
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CDPC

1.480074389

Supplementary Table 4: The quantification of Western Blot densitometry values in relation to
loading control β-actin for Supplementary Fig 3 (calculated using Image-J software).
Days after Drug
Removal
C
0
5
10
15
20
25
30
35

CD44
0.209981839
0.895492234
0.804897313
0.260869891
0.601404075
0.149114788
1.697150291
0.682945733
0.696615458

